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Abstract 
 
Background Rationale 
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity 
and mortality worldwide. It is a chronic inflammatory disease characterised by a not fully 
reversible airflow limitation. Several pro-inflammatory biomarkers are thought to be involved in 
the pathogenesis of COPD, but the association of particular biomarkers with COPD is still 
unclear. Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) may be effective therapeutically 
in reducing airway inflammation in individuals exposed to smoke or other irritants. The results 
of previous studies have indicated that omega-3 PUFAs may have beneficial effects on COPD. 
 
Aim 
The aim of the present work is to determine systemic and pulmonary inflammatory 
biomarkers level in patients with COPD, smokers without COPD and healthy controls. Further, 
to determine in vitro the inflammatory mediator release from inflammatory immune cells 
particularly peripheral blood mononuclear cells (PBMCs). To investigate the effect of omega-3 
PUFAs, Eicosapentaenoic acid, docosahexaenoic acid, on biomarkers release in PBMCs, and the 
relationships between these biomarkers activity, fatty acid analysis and COPD. 
 
Methods 
The current study data is from case-control study of 42 subjects; 15 patients with COPD 
(COPD), 15 healthy smokers (HS), and 12 healthy non-smoking controls (HNS), recruited from 
University Hospital South Manchester. Blood samples were processed to separate plasma, 
PBMCs and RBCs fractions. IL-6, TNF-α, IL-8, IP10, CRP, fibrinogen, SPD, CC16, CD31, 
CCL18, and RAGE level were measured in plasma by ELISA. Additionally, IL6, IL8, TNFα, 
CD31, IP10, and RAGE release were measured in PBMCs, with and without EPA and DHA 
  
xx 
 
treatment, by ELISA. Individual PUFAs profile was carried out on RBCs. Comparisons between 
data of the three groups were made. 
 
Result 
Highly significant differences were observed in data (mean ± standard deviation) of patients’ 
respiratory functions when comparing COPD to HS and HNS groups. The preFEV1% of COPD 
(52 ± 22) and FEV1/FVC ratio (41.5 ± 12) are highly considered significantly higher than those 
from HS (99.5 ± 10.2), (69.2 ± 19.3) and HNS (99.6 ± 13), (76 ± 5.38) groups (p < 0.001). There 
was a significant correlation between FEV1% and age (P=0.0009) as well as BMI (P=0.024) of 
entire study subjects. Similarly, a significant correlation was seen between FEV1/FVC ratio and 
age (P<0.0001), BMI (P=0.0009) as well as weight of entire study subjects (P=0.022). 
The levels of CRP, Fibrinogen were all significantly high in plasma of COPD group 
(4.48±28 mg/L) and (409±181mg/dl) when compared to those in HNS groups (2.27±2 mg/L) (p 
=0.007) and (137±49 mg/dl) (p <0.0001) respectively. The plasma levels of CC16 significantly 
were lower in plasma of COPD group (2.75±1.19 ng/ml) compared to HNS groups (5.77±2.66 
ng/ml) (p =0.014). The release of IL-6, IL-8, and TNF-α, from PBMCs was significantly higher 
in COPD (4.07±0.46 ng/ml), (16.3 ±0.22 ng/ml), (219±11.9 pg/ml) when compared to HNS 
groups (0.16 ng/ml), (6.6±0.1.07 ng/ml), and (0 ng/ml) (p<0.001). PBMCs treated with 100µmol 
EPA or DHA showed decrease of IL6, IL8, and TNFα release.  
 
Discussion 
This study showed significant associations of higher level of several biomarkers that were 
detected in COPD group with the disease inflammation. The results also suggest that PBMC are 
already activated in the circulation in COPD patients, which confirms further that COPD is a 
multicomponent disease, involving both airway and systemic inflammation. The statistically 
significant correlation between the levels of CRP in plasma of patients with COPD and the 
percentage of Pre FEV1/FVC ratio could be beneficial for patient treatment. CRP, fibrinogen and 
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CC16 in particular have emerged as potentially useful biomarkers and require further 
investigation. Additionally, omega-3 fatty acids; EPA and DHA have the ability to reduce 
cytokines release from PBMCs.  
Keywords: COPD, Inflammation, biomarker, PBMCs, omega-3 PUFAs, EPA, DHA 
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Chapter 1 
 
1. Introduction 
1.1 Inflammation  
Inflammation is the body’s natural immediate response to infection or injury. This 
response triggers the immunological process of eliminating foreign pathogens, irritants and 
toxins and repairing damaged tissue in order to maintain tissue homeostasis. Inflammatory 
activation involves several biological functions such as leukocyte migration, proliferation of T-
cells, interferon response, nuclear factor kappa beta (NF-κB) signaling, and regulation of cell 
death (Koniarevic et al., 2014). It is initiated when an injury to cells or tissue occurs and is 
mediated by a complex network of pro-inflammatory mediators, inflammatory cells and 
signalling pathways. The innate immune system can recognize either microbial derived 
constituents known as pathogen associated molecular patterns (PAMPs), released during 
infection or endogenous damage-associated molecular patterns (DAMPs). These molecules are 
identified by pattern recognition receptors (PRRs), which can be found either attached to the cell 
membrane on toll-like receptors (TLRs) or within the cytoplasm on nucleotide-binding 
oligomerization domain-like receptors (NLRs). After the recognition of the pathogen or other 
irritant, the innate immune system responds with an inflammatory response by stimulating innate 
immune cells such as macrophages and neutrophils which secret pro-inflammatory factors to 
promote inflammation (Hosseinian et al., 2015; Lee et al., 2016). 
Pro-inflammatory mediators include; cytokine proteins termed interleukins (IL), which 
regulate differentiation, function and inflammation communication and response with immune 
cells; chemokines, which drive chemotaxis; and interferons, which react against viral invasion. 
These molecules are involved in both innate and adaptive immunity. The chemokines and 
adhesion molecules expressed by endothelial cells initiate interactions among circulating 
immune cells. Cells of the innate immune system, including monocyte-derived macrophages, 
dendritic cells, and granulocytes; neutrophils, basophils, and eosinophils, and the acquired 
immune system, including T and B lymphocytes, are involved in the inflammation process 
(Profumo et al., 2012). For example, granulocytes and macrophages eliminate pathogens and 
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clear away cellular waste and damaged tissues. Helper T lymphocytes regulate the activities of 
macrophages, natural killer cells and B lymphocytes, while cytotoxic T lymphocytes and B 
lymphocytes are involved in eliminating pathogens (Calder, 2002) (Figure 1.1, next page).   
It is suggested that inflammasomes, specialised inflammatory signaling pathway, regulate 
the maturation and secretion of pro-inflammatory cytokines, via the regulation of caspase-1–
dependent proteolytic processing. Cytokines are extracellular signalling small proteins <80 kDa 
in mass and produced by different cell types. Cytokines are involved in cell-to-cell interactions 
and their effect may be influenced by other cytokines released from the same cell or from target 
cells following activation by the cytokine (Chung 2001). Inflammation is intended to be a 
protective process and should be controlled to eliminate the initial cause of the injury; however 
any defect within the normal resolution process may convert acute inflammation to chronic 
inflammation. Uncontrolled inflammation response also my result in severe inflammation that 
can cause tissue damage, impair tissue healing, and fibrosis (Lee et al., 2016). In addition, 
deregulation of cytokines and chemokines can enhance the progression of pathologies related to 
chronic inflammatory and autoimmune diseases. Therefore, investigation of various systemic 
cytokines and chemokines may increase understanding of the immunological changes in patients 
suffering from autoimmunity and chronic inflammation (Giudetti and Cagnazzo, 2012; Kleiner et 
al., 2013).  
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Figure ‎1.1: The interplay between component of the innate and acquired immune 
responses. Immune cells involved in COPD including; macrophages, neutrophils and T-cells, are 
recruited to the injury tissue via the actions of various chemokines. Once activated, they contribute in 
irritant and pathogen elimination and tissue resolving and repair. 
 
1.2 Chronic Obstructive Pulmonary Disease (COPD) 
The lung is a vital organ and it main function is to uptake and transfer of oxygen which is 
essential for metabolism. The lung is highly susceptible to inhaled foreign materials, irritant 
particles and different pathogens such as dusts, fuels, and microorganisms, which can lead to 
infection, inflammation and tissue injury. The first defense mechanism to protect the respiratory 
system from infectious agents and irritants is played by the lining innate immune system. The 
lung tissue consists of different cell types, including epithelial, endothelial, secretory, and 
inflammatory cells. The lung tissue and epithelial airway with innate and adaptive immune cells 
are able to trigger the inflammatory events in response to endogenous and exogenous irritants. 
As previously mentioned, an exaggerated inflammatory response might result in chronic 
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inflammation which can lead to the development of chronic obstructive pulmonary disease 
(COPD) (Lee et al., 2016; Colarusso et al., 2017). 
COPD is a multicomponent chronic lung disease that decreases quality of life due to 
shortness of breath and chronic cough. Different pathogenic processes, inflammatory cells and 
their mediators are involved during disease progression and tissue damage, including; 
inflammation, alteration of immune responses, protease and anti-protease imbalance, cell 
proliferation and apoptotic cell death (Toraldo et al., 2013).  Many inflammatory mediators have 
been implicated in COPD, including lipids, free radicals, cytokines, chemokines and growth 
factors. These mediators are derived from inflammatory and structural cells in both the lung 
airways and the circulation, to interact with each other in the site of tissue injury.  
Alterations in the lungs are characterized by several complicated respiratory and 
pathological features including, destruction of the lung parenchyma and alveoli, inflammation of 
the central airways with chronic bronchitis, and inflammation of the small airways with chronic 
bronchiolitis (Tuder and Petrache, 2012; Caramori et al., 2014). This result in dyspnoea, 
progressive airflow obstruction that is not fully reversible, productive cough, fatigue, wheeze, 
weight loss, exacerbations and repeated respiratory infections (Fulton et al., 2012). Airway 
obstruction is caused by inflammation of the bronchi, which leads to increased mucus secretion 
with goblet cell and submucosal gland hyperplasia (Chung et al., 2001). Lung parenchyma 
becomes infiltrated by neutrophils, macrophages and other inflammatory immune cells causing a 
loss of surface area for gas exchange. The destruction of lung parenchyma leads to distal airway 
compression, known as emphysema. All these events lead to irreversible decline of lung function 
(Fulton et al., 2012; Matsuyama et al., 2005).  
In 1998, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) was 
established to direct global attention toward COPD. GOLD defined COPD as ‘a disease state 
characterized by airflow limitation that is not fully reversible’ (Korani et al., 2016). In 2001, 
GOLD divided patients with COPD into four grades: GOLD A (mild); GOLD B (moderate); 
GOLD C (severe); and GOLD D (very severe) in addition to grade 0, which included people 
with normal spirometry that had a history of smoking and respiratory symptoms. In 2011 GOLD 
guidelines have removed stage 0 and COPD grades are determined by a COPD assessment of 
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symptoms, severity of airflow obstruction, and history of exacerbations and presence of 
comorbidities. Airflow limitation is determined by spirometry using a fixed-ratio of a forced 
expiratory volume in the first one second to the forced vital capacity (FEV1/FVC) <0.70 after 
bronchodilator which considered diagnostic of COPD. FEV1is the amounts of air that the patient 
can exhale in the first second, while FVC is the total volume of air that the patient can exhale in 
one breathe. It is also a measure of the amount of air the lungs hold. (Table 1.1) (Bailey et al., 
2012) 
 
Table ‎1.1: COPD severity according to 2011 GOLD grades A–D. 
Grade Risk Symptoms Airflow obstruction Exacerbation history 
GOLD 
A 
 
Low 
 
Low symptom 
burden 
 
FEV1 of 50% or 
greater 
Low exacerbation rate (0–
1/year) 
GOLD 
B 
 
Low 
 
Higher symptom 
burden 
 
FEV1 of 50% or 
greater 
Low exacerbation rate (0–
1/year). 
GOLD 
C 
 
High 
 
Low symptom 
burden 
 
FEV1 of 50% 
and/or high exacerbation rate 
(≥2/year). 
GOLD 
D 
 
High 
 
Higher symptom 
burden 
 
FEV1 of 50% 
and/or high exacerbation rate 
(≥/year). 
 
Symptom burden was measured by either the modified Medical Research Council (mMRC) questionnaire 
or the COPD assessment test (CAT) (Meng et al., 2016). 
 
The GOLD guidelines suggest that the presence of FEV1 (% predicted) < 80% of the 
predicted value in combination with a FEV1/FVC < 70% confirms the diagnosis of COPD 
(Queiroz et al., 2016). The percent predicted FEV1 is used as marker of disease severity and 
progression. While the post bronchodilator FEV1 is used to determine severity stage. However, 
FEV1 is an unreliable marker of disease activity, as it correlates poorly with both symptoms and 
disease progression (Vestbo et al., 2013). The degree of emphysema and airway wall thickness 
can be measured by chest computed tomography (CT) scan (Lee et al., 2018). 
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The inflammatory process is not limited to the pulmonary system, and its impact can 
extend to extra-pulmonary organs resulting in complications involving endocrine, metabolic and 
cardiovascular systems (Heidari 2012). Lung inflammation can pass through the systemic 
circulation causing systemic inflammations and comorbidities, which are frequently found in 
COPD patients, including cardiovascular disease (CVD), lung cancer, skeletal muscle 
dysfunction, diabetes, osteoporosis, and cachexia. CVD include four separate entities: ischemic 
heart disease, heart failure, atrial fibrillation, and hypertension. Psychiatric conditions, such as 
depression and anxiety, are also comorbidities of COPD (Lee et al., 2018). These COPD 
comorbidities can occur at any COPD stage. Lung cancer and CVD are the most frequent 
comorbidity in COPD. It has been found that lung cancer is the most frequent cause of death in 
patients with mild to moderate COPD. Osteoporosis is often associated with decreased body 
mass index and low fat-free mass (Vestbo et al., 2013). Skeletal muscle dysfunction is one of the 
main systemic effects of COPD and is often accompanied by loss of muscle mass. The 
mechanisms involved in loss of skeletal muscle mass and strength are likely caused by 
interaction between local and systemic factors to modify, the phenotype and function of any 
specific muscle. Systemic factors including inflammation and oxidative stress are thought to 
interact with local factors such as muscle inactivity. These result in functional, metabolic, and 
structural changes that weaken muscle work (Barnes and Celli, 2009). 
It is unclear whether systemic inflammation is pathological or results from an overspill of 
inflammatory mediators from the lung to the circulation (Fulton et al., 2012). Systemic 
inflammation and inflammation of non-pulmonary organs are known to adversely affect a 
patient’s quality of life, which lead to increase the risk of hospitalization and mortality as well as 
costs (Tuder and Petrache, 2012; Calder, 2012; Toraldo et al., 2013; Caramori et al., 2014). CVD 
and lung cancer are the most common causes of death in COPD patients. In addition, at least 
50% of COPD patients have bacterial infection of the lower airways that can increase both acute 
exacerbations and the risk of community acquired pneumonia (Barnes, 2010). Furthermore, 
respiratory viral infections including influenza and respiratory syncytial virus account for 64 % 
of COPD exacerbations (Wu et al., 2016).  
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1.2.1 Prevalence  
Most data available on COPD come from developed countries. There is a lack of studies 
in Africa, South East Asia and the Eastern Mediterranean region (Adeloye et al., 2015). The 
prevalence of COPD is 0.2% in Japan, and 37% in USA, while India and China account for 66% 
worldwide COPD mortality. About 90% of COPD deaths occur in low and middle income 
countries (Rajkumar et al., 2016). It has been estimated that 4‒15% of the world’s adult 
population suffers from COPD (Novgorodtseva et al., 2013). It is the fourth leading cause of 
chronic morbidity and mortality. However, the World Health Organization (WHO) has predicted 
that by 2030, COPD will be the third leading cause of death worldwide (from sixth in 1990). 
   In 2005, 3 million people died of COPD, representing 5% of all worldwide deaths, and 
the number is estimated to increase to 8.6% in 2030 (Rajkumar et al., 2016). The WHO 
estimated that about 65 million people worldwide have moderate-to-severe COPD. The mortality 
rate is higher in men than in women, and in the next 40 years the risk of developing COPD in 
healthy population over the age of 40 will be 12.7% for men and 8.3% for women. However, the 
prevalence in women has increased because of the rising number of those older than 50 years 
who smoke. In general, women smoke less than men, suggesting that they may be more 
susceptible to developing COPD in response to cigarette smoke exposure than men. During 
2000, similar numbers of men and women died from COPD in the USA (Decramer et al., 2012; 
Fulton et al., 2012; Toraldo et al., 2013; Nurwidya et al., 2016). In the US, the annual cost of 
COPD has been estimated at about $50 billion, most of it related to hospitalization (Caramori et 
al., 2014). In Europe about 23 million people have COPD, with an estimated annual cost of €141 
billion including health care cost (Müller et al., 2016).  
The UK National Health Service (NHS) has suggested that more than 3 million people in 
the UK have COPD, and more than 1.5 million adults have been diagnosed with it (Dixon et al., 
2016). It has been estimated that COPD causes about 25,000 deaths in the UK annually. In 
England, a study was done to estimate the prevalence, healthcare costs, and mortality rate among 
people with COPD for the period 2011–2030; such a study could help governments to plan their 
healthcare budgets and financial resources. The study findings showed that in England, the 
number of people with COPD is increasing particularly in females by 54% comparing to 24% in 
males. These increases were driven by more women developing COPD. The annual healthcare 
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costs of COPD will increase from £1.50 billion in 2011 to £2.32 billion in 2030, while the 
number of deaths will increase from 99,200 in 2011, to 129,400 by 2030 (Figures 1.2, 1.3, and 
1.4) (McLean et al., 2016). The priority for the NHS regarding COPD management is to improve 
the health quality of life for patients with COPD, to reduce premature death, avoid unnecessary 
admissions and time in hospital (Dixon et al., 2016). 
 
Figure ‎1.2: Projected number of people with COPD in England (McLean et al., 2016) 
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Figure ‎1.3: Projected number of deaths among people with COPD in England (McLean et 
al., 2016). 
 
Figure ‎1.4: Projected direct healthcare costs of COPD in England (McLean et al., 2016) 
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1.2.2 Risk factors  
Smoking is a major risk factor for various lung diseases and is the fifth leading cause of 
deaths worldwide (Hsiao et al., 2013). However, in 2012 smoking was the third most common 
cause of death (WHO, Titz et al., 2016). The WHO estimated that in 2005, 5.4 million people 
died due to smoking, and that the number will increase to 8.3 million per year by 2030. The main 
risk factor for COPD is cigarette smoking, which accounts for more than 90% of COPD cases in 
western countries. Smoking is considered a pro-inflammatory factor and it has been associated 
with development of chronic respiratory and airflow-obstruction diseases. The prevalence of 
COPD in women has increased because the number of smoking women has increased (Decramer 
et al., 2012). In addition to nicotine, cigarette smoke contains other injurious agents, including 
heavy metals and carcinogens. It is believed that oxidative stress induced by cigarette smoke 
exposure is also involved in the pathophysiology of COPD. Smokers are exposed to various 
oxidants, including free oxygen radicals such as peroxide (O2
−
), which cause lipid peroxidation; 
α- and β-unsaturated aldehydes; acrolein ( C3H4O) and crotonaldehyde (CH3CH=CHCHO), 
which cause protein carbonylation; and superoxide (O
-2
); hydroxyl radical (OH
−
), hydrogen 
peroxide (H2O2) (Tuder and Petrache, 2012). 
However, 25–45% of COPD patients have never smoked, and only 20 % of smokers 
develop COPD and smokers who do not have COPD have a lesser degree of inflammation than 
those who have COPD. Such statistic suggests that genetic and environmental factors other than 
smoking may be involved. Individual genetic predisposition to develop COPD and exposure to 
environmental pollution and biomass smoke may have an impact on disease predisposition, and 
may explain why some patients who develop COPD are never smoke (Eickmeier et al., 2010; 
Wald et al., 2014; Varraso et al., 2015). The combination of these risk factors alters lung 
development and immunity and results in the predisposition for COPD (Decramer et al., 2012) 
(Figure 1.5).  
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Figure ‎1.5: Systemic inflammation and comorbidities in COPD. Patients with COPD have lung 
inflammation that may spill over into the systemic circulation, leading to increase the propensity to 
cardiovascular, metabolic, and bone diseases. There might be a genetic predisposition to developing 
COPD in smokers in addition to outdoor irritants factors. 
 
Other risk factors include maternal smoking, respiratory infections, poor nutrition, and 
exposure to indoor and outdoor air pollution, noxious particles, gases, occupational chemicals 
and dust at the workplace (Decramer et al., 2012; Tuder and Petrache, 2012). About 15–20 % of 
COPD cases are due to occupational exposures to pollutants, and about 50 % of COPD death rate 
found in developing countries as a result of the exposure to biomass smoke during lifetime 
(Terzikhan et al., 2016). Other chronic respiratory disease such as asthma and post-tuberculosis 
are important predisposing conditions for progression of COPD (Rajkumar et al., 2016).  
 
  
12 
 
1.2.3 Pathophysiology of COPD 
In COPD the pathogenesis of inflammation, airway remodeling, and alveolar destruction 
is complex and not completely understood (Toraldo, 2013). Lung inflammation is regulated by a 
complex mechanism that involves various types of cells and pro-inflammatory mediators. (Berg 
and Wright 2016).The exposure of cigarette smoke, microorganisms and other noxious inhaled 
substances cause chronic airway inflammation and tissue destruction by activating structural and 
inflammatory cells, including airway epithelial cells and alveolar macrophages, within the lungs. 
These cells stimulate the release of early cytokines and chemotactic mediators, which attract 
immune system inflammatory cells, including neutrophils, monocytes and lymphocytes, into the 
lung, which in turn causes chronic inflammation (Rovina et al., 2013). Cigarette smoking also 
causes structural and functional changes in the airway ciliary epithelium, and immune cells such 
as alveolar macrophages, neutrophils, and lymphocytes (Nurwidya et al., 2016). According to 
Lapperre et al (2006) it is possible that inflammation which caused by smoking occurs in two 
stages; an early stage, during which neutrophils and macrophages are present in pulmonary 
epithelial and submucosal tissue, and a late phase with the additional participation of 
lymphocytes and eosinophils from circulation.  
Epithelial changes occurred mostly in the large airways than the small airways, with an 
increase in goblet and basal cell hyperplasia, and squamous cell metaplasia. The small airways is 
the major site of airway obstruction in subjects with COPD (Hogg et al., 2013).Unlike large 
airways, small airways lack cartilage, and have a greater mass of smooth muscles and fewer 
goblet cells in the epithelial layer (Stewart and Criner, 2013). In the airway lumen, more mucus 
can be found, which is produced by the goblet cells and enlarged mucus glands. The 
inflammatory cells infiltrate into the mucosa, submucosa, and glandular layers of lung tissue 
resulting in structural changes in small airways, thickening of their walls and emphysema, loss of 
tissue elasticity, mucus hypersecretion and defects in the tissue-repair process. The increased 
thickness of the airway walls occurs as a result of increases in smooth muscle mass,  mucus 
gland activity and  extracellular matrix (ECM) deposition (Brandsma et al., 2017) (Figure 1.6).  
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Vascular changes constitute another histopathological feature in patients with COPD. Vascular 
changes are caused by the pathophysiological changes in the normal biochemical function of the 
endothelium. The main vascular changes can be seen in thickened arteriole walls, reduced lumen, 
increased contraction, and reduced ability to vasodilate, together causing pulmonary 
hypertension, which is a major cause of morbidity in COPD. The increased thickness of the 
intima in the arterial vasculature caused by smooth muscle proliferation, with increased 
deposition of both elastin and collagen (Berg and Wright, 2016).The distance between the 
leading edge of the lumen intima echo and the leading edge of the media-adventitia layer is 
known as intima media Thickness (IMT), and consider as a measure of atherosclerosis that 
independently predicts CVD. The normal IMT of healthy subjects is 0.74 ± 0.14 mm. Some 
studies reported that IMT <0.8 mm is associated with normal healthy individuals and a value >1 
mm is associated with atherosclerosis and increased CVD risk. A previous study found that IMT 
of healthy subject was 0.75 ± 0.011 mm (Paul et al., 2012). Increased IMT in patients with 
COPD has been found to be associated with deaths from CVD. IMT was significantly higher in 
COPD patients than in control group (1.07 mm vs 0.86 mm) (Alpaydin et al., 2013). In the same 
line, IMT was also significantly higher in patients with COPD than in those without COPD (1.40 
mm and 1.24mm, respectively). Another study found that IMT increased more in patients with 
COPD than in patients without COPD, and such an increase was higher in patients with both 
COPD and CVD than in patients with CVD or COPD only (Köseoğlu et al., 2016). 
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Figure ‎1.6: Comparison of airway in a healthy individual and in-patient with COPD. (A) In 
normal subjects the airway is distended by alveolar attachments which allowing alveolar emptying on 
expiration and lung deflation. (B) In COPD airways are narrowed by infiltration of inflammatory cells, 
mucosal, alveolar attachments are disrupted because of emphysema, thus contributing to airway closure, 
trapping gas in the alveoli and resulting in hyperinflation (Barnes 2004; Decramer et al, 2012). 
 
As COPD progresses, aggregations of lymphoid tissues develop around the small 
airways, causing alveolar enlargement. Cigarette smoke dysregulates the alveolar repair 
processes by stimulating airway epithelial cells to release transforming growth factor-β (TGF-β), 
which induces fibrotic tissue remodeling. In healthy subjects, to maintain lung homoeostasis 
cellular apoptosis and matrix destruction are countered by cellular renewal and matrix repair, 
controlling the inflammation process. As previously mentioned, an uncontrolled inflammatory 
response might result in chronic lung inflammation which can progress to COPD. In COPD cells 
are metabolically active, but do not divide, which leads to increased inflammation, reduced cell 
regeneration and carcinogenesis (Decramer et al., 2012).  
Oxidative Stress is reported to play an important role in the pathophysiology of COPD. 
An imbalance between oxidants and antioxidants has been proposed as a critical event in the 
pathogenesis of COPD (Ilieva et al., 2014).When ROS are produced in excess of the antioxidant 
defense mechanisms, oxidative stress occurs causing damage to lipids, proteins and DNA. Lipid 
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peroxidation is the major consequence of oxidative stress which leads to cellular damage PUFAs 
react with oxygen radicals and oxidised to produce several lipid end-products like 
hydroperoxides and aldehydes. For examples, Malondialdehyde (MDA) aldehyde is considered 
as potential biomarker to assess oxidative stress status in COPD patients (Waseem et al., 2011; 
Zinellu et al., 2016). Various Studies have reported that the plasma levels of MDA are increased 
in COPD patients compared to healthy controls. Waseem et al, 2001, reported an increase in 
MDA levels in COPD patients, as compared to healthy Controls, and it level negatively 
correlated with lung functions. Another Study conducted by Ilieva et al., 2014, showed that 
MDA levels are significantly higher in patient with COPD than in healthy controls. Increased 
oxidative stress in patients with COPD, demonstrated by the increased of MDA in the plasma of 
these patients. Another study found that oxidative marker MDA is higher in COPD patients and 
its level correlate with lung functions and disease severity (Bajpai et al., 2017). 
1.2.4 Inflammatory cells involved in COPD  
The inflammation seen in COPD patients involves inflammatory cells of the innate 
(macrophages, neutrophils, eosinophils, mast cells, natural killer cells, innate lymphoid cells and 
dendritic cells), and adaptive (T and B lymphocytes) immune system, as well as structural cells; 
airway epithelial cells, endothelial cells, fibroblasts, and smooth-muscle cells. These cells secrete 
various pro-inflammatory mediators, including cytokines, chemokines, growth factors and lipid 
mediators, which are implicated in COPD pathogenesis (Barnes 2016) (Figure 1.7). 
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Figure ‎1.7: The complexity of inflammation in COPD. Different activated inflammatory immune 
and lung cells release several mediators; chemokines, ROS, which prolongs neutrophils’ survival; 
cytokines that amplifies inflammation. Macrophages secrete many inflammatory proteins that trigger the 
inflammatory process in patients with COPD including several chemokines that attract Neutrophils and 
lymphocytes. Proteinases including, NE, proteinase C (cathepsins), and MMPs cause elastolysis, and 
contribute to emphysema together with T lymphocytes. NE also causes mucus hypersecretion. Release of 
growth factors can induce fibrosis of the small airways. This combination of mediators that attract and 
activate inflammatory cells and proteinases results in the typical pathophysiology of COPD. 
Abbreviations: NE, neutrophils elastase; MMPs, matrix metalloproteinases; ROS, reactive oxygen 
species (adapted and updated from Barnes 2004). 
1.2.4.1 Structural Cells involved in COPD 
Airway epithelial cells can secrete cytokines that either initiate local inflammatory effects 
or amplify inflammatory events previously initiated by inflammatory cells. Airway epithelial 
cells activated by cigarette smoke and other noxious agents, produce inflammatory mediators, 
including tumour necrosis factor (TNF-α), interleukin-1β (IL-1β), granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and TGF-β1, which activate myofibroblasts and airway 
smooth-muscle cells, causing cell proliferation and fibrosis. In addition, epithelial cells produce 
several chemokines that activate neutrophil recruitment in COPD, including leukotriene B4 
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(LTB4), IL-1 (CXCL1), IL-8 (CXCL8), CXCL9 or monokine induced by gamma 
interferon (MIG), CXCL10 (IFN-inducible protein 10) (IP-10) or small-inducible cytokine B10, 
and growth-related oncogene-a (GRO-a). IL-8 also mediates the chemotaxis of neutrophils, 
eosinophils and T-cells (Rovina et al., 2013).  
In patients with COPD, expression of CXCL10 by bronchial epithelial cells is increased, 
which may lead to accumulation of CD8 Tc1 and CD4 Th1 cells in the lung tissue. Airway 
epithelial cells secrete mucus from goblet cells, antioxidants and anti-proteases, all of which are 
involved in the defence system of the airways. However, cigarette smoke and other irritants 
affect this defence mechanism, causing mucus hyperplasia, which is common feature in COPD 
patients (Barnes 2016). Airway epithelial cells can modulate the production of histamine by 
basophil, and inhibit the production of the IL-4-mediated B-lymphocytes IgE production. Other 
structural cells include; Fibroblasts, myofibroblasts and smooth-muscle cells are thought to be 
involved in airway remodelling via production of collagen and proteoglycans (Giudetti and 
Cagnazzo 2012).  
1.2.4.2 Innate Immunity Cells 
The lungs of a COPD patient are infiltrated with increased numbers of macrophages, 
neutrophils, T lymphocytes, dendritic cells and B lymphocytes. Macrophages and neutrophils 
play a role in the pathogenesis of COPD by releasing proteinases that degrade the ECM and 
damage the lung parenchyma, leading to emphysema (Tubby et al., 2011).  
Monocytes recruited from the blood enter the lung tissues, where they differentiate into 
macrophages in addition to the tissue resident macrophages. A study reported the presence of 
macrophages with different phenotypes in lungs tissue of healthy subjects. Those cells either 
originate locally from pulmonary dendritic cells and alveolar macrophages or derived from blood 
monocytes (Desch et al., 2016). Macrophages are found in an increased number in the lungs of 
patients with COPD and are involved in host defence, airway remodeling and parenchymal 
destruction. It has been suggested that increased lung macrophage numbers are due to increased 
recruitment of blood monocytes. Further, cigarette smoke, which stimulates the expression of 
anti-apoptotic genes in macrophages, may delay apoptosis causing accumulation of macrophage 
in lung tissue and airways of patients with COPD (Ravi et al., 2017). Several studies have 
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reported that the increased numbers of macrophages, in the airways, lung tissue, Bronchial-
alveolar Lavage (BAL) fluid and sputum of COPD patients is correlated with the severity of 
emphysema. Data indicate that in COPD patients, alveolar and monocyte-derived macrophages 
are more activated and release higher levels of inflammatory mediators, includes chemokines, 
cytokines and proteases, while their phagocytic ability and apoptotic activity is reduced (Barnes, 
2016).  
When stimulated by cigarette smoke, activated neutrophils and macrophages release 
several inflammatory mediators, including, IL-6, IL-10, TNF-α, CXCL1, IL8, monocyte 
chemoattractant protein 1 (CCL2), LTB4 and (reactive oxygen species) ROS, all of which cause 
membrane lipid peroxidation and alveolar epithelial injury. Macrophages also secrete CXCL9, 
CXCL10 and CXCL11, which are chemotactic for Tc1 and Th1 cells. Alveolar macrophages 
release proteinases, including the matrix metalloproteinases (MMPs) MMP-2, MMP-9 and 
MMP-12; cathepsins K, L and S; and NE (Barnes 2016). Macrophages also secrete IL-8 and 
LTB4, to stimulate neutrophils to release IL-8 and LTB4 to attract further neutrophils to the site 
of inflammation (Toraldo et al., 2013). 
Increased numbers of neutrophils have been found in the sputum and BAL fluid of COPD 
patients and correlate with the severity of the disease. The migration of neutrophils from 
circulation into the respiratory tract involved adhesion molecules, cytokines, and chemotactic 
mediators include, LTB4, CXCL1, CXCL2, CXCL3, CXCL5 and IL-8, released by epithelial 
cells, alveolar macrophages and T-cells. The levels of these chemotactic factors have been found 
to be elevated in the airways of COPD patients (Blidberg et al., 2013; Caramori et al., 2014). 
Like macrophages, neutrophils secrete serine proteases, including NE, cathepsin G, proteinase-3, 
MMP-8 and MMP-9, all of which may contribute to alveolar destruction.  
It is likely that airway neutrophilia is linked to mucus hypersecretion in chronic 
bronchitis, because neutrophil elastase (NE), cathepsin G, and proteinase-3 are potent stimulants 
of mucus secretion from submucosal glands and goblet cells. It is suggested that mucus 
hyperplasia is induced by epidermal growth factor receptors (EGFRs), which are activated by NE 
secreted by neutrophils, causing release of transforming growth factor alpha (TGF-α) (a ligand of 
EGFRs) (Barnes 2004; Rovina et al., 2013). Andelid et al. (2015) found that concentrations of 
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neutrophil and NE protein were higher in both smokers with COPD and in healthy smokers than 
in healthy non-smoker subjects. 
Increased eosinophil numbers have been observed in the airways and BAL fluid of 
patients with COPD. However, others studies have not reported the same observation in airway 
biopsy specimens, BAL fluid or sputum. Dendritic cells can activate various inflammatory 
immune cells, including macrophages, neutrophils and T and B-lymphocytes, and may play an 
important role in the lungs inflammation response to cigarette smoke and irritants. Dendritic cells 
are located near the surface in airways and lungs, and so can inspect the entry of inhaled 
substances. Studies have shown increased numbers of dendritic cells in the lungs of COPD 
patients (Barnes 2016).  
1.2.4.3 Adaptive Immunity Cells 
B-cells have been observed in the airways organized into small primary or secondary 
follicles, and also found scattered in the parenchyma. These follicles are notable in patients with 
severe COPD but less in healthy smokers (Brandsma et al., 2017). Increased numbers of 
neutrophils and B lymphocytes are usually associated with severe COPD (Caramori et al., 2014). 
Several studies have examined the phenotype of T lymphocyte in the alveolar wall as different 
populations of lymphocytes involved in alveolar enlargement and lung destruction in COPD 
(Borchers et al., 2007).  
T-cells progenitors originate in the bone marrow and develop in the thymus. The major 
families of T-cells express either CD4 or CD8 on their surface. Different immunologic stimuli 
trigger differentiation of naive CD4 T-cells via different developmental pathways give arise to 
different T-cell phenotypes subsets such as; T-helper 1 (Th1) and T-helper 2 (Th2) cells, T-
helper 17 (Th17) cells and regulatory T-cells (Tregs). All these phenotypes are involved in host 
defence in different pathological or disease states. Other subsets of T-cells include cytotoxic T 
(Tc) CD8 cells are involved in pathogen elimination (George, 2008; Lane et al., 2010; Calder 
2015).  Th1 cells are involved in host defence against intracellular pathogens by secreting IL-12, 
IFN-γ, macrophage inflammatory protein (MIP)-1α, and MIP-1β which mainly activate 
macrophages during inflammation. Th2 cells are involved in clearance of extracellular 
pathogens, eosinophilic inflammation, and secret IL-10, IL-5, IL-4, IL-9, IL-13, and IgE in 
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allergic reactions, and enhance antibody production by B-cells. Treg cells have anti-
inflammatory, immune-regulatory and suppressive effects and are involved in adaptive immune 
responses. Tregs are able to suppress CD4 and CD8 T-cells and can be further subdivided into 
natural Tregs, inducible Tregs, Th3 cells that produce TGF-β and type I regulatory cells.  
Another T-cell, the γδ T-cell, can suppress the proliferation of and cytokine production 
by activated effector T-cells (George, 2008; Lane et al., 2010; Profumo et al., 2012). Other 
subtypes, the Th17 and Th9 cells, are involved in inflammation and pathogenesis in autoimmune 
diseases (Jager and Kuchroo, 2010; Profumo et al., 2012). IL-17 (IL-17A), which is produced 
mainly by Th17 CD4 and Tc17 CD8 cells, activates the release of CXCL1, CXCL8 and GM-
CSF from airway epithelial cells and smooth-muscle cells (Caramori et al., 2014). One study has 
suggested that Th17 cytokines are involved in the pathogenesis of COPD, as the levels of IL-
17A, IL-17F and IL-17R were increased in epithelial cells and infiltrated cells in the sub-
epithelium of both the small and large airways of COPD patients than in healthy controls 
(Montalbano et al., 2015). 
Cigarette smoke can stimulate adaptive immune responses in the lungs of COPD patients, 
through the activation of Tc, Th1 and Th17 cells, alongside B-cell antibody production. CD8 T-
cells, that clear viral infections, have been shown to be present in increased numbers in the lungs 
of patients with COPD. However, they fail to protect against respiratory viral infection. A study 
by McKendry et al (2016) confirmed a dysregulation of CD8 T-cells responses to viral infection 
in the lungs of COPD patients, which may explain both their susceptibility to viral infection and 
exacerbations. CD8 T-cells activate and recruit macrophages via producing different chemokines 
and cytokines such as IFN-γ.  Further, CD8 T-cells are able to induce cytolysis and apoptosis of 
alveolar epithelial cells through release of proteolytic enzymes such as perforins, granzyme-B, 
and TNF-α causing cell death (Majo et al., 2001). Some studies documented that the number of 
CD8 T-cells is increased in lung parenchyma and airways of patients with COPD with late stages 
of airflow limitation and emphysema. These findings may suggest a possible role of CD8 T-cells 
in the pathogenesis of emphysema in patients with COPD (Finkelstein et al., 1995; Saetta et al., 
1999; Majo et al, 2001). Domagała-Kulawik et al (2011) also showed that the proportions of 
CD8 T-cells in the blood of COPD patients were significantly higher than in healthy subjects. 
CD8 T-cells belong to regulatory cells family and this observation adds another argument to the 
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hypothesis that the autoimmune reaction plays a role in the pathogenesis of COPD. In contrast to 
the previous result, another study found that the number of CD4 T-cells was lower in COPD 
compared to controls, while there was no difference between COPD and control in CD8 T-cell 
and monocyte number (Roberts et al., 2015). 
It is thought that CD8 T-cells in COPD mainly protect lung epithelial tissue after 
exposure to smoke or other irritants. While different cell types and tissue continue to accumulate 
this affect T-cells function causing an increase of inflammation. Motz and colleagues reported 
for the first time that cigarette smoke exposure leads to the generation of pathogenic T-cells 
capable of inducing COPD-like disease in mice. Transfer of CD3 T-cells from the lungs of 
cigarette smoke-exposed mice into Rag2
-/- 
recipients induce pulmonary changes pathognomonic 
of COPD included; monocyte/macrophage and neutrophil accumulation, increased expression of 
cytokines and chemokines, activation of proteases, apoptosis of alveolar epithelial cells, ECM 
degradation, and emphysema (Motz et al., 2010). The numbers of Th17 cells, which secrete IL-
17A and IL-22, are also increased in the airways of patients with COPD and might involve in 
neutrophilic inflammation (Barnes 2016). Natural killer (NK) T-cells, also found in increased 
numbers in COPD lungs, may drive alveolar cell apoptosis via lung epithelial cell NKGD2 
ligands (Borchers et al., 2009). The interaction between inflammatory immune and structural 
cells involved in inflammatory mechanisms of COPD is simplified in (Figure 1.8). 
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Figure ‎1.8: Inflammatory and immune cells involved in inflammatory mechanisms of 
COPD. Inhaled substances such as cigarette smoke and other irritants activate alveolar macrophages 
(derived from circulating monocytes and differentiate within the lung) and epithelial cells in the 
respiratory tract to secret growth factors such as TGF-β and FGFs, which stimulate fibroblast 
proliferation, resulting in fibrosis in the small airways. These cells also release the pro-inflammatory 
cytokines TNF-α, IL-1β, and IL-6, all of which amplify inflammation,  and several chemotactic factors 
that attract inflammatory cells to the lungs, including CC-chemokine ligand 2 (CCL2), which acts on CC-
chemokine receptor 2 (CCR2) to attract monocytes, CXC chemokine ligand 1 (CXCL1) and CXCL8, 
which attract neutrophils and monocytes (which differentiate into macrophages in the lungs) and CXCL9, 
CXCL10 and CXCL11, which act on CXCR3 to attract T helper 1 (Th1) cells and cytotoxic T-cells (Tc 
cells). These inflammatory cells together with macrophages and epithelial cells release proteases, such as 
matrix metalloproteinase 9 (MMP9), which cause elastin degradation and emphysema and stimulate 
mucus hypersecretion. Abbreviations: Gran, granzymes; Per, perforin; neutrophils elastase, NE; (TGF)-
β, transforming growth factor; FGF, fibroblast growth factors, CTGF, connective tissue growth factor; 
MMPs, matrix metalloproteinases; NKT, natural killer T cells; NK, natural killer cells (adapted and 
updated  from Barnes 2010; Tubby et al., 2011). 
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1.2.5 Pro-inflammatory Biomarkers in COPD 
As previously mentioned, various immune cells and lung structural cells secrete a variety 
of pro-inflammatory mediators, including cytokines, chemokines, growth factors and lipid 
mediators, which play an important role in COPD pathogenesis and inflammation. Studies of the 
pathogenic mechanisms of COPD and newer technologies have identified diagnostic biomarkers 
of disease activity, which can be considered therapeutic targets of COPD. A biomarker may be 
defined as an indicator of measurable characteristics of normal biologic processes, the 
progression or severity of a disease or response to treatment. Hence, biomarkers could help 
physicians design targeted therapies based on patient biomarker levels. However, to evaluate the 
clinical utility of biomarkers in treating COPD patient, further research is required (Khan and 
Daga, 2015; Chen et al., 2016). Several biomarkers involved in the pathophysiology and 
inflammatory process of COPD have been identified and measured, but little is known about 
their relationship to COPD development, progression and severity (Korani et al., 2016).  
It has been documented that various pulmonary and systemic inflammatory biomarkers 
including, TNF-α, IL-6, IL-8, IL-18, fibrinogen, acute phase proteins, including C-reactive 
protein (CRP), serum amyloid A (SAA) and surfactant protein (SP-D), are elevated in patients 
with COPD when compared with healthy subjects (Barnes 2010, Toraldo et al., 2013, Williams 
et al., 2016). Previous studies have identified specific biomarkers that may distinguish 
individuals with COPD from healthy subjects. These biomarkers include, lung-derived Clara cell 
protein-16 (CC16), SP-D, extracellular matrix breakdown markers; MMP-8 and -9, and systemic 
inflammatory biomarkers include; fibrinogen, CRP, and cytokines; IL-6 and IL-8, CCL-18 
(Pinto-Plata et al., 2007). Markers that have been investigated as potential indicators for COPD 
can be determined from different samples include sputum, exhaled breath condensate, BAL 
fluid, lung biopsies and blood (Comes et al., 2016).  
A three-year cohort study of 1,843 COPD patients investigated the associations between 
mortality and the levels of several biomarkers, including SP-D, IL-6, IL-8, CC16, TNF-α, 
fibrinogen and CRP. Elevated plasma fibrinogen levels were found to be associated with 
increased risk of exacerbations in COPD patients. The results suggested that using a panel of 
specific biomarkers rather than individual biomarkers helped to establish clinical variables to 
predict COPD mortality (Celli et al., 2012). Furthermore, Chen et al. (2016) conducted a 
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systematic review to evaluate biomarkers that might be involved in COPD. The review included 
59 studies, in which the most commonly studied biomarkers were CRP, IL-6 and TNF-α. The 
results showed that CRP levels were higher in COPD patients than in control subjects, while IL-6 
and TNF-α had variable results. The use of CRP as a biomarker was investigated in 28 of the 59 
screened studies, and 26 of those studies reported a significant increase in CRP concentration. In 
the same line, another study reported that serum levels of circulating CRP were significantly 
higher in COPD patients than in healthy subjects. CRP is an acute-phase protein synthesized 
mainly by the hepatocytes in response to tissue damage or inflammation (Korani et al., 2016). 
Also a study by Kleniewska et al. (2016) concluded that CRP and fibrinogen are important 
systemic biomarkers and that IL1-β, IL-6, TNF-α and MMP-9 could be considered local 
biomarkers of inflammation in the airways of COPD patients. 
Fibrinogen could be the most promising blood biomarker of COPD and has been 
considered for qualification as a drug-development tool by the US Food and Drug 
Administration (USFDA) and the European Medicines Agency (Duvoix et al., 2012). 
Fibrinogen, an acute-phase plasma glycoprotein, is synthesized in the liver and converted by 
thrombin into fibrin during blood coagulation. The normal range of blood fibrinogen level is 1.5‒
3.5 g/L but can increase three folds when stimulated by increased IL-6 production (Khan and 
Daga, 2015). Several studies have investigated the association between fibrinogen and the risk of 
developing COPD, its progression, severity and related mortality. A higher level of blood 
fibrinogen was reported in COPD patients when compared with healthy subjects (Mannino et al., 
2015). Duvoix et al. (2012) reviewed the association between fibrinogen and COPD and 
concluded that fibrinogen is associated with COPD severity but does not predict the decline of 
lung function. In addition, fibrinogen may help to identify COPD patients at high risk of 
mortality and those at risk of future exacerbations. Furthermore, a review of data from five 
COPD studies reported high fibrinogen levels in 44.7% of COPD patients. It has been suggested 
that fibrinogen level higher than 350 mg/dL may increase the risk of exacerbation and mortality 
(Mannino et al., 2015). 
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The level of pulmonary biomarkers has been shown to be different in patients with COPD 
when compared with healthy control. Lower levels of CC16 secreted by Clara cells have been 
observed in the serum of COPD patients. Clara cells are epithelial cells located in terminal 
bronchioles and are involved in airway regeneration and immune responses following injury. In 
addition, the expression of SP-D decreases in the lungs of COPD patients, while the level 
increases in the plasma. SP-D, which is located in the endoplasmic reticulum of type II 
pneumocytes and the secretory granules of Clara cells, is thought to be implicated in COPD 
pathogenesis, including ROS production and inflammatory responses in alveolar macrophages 
(Khan and Daga, 2015).  
Cytokines are small extra-cellular signalling glyco-proteins that regulate the growth, 
differentiation and function of cells related to immune system response and inflammation 
(Arican et al., 2005). TNF-α is secreted by various structural and immune cells, including 
epithelial cells, macrophages, T lymphocytes and airway smooth-muscle cells, in response to 
pathogenic infection and during autoimmune response (Himmerich et al., 2006). TNF-α is 
involved in the pathogenesis of COPD by stimulating and releasing various pro-inflammatory 
mediators that cause tissue damage and remodelling. Serum levels of TNF-α is significantly 
higher in COPD patients than in healthy subjects (Korani et al., 2016). Furthermore, Selvarajah 
et al. (2016) found increased levels of TNF-α and IL-1β in the serum of COPD patients (GOLD 
stages A–C) and in some healthy smokers and healthy non-smokers. The levels of IL-1β are 
elevated in the sputum, BAL and serum of patients with stable COPD (Caramori et al., 2014).  
Another study confirmed that COPD patients had higher sputum concentrations of IL-6 
and IL-1β. IL-6 strongly triggers CRP production in the liver, and increased IL-6 plasma levels 
are associated with increased CRP levels in COPD patients. IL-6 levels in both the plasma and 
sputum of patients with stable COPD are higher than in controls (Caramori et al., 2014). 
Several CXC chemokines involved in recruiting inflammatory cells from the circulation 
to the lungs are elevated in COPD patients. IL-8 levels were found to be elevated in the induced 
sputum of patients with COPD, and this elevation was correlated with disease severity and 
increased further during exacerbations. In line with this observation, CXCL1 levels were found 
to be highly elevated in the sputum and BAL fluid of COPD patients, while CXCL5 expression 
was found to be increased in the airway epithelial cells during COPD exacerbations (Caramori et 
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al., 2014). Inflammasomes are multimeric cytoplasmic protein signalling complexes that regulate 
the expression of the pro-inflammatory cytokines IL-1β, IL-18 and IL-33 in response to various 
irritants, causing neutrophilic inflammation. NLRP3 inflammasomes have been found to be 
activated in patients with inflammatory lung diseases, especially during acute exacerbations, in 
response to invading pathogens, oxidative stress and ATP (Barnes, 2016). However, no increases 
in NLRP3 inflammasomes were found in patients with stable COPD, and only small increases 
were found in patients with severe COPD (Caramori et al., 2014).  
Human plasma and serum samples are widely used in clinical and biological studies. 
Plasma sample is the predominant biological sample to assess health and disease in clinical 
settings and in most of clinical trials (Yu et al., 2011). Serum is obtained from blood that has 
coagulated. During coagulation Fibrin clot formation removes proteins (e.g., fibrinogen) from 
the blood sample along with blood cells and related coagulation factors, which are separated 
from serum by centrifugation after blood collection. During this process, activated platelets 
release proteins include; proinflammatory cytokines and various metabolites into the serum, 
which can alter the biomarkers levels relative to plasma (Yu et al, 2011; O’Neal et al., 2014). 
Previous studies investigated the advantage of using plasma sample over serum. For 
examples, the concentrations analysis data of 163 metabolites in plasma and serum samples 
collected from 377 fasting individuals indicating good reproducibility in both matrices, and 
significantly better stability of plasma compared to serum (Yu et al., 2011). In the same line, a 
pilot study was performed in 24 COPD patients comparing serum, Ethylenediaminetetraacetic 
acid (EDTA) plasma, and EDTA plasma with proteinase inhibitors (P100™), to determine the 
most reliable sample type for measuring blood biomarkers in COPD cohort. Several biomarkers 
candidate involved COPD pathogenesis has different values in plasma and serum (e.g., 
fibrinogen, MMPs, and cytokines).The study results concluded that using serum and plasma 
were similar for most measured markers, with few exceptions include fibrinogen and 
MMP2.There was no difference in mean markers levels between EDTA plasma and P100 
plasma. These results suggesting that platelet activation alters concentrations of many 
biomarkers which in turn increase serum values, relative to plasma, for factors that are released 
from platelets or leukocytes during clotting. On the other hand, serum values decrease, relative to 
plasma, for factors that localized in clots (O’Neal et al., 2014). In the current study plasma 
  
27 
 
sample was preferred over serum because it can be separated immediately after blood collection, 
thus minimizing potential changes that may occur ex vivo. In addition, coagulation process 
consumes all blood clotting factors, and release biomarkers from platelets or leukocytes which 
makes serum unsuitable in measuring many biomarkers (Dakappagari et al., 2017). The 
variations of different biomarkers levels and age between patients with COPD and healthy 
controls from previous studies are summarised in (Table 1.2). In most of those studies COPD 
patients’ age is matching the healthy controls age. Thus variability in biomarkers level between 
patients and healthy subjects is not related to age. 
Table ‎1.2: Variations of biomarkers levels between patients with COPD and healthy 
controls from previous studies. 
Marker Proposed 
Pathophysiological 
role 
Sample Concentration 
in COPD 
Age 
Concentration  
in control 
Age 
Reference 
IL-6  
pg/ml 
Inflammatory cytokine Serum 
 
 
 
1.5 [0.8-3.1] 
40–75 yrs 
0.4 [0.2-0.9] 
40–75 yrs 
Agusti et al., 
2012 
14.016 ± 3.018 
[6.6-17.8]  
21- 77 yrs 
3.030 ± 1.076 
[1.9-5]  
18 - 68 yrs 
El-Shimy et 
al., 2014 
39.21±27.34 
73.1±13.0 yrs 
23.41±12.86 
74.5±7.9 yrs 
Wang et al., 
2014 
1.4 [0.42-2.1] 
66 (57-73) yrs 
 
0 Queiroz et al., 
2016 
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IL-8  
pg/ml 
Inflammatory 
chemokine 
 
 
Serum 
 
 
6.9 [3.2-13.3] 
40–75 yrs 
4.3 [2.3-7.2] 
40–75 yrs 
Agusti et al., 
2012 
47.12±30.00 
 
73.1±13.0 yrs 
21.70±18.61 
 
74.5±7.9 yrs 
 
Wang et al., 
2014 
10.57±0.55 
72 ± 4.7 yrs 
NA Liu et al., 
2014 
146.43 ± 28.52 
[64.8–188] 
21- 77 yrs 
36.2 ± 6.33 [25–
44] 
18 - 68 yrs 
El-Shimy et 
al., 2014 
 
6.0 
70.8±8.1 yrs 
 
 
5.5 
59.0±10.2 yrs 
 
 Ishikawa et 
al., 2015 
[0-57.5] 
 
66 (57-73) yrs 
0 
Queiroz et al., 
2016 
Fibrinogen 
mg/dl 
Blood coagulation 
factor  
Plasma 448.0 
[388.-517] 
40–75 yrs 
369.0 
[326-432] 
40–75 yrs 
Agusti et al., 
2012 
g/L 5.09±1.86 
 62.29± 7 yrs 
2.07±0.57 
62.29± 7 yrs 
Fattouh and 
AlKady 2014 
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Fibrinogen 
mg/dl 
Blood coagulation factor plasma 445 [387-512] 
63 (7) yrs 
NA Müllerova et al., 
2015 
300.0 
70.8±8.1 yrs 
289.0 
59.0±10.2 yrs 
Ishikawa et al., 
2015 
μg/ml  
 
Plasma 2,992 
[2,550-3,965] 
62 (50-71) yrs 
3,135 
[2,730-3,597] 
55 (51-64) yrs 
Akiki et al., 2016 
mg/dl 250.87 162.7 Thomas and 
Yuvarajan 2016 
CRP  
mg/L 
  
Acute phase reactants 
 
 
 
 
 
 
 
 
Serum 4.82 ± 1.97 
54 ± 7.58 yrs 
0.88 ±0.48 
53 ± 8.68 yrs 
Agarwal et al., 
2013 
39.46 
54 ± 7.58 yrs 
 
4.2 
53± 8.68 yrs 
Fattouh and Al-
kady 2014 
7.50±5.46 
73.1±13.0 yrs 
3.86±3.75 
74.5±7.9 yrs 
Wang et al., 
2014 
Plasma 
 
3.4 [1.7-8.5] 
63 ± 8 yrs 
0.6 [0.1-0.9] 
58 ± 5.9 yrs 
Gopal et al., 
2014 
3.2 [1.6-7.1] 
63 (7) yrs 
NA Müllerova et al., 
2015 
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CRP 
ng/ml 
 
 Serum 
 
594.0 
70±8.1 yrs 
327.0 
59±10.2 yrs 
Ishikawa et al., 
2015 
8.41 
[3.48-14.3] 
62 (50-71) yrs 
9.72 
[4.37-15.5] 
55 (51-64) yrs 
Akiki et al., 2016 
µg/ml 3.74± 0.20 
53.9± 5.95 yrs 
1.30 ±0.14 
49.37±14.37 
yrs 
Korani et al., 
2016 
TNF-α 
pg/ml 
 
 
 
 
 
 
 
 
 
 
 
 
Inflammatory cytokine 
 
 
 
 
 
 
 
 
Serum 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.35 
[2.35-7.80] 
40–75 yrs 
2.35 
[2.35-2.35] 
40–75 yrs 
Agusti et al., 
2012 
 
112.7±80.20 
73.1±13.0 yrs 
 
73.46±50.44 
74.5±7.9 yrs 
Wang et al., 
2014 
3.16±0.77 
72 ± 4.7 yrs 
 
NA Liu et al., 2014 
43.833 ± 10.53  
[30.22–74.4] 
21- 77 yrs 
18.52 ± 4.028  
[12.2–24.2] 
18 - 68 yrs 
El-Shimy et al., 
2014 
35.88± 5.97 
53.9± 5.95 yrs 
8.79 ±0.57 
49.37±14.37 
yrs 
Korani et al., 
2016 
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TNF-α  
pg/ml 
 
Serum 
2.9 
[0.95-6.03] 
66 (57-73) yrs 
0.35 
[0-1.9] 
Queiroz et 
al.,2016 
CCL18/ 
PARC 
ng/ml 
 
Lung-inflammatory 
protein 
Chemokine/lymphocytes 
 
Serum 105 
63 (7) yrs 
80 
54 (9) yrs 
Sin et al., 2011 
Plasma 105 [82-136] 
63 (7) yrs 
NA Müllerova et al., 
2015 
IP10/ 
CXCL-10  
Inflammatory chemokine 
 
Serum 149.4 
[103-215] 
72.6 yrs 
111.7 
[82-178] 
67.4 yrs 
Quint et al., 2010 
CC16 
ng/ml 
 
 
Lung inflammatory protein 
 
 
Serum 
 
 
 
4.9 
64.5 (6.0) yrs 
 
6.4   
59.7 (8.8) yrs 
Lomas et al., 
2008 
8.5 
70.8±8.1  
yrs 
5.6 
59.0±10.2 yrs 
Ishikawa et al., 
2015 
7.29 
71.7 (8.23) yrs 
NA Labonté et al., 
2016 
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SP-D 
ng/ml 
 
 
 
 
 
 
 
Pulmonary protein 
involved in innate 
immunity 
 
 
 
 
 
 
Serum 
 
 
 
 
 
Sputum 
Serum 
 
 
 
 
Sputum 
Serum 
121.1 
[84.9–174.2] 
63.4±7.2 yrs 
82.2 
[56.1–117.7] 
53.2±8.6 yrs 
Lomas et al., 
2009 
138.07 
40–75 yrs 
NA Agusti et al., 
2012 
 
45.46±37.78 
173.23±186.93 
72 ± 4.7 yrs 
 
31.68±12.04 
89.59±70.29 
44 ± 8.5 yrs 
 
Liu et al., 2014 
 
 
 
 
 
59.6 
36.7 
70±8.1 yrs 
 
45.5 
21.1 
59±10.2 yrs 
 
Ishikawa et al., 
2015 
155.175 NA Doubková et al., 
2015 
1,510 
[986-2,174] 
62 (50-71) yrs 
1,269 
[664-1884] 
55 (51-64) yrs 
Akiki et al., 
2016 
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sRAGE  
pg/ml 
Pro-inflammatory 
recognition receptor of 
cell surface 
Plasma 
 
 
 
 
 
Sputum 
1351 
63.6 ± 6.9 yrs 
1797 
53.8 ± 8.9 yrs 
Cheng et al., 
2013 
512 
63 ± 8 yrs 
2531 
58 ± 5.9 yrs 
Gopal et al., 
2014 
500  
[300-900] 
5400 
[2800–5450] 
42.73 ± 6.26 yrs 
400  
[300-800] 
3630 
[2530–4550] 
37.29±4.46 yrs 
Hassanein et al., 
2016 
Data expressed as mean, mean ± standard deviation or mean [range]. Definition of abbreviations: IL-6, 
Interleukin-6; IL-8, Interleukin-8; TNF-α,Tumor necrosis factor;  CRP, creative reactive protein; CC16, 
clara cells 16; CCL18, Chemokine (C-C motif) ligand 18; CD31, cluster of differentiation 31; SP-D, 
Surfactant protein D; IP10, Interferon gamma-induced protein 10; sRAGE, Soluble receptor for 
advanced glycation end products. 
 
Findings of elevated levels of a cytokine or chemokine in COPD do not guarantee that 
blocking their actions will be effective as an anti-inflammatory therapy. Furthermore, although 
anti-cytokine trials were effective in animal models of the disease, inhibiting these mediators was 
not effective in clinical trials in human subjects with COPD. Some studies have reported that 
using antibodies to block IL-1β and IL-8 were not successful in treating COPD. In line with that, 
anti-TNF therapies were also ineffective in treating COPD and may increase the risk of infection 
and many side effects. For example, treatment with infliximab for six months showed no clinical 
benefit, with increased risk of lung cancer and pneumonia being observed (Caramori et al., 
2014).  
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Cytokines are not disease-specific biomarkers, as their levels may increase for various 
reasons, including inflammation, infection and autoimmunity. Therefore, cytokine levels may 
also be elevated in some healthy non-smokers as well as smokers and COPD patients, making it 
difficult to identify cytokines that are COPD-specific biomarkers. In summary, biomarkers could 
be used as factors predictive of the severity of inflammation in COPD patients, as their increase 
may indicate inflammation. However, many of these biomarkers are variable in stable COPD and 
are not appropriate to use when diagnosing or predicting the disease. In addition, some 
circulating cytokines have been found to be increased in combination but not individually 
(Selvarajah et al., 2016). The challenge is to determine whether all these biomarkers individually 
or in combination are useful in clinical practice. In addition, a clinically useful biomarker must 
be reproducible in stable disease, as are fibrinogen, SP-D and CC-16. Lack of reproducibility 
may limit the use of other biomarkers, including CCL18, CRP, IL-6 and IL-8 (Duvoix et al., 
2012). Therefore, the search continues for a single biomarker or combination of them that is 
viable for use in individual patients. 
In COPD patients, various growth factors enhance the differentiation and survival of 
inflammatory cells and structural cells, causing airway remodelling. For example, GM-CSF, 
which is secreted by macrophages, epithelial cells and T-cells in response to inflammation, 
stimulates the differentiation and survival of macrophages and neutrophils. In addition, TGF-β 
and fibroblast growth factors (FGFs) induce proliferation of fibroblasts and airway smooth-
muscle cells, causing fibrosis of the small airways (Barnes, 2009). There is an increase in pro-
inflammatory lipid mediator prostaglandins, PGE2 and PGF2α, and LTB4 levels in exhaled 
breath condensates of patients with COPD. LTB4 concentration is also increased in induced 
sputum (Barnes 2016). 
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1.2.6 Treatment 
Early diagnosis of COPD is recommended as lack of awareness and knowledge from 
patients with COPD leads to delayed diagnosis and medical treatment, especially in non-smoking 
individuals (Novgorodtseva et al., 2013; Dixon et al., 2016). To improve the health of COPD 
patients, smoking must be stopped and exposure to environmental and occupational risk factors 
must be reduced. In addition, yearly influenza vaccinations are recommended. Current treatments 
available for COPD include bronchodilator medications, corticosteroids, long-term oxygen 
therapy and pulmonary rehabilitation. The main corticosteroids and inhaled bronchodilators 
include improved long-acting β2-adrenergic receptor agonists, long-acting anticholinergics, 
theophylline and a combination of one or more of these. In addition, the phosphodiesterase-4 
inhibitor roflumilast decreases exacerbations in patients with severe airflow obstruction and 
chronic bronchitis. Novel therapies targeting systemic inflammation and oxidative stress include 
combination of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
statins, antioxidants and omega-3 PUFAs still under investigation (Williams et al., 2016). In a 
few severe cases of COPD, surgery, including lung transplantation and lung-volume reduction, 
may be recommended.  
Current treatments may decrease the frequency and severity of exacerbations and 
increase exercise capacity but are expensive and associated with side effects. While the global 
therapies cost for COPD exceeds $44 billion per year, these therapies still do not completely 
prevent symptoms, stop disease progression or systemic inflammation, reduce mortality or slow 
the long-term decline in lung function. Therefore, an effective, safe, affordable, therapy is 
needed to manage the progression of COPD and prevent exacerbations, thereby providing 
significant health and economic benefits (Meng et al., 2016; Kunnumakkara et al., 2018). 
Therefore, it is necessary to target specific inflammatory mediators or cytokines to block the 
inflammatory and remodelling processes. However, developing such COPD therapies continues 
to be a challenge because of the heterogeneity of the disease, as the symptoms not reflect 
specifically the biological process of the disease phenotype, and the lack of disease-specific 
biomarkers. (Decramer et al, 2012; Caramori et al., 2014; Roberts et al., 2015; Sin et al., 2015; 
Williams et al., 2016).  
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There is a need for a novel and accurate diagnostic test that would lead to early diagnosis 
to differentiate COPD from other respiratory diseases, to monitor disease progression, to predict 
exacerbation, to establish correct treatment to improve symptoms, quality of life and to avoid 
unnecessary hospital admissions (Comes et al., 2016, Dixon et al., 2016). Several studies have 
focused on improving dietary intake, which could slow COPD progression and improve 
management. In addition, many observational and experimental studies have evaluated dietary 
intake of individual nutrients throughout disease stages to clarify their role in the disease 
(Berthon and Wood, 2015). The next section focuses on the role of omega-3 PUFAs in COPD. 
 
1.3 Polyunsaturated Fatty Acids  
1.3.1 Biological Effects and Metabolic Functions  
PUFAs are the structural components of the phospholipids of all biological cells 
membranes and the substrates for eicosanoid synthesis (Liu et al., 2014). The length and degree 
of unsaturated fatty acids in membrane phospholipids are significant (Ristić-medić et al., 2013). 
Any changes in the fatty acids composition of the cell membranes may alter membrane fluidity, 
activities, including formation of lipid rafts, the permeability and transportation of membrane-
bound enzymes and the function of receptors. In addition, changes in composition affect cell-
signalling pathways, which may alter the activity of transcription factors, gene expression and 
most of the functions of immune system cells, including secretion, chemotaxis and sensitivity to 
microorganisms (Calder 2012; Novgorodtseva et al., 2013; Wald et al., 2014). PUFAs play an 
important role in regulating inflammatory processes and responses, and the balance between 
omega-3 and -6 PUFAs may play an important role in the progression and severity of 
inflammatory responses (Calder 2007). It suggested that chronic respiratory disease development 
is associated with disruption of the fatty acid composition in erythrocyte membranes and in the 
ratio between precursors of pro- and anti-inflammatory eicosanoids (Novgorodtseva et al, 2013). 
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Omega-6 fatty acid, linoleic acid (LA), and omega-3, α-linolenic acid (ALA), are 
essential fatty acids that the human body cannot synthesize and must obtain from the diet (Ristić-
medić et al., 2013). These essential fatty acids are absorbed by intestinal cells and then 
transported to the liver, to be metabolized via desaturation and/or elongation reactions to 
generate the long chains of the omega-3 and -6 PUFA families (Giudetti and Cagnazzo, 2012). 
Omega-3 and -6 PUFAs are recognised depending on the position of the first double bond from 
the methyl group end (Matsuyama et al., 2005). The omega-6 PUFAs include arachidonic acid 
(ARA), and the omega-3 PUFAs (also known as n-3 or ω-3) include eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA), a-linolenic acid (ALA), and docosapentaenoic acid 
(DPA) (Khorsan et al., 2014). Omega-3 fatty acids are an important family of PUFAs and 
involved in normal growth and development of various human tissues. EPA has 20 carbon atoms 
and 5 double bonds (20:5n-3). DHA has a chain with 22 carbon atoms and 6 double bounds 
(22:6n-3) (Figure 1.9) (Calder 2015). 
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Figure ‎1.9: Outline of the metabolic pathway of biosynthesis omega-3 fatty acids. DHA, 
docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid (Calder 2015). 
 
LA can be found in green leaves, various seeds and vegetable oils, including corn, 
sunflower, soybean, grapeseed and walnut. Omega-3 PUFAs like DHA and EPA are present in 
lean fish (cod), oily fish (salmon, tuna, mackerel, herring and sardine), other seafood, range-fed 
poultry, eggs and farm animals. Lean fish store lipids in their livers, while oily fish store lipids in 
their flesh. Other less biologically potent FAs include ALA found in green plant tissues, 
vegetable oils, including soybean, rapeseed, walnuts, canola oil, and flaxseed and linseed 
(Calder, 2012; Khorsan et al., 2014). 
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Several studies investigated the significance of the omega-6 to omega-3 fatty acid ratio in 
chronic inflammatory diseases. The ratio of omega-6 PUFA in the western diet has increased 
significantly compared to previous decades. The current western diet has a ratio of omega-6 to -3 
PUFAs that ranges from 20‒25/1, up from 1/1 (Mansara et al., 2015). Current studies 
recommended that lower intake of omega-6 compared to greater intake of omega-3 fatty acids 
may reduce the risk of many chronic inflammatory diseases; include CVD, inflammatory bowel 
disease, cancer, and rheumatoid arthritis. A lower omega-6 to omega-3 PUFAs ratio diet has 
been recommended in order to reduce the formation of pro-inflammatory eicosanoids from 
omega-6 PUFAs and to increase the production of anti-inflammatory mediators from omega-3 
PUFAs. The PUFA profiles in patients could be changed through consumption. A diet 
supplemented with omega-3 PUFAs partially replace omega-6 PUFAs in the cell membranes of 
erythrocytes, platelets, monocytes, lymphocytes and granulocytes, and colon, and hepatic cells 
(Ristić-medić et al., 2013; Khorsan et al., 2014). Thus, the fatty acid composition of human 
inflammatory cells influences the function of those cells (Calder, 2015). 
 
1.3.2 The role of PUFAs in Inflammation  
In Western diets the human cell membrane is typically rich in Omega-6 PUFA; ARA, 
which is the major substrate for the biosynthesis of the eicosanoid, a class of pro-inflammatory 
mediators, including, prostaglandin, thromboxanes, and leukotrienes. Eicosanoids are generated 
from ARA via the action of cyclooxygenase (prostaglandins, thromboxanes), lipoxygenase 
(leukotrienes) and/or cytochrome P450 pathways. These pro-inflammatory mediators are 
involved in regulation of inflammation, immunity, platelet aggregation, and smooth muscle 
contraction. However, excess production of eicosanoids from ARA may play a crucial role in the 
development of COPD, particularly in the recruitment of inflammatory cells in the airways, the 
regulation of vascular and bronchial tone and the development of oxidative stress which result in 
lipid peroxidation (Calder, 2014; Antus and Kardos, 2015). 
ARA can be replaced through oral administration of the omega-3 PUFAs; EPA and 
DHA, causing decreased production of eicosanoid pro-inflammatory mediators, and an increase 
in proportions of EPA and DHA in inflammatory cells. The effect of omega-3 fatty acids on 
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inflammatory cell responses, and on inflammatory processes, involves various mechanisms 
include modified cell membrane phospholipid fatty acid composition, alteration of lipid rafts, 
inhibition of activation of the pro-inflammatory transcription factor NF-κB so reducing 
expression of inflammatory genes, and activation of the anti-inflammatory transcription factor 
NR1C3 include; peroxisome proliferator activated receptor ɣ (PPAR-γ) (Calder, 2012; Calder, 
2015).  
In healthy subjects, dietary supplementation with omega-3 PUFAs has been associated 
with reduced levels of IL-1, thromboxane 2 and prostaglandin E2 and down-regulated expression 
of TGF-β (Ristić-medić et al., 2013). Furthermore, omega-3 PUFAs attenuated the ability of 
immune system inflammatory cells to produce several inflammatory cytokines; IL-1, IL-6, IL-8 
and TNF-α in healthy subject and rheumatoid arthritis patients (Matsuyama et al., 2005). The 
decrease of the inflammatory cytokines production may occur indirectly by altering the 
transcription-factor activation of various inflammatory genes. Thus, omega-3 PUFAs were 
investigated in many studies as therapeutic options in various chronic inflammatory diseases 
(Calder, 2015).  
1.3.3 Epidemiological and Clinical Studies of Omega-3 PUFAs in COPD 
The omega-3 PUFAs are involved in several human metabolic processes and considered 
as important components of cell membranes (Scaglia et al., 2016). Diets enriched with high 
amounts of omega-3 PUFAs have been shown to be beneficial in treating autoimmune diseases 
and inflammatory diseases, including rheumatoid arthritis (Miles and Calder 2012), CVD 
(Calder, 2017), neurological diseases, Crohn’s disease, and may benefit COPD patients (Calder, 
2012). Omega-3 PUFAs are beneficial in several inflammatory lung conditions including asthma 
(Miyata and Arita 2015), and COPD (Liu et al., 2014; Williams et al., 2016; Calder, 2018). In 
patients with COPD, a low omega-3 PUFA intake or conversion might be considered as a risk 
factor for chronic inflammation, and lung functional decline, through a variety of mechanisms, 
including cell surface and intracellular receptors, that control inflammatory cell signalling and 
gene expression (Atlantis and Cochrane 2016). There is support for this notion from a number of 
epidemiological and observational studies that have investigated the effects of omega-3 PUFAs 
on lung inflammation and COPD (Wood, 2015). In addition, experimental studies have shown 
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that higher intake of omega-3 PUFAs improves the immune system and may play a protective 
role in preventing and managing COPD (Toraldo et al., 2013; Wald et al., 2014).  
Fan et al. (2003) published the first study describing the correlation between dietary 
omega-3 PUFAs and T-cells. Their findings indicated that omega-3 PUFAs modulated the fatty 
acids composition of T-cell membranes and thus may influence the signalling pathway and 
modulate T-cells activation in vivo. Matsuyama et al. (2005) examined the effect of omega-3 
PUFAs on COPD patients. Their study investigated the l e v e l  o f  inflammatory mediators in 
64 COPD patients over two years. Patients were divided into two groups, each of which received 
a supplement. The first group received omega-3 PUFAs, and the second group received 
omega-6 PUFAs. The results showed that in those receiving the supplement rich in omega-3 
PUFAs, LTB4 levels in the serum and sputum decreased significantly, as did TNF-α and IL-8 
levels in the sputum. There was no significant change in the omega-6 PUFA-rich supplement 
group. This result indicated that diets supplemented with omega-3 PUFAs significantly 
decreased selected cytokine levels in COPD patients. Further, a longitudinal study published 
by Varraso et al. (2015) examined the effect of omega-3 PUFA intake from 1984–2000 on the 
risk of developing COPD. The study included 120,175 women and men. The results indicated 
that increased fish intake was inversely associated with the risk of COPD. Nordgren et al. (2014) 
examined whether dietary DHA supplementation could reduce the airway inflammation caused 
by organic dust exposure (ODE). They used DHA-treated human bronchial epithelial cells, lung 
fibroblasts, monocyte cell cultures, murine lung slices and an animal model in an in-vivo study. 
The results showed that DHA pre-treatment decreased production of ODE-induced inflammatory 
cytokines (IL-6 and TNF-α) dose-dependently. Collectively, these data demonstrate that DHA 
affects several types of lung cells to reduce airway inflammation and may be considered a 
therapeutic strategy for doing so.  
Omegas-3 PUFAs down-regulate the production of pro-inflammatory cytokines from 
monocytes and macrophages, decrease the expression of cellular adhesion molecules on 
monocytes and endothelial cells and reduce production of ROS in neutrophils (Berthon and 
Wood, 2015). It has been suggested that DHA and EPA are able to inhibit the activation of 
transcription factor NF-κB, consequently reducing the transcription of a number of inflammatory 
cytokines and chemokines. NFκB is involved in inducing the expression of inflammatory genes 
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encoding several cytokines, adhesion molecules, MMPs, COX-2, TNF-α, IL-1β, IL-6 and 
inducible NO synthase in response to inflammatory stimuli. In addition, EPA and DHA have 
been reported to decrease the production of the pro-inflammatory lipid mediators, prostaglandin 
E2 and LTB4 (Calder, 2012). EPA and DHA significantly decreased MMP-9 production and 
activity in PBMCs from healthy controls (Shinto et al., 2011). Yan et al. (2013) reported that the 
omega-3 PUFAs DHA and EPA exerted an anti-inflammatory effect by inhibiting activation of 
the NLRP3 inflammasomes, which prevented subsequent caspase-1 activation and IL-1β 
secretion. Another study reported increased levels of IL-10, an anti-inflammatory cytokine that 
inhibits the synthesis of many pro-inflammatory cytokines, when monocytes were treated with 
EPA and DHA. However, treatment did not affect levels of TNF-α and IL-6 (Jaudszus et al., 
2013). From all these data, it may be concluded that omega-3 PUFAs have anti-inflammatory 
effects and can decrease production of inflammatory markers associated with COPD progression. 
As mentioned earlier, cigarette smoke activates the ROS-sensitive MAPKs/NFκB 
signalling pathway, resulting in lung inﬂammation. Liu et al. (2014) confirmed that EPA 
possesses anti-inflammatory and anti-oxidant properties. They used a murine model and primary 
human bronchial epithelial cells to determine the effect of EPA. Their in-vivo and in-vitro 
observations confirmed that events induced by cigarette smoke were inhibited by either pre-
treatment or daily supplementation with EPA. These data confirmed that dietary antioxidant 
therapies targeting oxidative stress should help to improve lung inflammation induced by 
cigarette smoke. Another study investigated the effect of a novel anti-inflammatory intervention 
that included antioxidants, statins, omega-3 PUFAs; DHA and EPA, and lycopene on airway and 
systemic inflammation in COPD. The results confirmed that statins, omega-3 PUFAs and 
lycopene may have some anti-inflammatory effects systemically and that omega-3 PUFAs 
decreased expression of the leukotriene B4 receptor (LTB4R) gene and systemically increased 
levels of CXCL10. However, one limitation of that study is that it does not confirm whether the 
anti-inflammatory effects seen are from the combined use of rosuvastatin, lycopene and, omega-
3 PUFAs or whether they are an effect of long term statin use or just an effect of lycopene and, 
omega-3 PUFAs supplementation (Williams et al., 2016).  
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Several recent studies have linked higher blood levels of omega-3 PUFA and/or diet enriched 
with omega-3 PUFAs with higher longevity. For instant, Japanese are among the longest lived 
populations, have very high omega-3 PUFA levels. In 2004, the level of EPA and DHA in red 
blood cell (RBC) membrane was defined as the omega-3 index. It reflects the sum of the 
percentages of EPA and DHA measured in RBC cell membrane to total fatty acids content.  The 
omega-3 index is considered a marker of PUFA status. The recommended value of 8% or more 
of the total PUFAs probably prevents CVD in western populations. However, if the index value 
is lower than 4 %, there is an increased risk of mortality due to cardiovascular events. The 
question of whether increased intakes of EPA and DHA will prolong life remains unclear, as 
observational studies cannot confirm whether higher Omega-3 index will lower risk for death.  
Unfortunately, omega-3 index role has not been studied in other diseases (Scaglia et al., 2016; 
Harris et al., 2017). 
1.3.4 Omega-3 PUFAs Metabolites 
Resolution of the inflammation process is mediated by several endogenous pro-resolving 
lipid metabolites, and the entire system is balanced between pro-inflammatory and pro-resolving 
pathways. Several studies have reported that lipid mediators in the lungs may be involved in 
resolving lung inflammation. These pro-resolving lipid mediators are generated by the 
metabolism of PUFAs via several enzymatic reactions involving the cyclo-oxygenase and 
lipoxygenase and/or cytochrome P450 pathways. The anti-inflammatory and pro-resolving 
effects of omega-3 lipid metabolites, including resolvins, protectins and maresin, have been 
observed in a variety of pre-clinical model studies, including those in cells, tissues and animal 
models (Hsiao et al., 2013). In contrast, lipid metabolites that derive from omega-6 PUFAs, 
including prostaglandins and leukotrienes, act as pro-inflammatory mediators (Figure 1.10 and 
1.11) (Miyata and Arita, 2015). These metabolites often termed oxylipins to cover several 
metabolites originating PUFAs (Schunck et al., 2018). Omega-3 oxylipins display 
cardioprotective, anti-inflammatory, and anti-allergic properties that contribute to the beneficial 
effects of omega-3 PUFAs in different disease conditions. Include renal fibrosis (Sharma et al., 
2016), asthma and airway inflammatory diseases (Mochimaru et al., 2018). 
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Figure ‎1.10: Outline of the pathway of Omega-3 fatty acids and bioactive metabolites 
biosynthesis from ALA. Metabolism of eicosapentaenoic acid (EPA, C20:5, n-3) by COX-2 in 
combination with aspirin generates resolvins of the E series, which have pro-resolving activity. EPA 
conversion to DHA occur in multiple steps involving elongation, 6 desaturation, and -oxidation. DHA 
metabolism by LOX and COX in combination with aspirin generates resolvins and protectins of the D 
series. Abbreviations: ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, Eicosapentaenoic Acid; 
COX, cyclooxygenase; LOX, lipoxygenase (adapted and updated from Giudetti and Cagnazzo 2012). 
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Figure ‎1.11: The biosynthesis of pro-resolving lipid metabolites. Omega-6 FAs arachidonic acid 
is a metabolic precursor to eicosanoids (prostaglandins and leukotrienes), that act as pro-inflammatory 
mediators. Omega-3 FAs are converted to resolvins and protectins with anti-inflammatory and pro-
resolving Properties (Miyata and Arita, 2015). 
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Several in-vivo studies have reported that resolvin E1, resolvin D1 and protectin D1 
inhibit the trans-endothelial migration of neutrophils, thereby preventing neutrophilic influx to 
the site of inflammation, and also enhance neutrophil removal by macrophage efferocytosis, 
increase phagocytic capacities, promote neutrophil clearance across the lung mucosa, and 
enhance wound healing. Defective macrophage efferocytosis in COPD patients may prevent the 
resolution of inflammation. In addition, these lipid mediators can increase lung resistance to 
infection during injury and decrease production of inflammatory cytokines induced by cigarette 
smoke (Nordgren et al., 2013; Barnes, 2016). It have been reported that the  biosynthesis of anti-
inflammatory lipid mediators, lipoxin A4 or protectin D1, are dysregulated in severe asthma, 
suggesting that chronic inflammation in the lung might result from an imbalance between pro- 
and anti-inflammatory molecule (Miyata and Arita, 2015). 
The intravenous administration of protectin D1 in a murine model decreased the number of 
inflammatory cells in mucus and BAL fluid and inhibited airway hyper-responsiveness. Protectin 
D1also inhibited TNF-α and IL-1β production and appeared to be involved in protecting tissue 
from damage (Serhan et al., 2008, Serhan et al., 2010). Resolvin D1 also has shown anti-
inflammatory effects. Its intravenous administration decreased IL-5 production, inhibited IL-1β 
and mucus production and eosinophil accumulation in the airways. In addition, resolvin D1 
enhanced phagocytosis in vitro and clearance of inflammatory apoptotic cells in the airway 
(Miyata and Arita, 2015). Furthermore, it promoted resolution of airway inflammation in mice 
caused by either acute lung injury or cigarette smoke (Hsiao et al., 2013). Resolvin E1 reduced 
the levels of IL-6 and IL-1β released in lung tissue following acute lung injury (Seki et al., 
2010). It also reduced IL-13 production, lymphocyte recruitment, and airway hyper-
responsiveness in a murine model of asthma (Aoki et al., 2008). Maresin-1 is the most potent 
pro-resolving mediator that activates macrophage efferocytosis. Therefore, a stable structural 
analogue of this mediator might be useful to COPD patients. Nordgren et al. (2013) showed that 
maresin-1 reduced the pro-inflammatory response of bronchial epithelial cells induced by 
exposure to organic dust. Thus, endogenous mediators or stable analogues of these mediators 
that activate the same receptors may promote resolution of inflammation in COPD patients 
(Barnes, 2016). 
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1.4 Aims and Objectives  
 
Aims 
There are several studies on COPD-related biomarkers. Recent studies indicated that 
several biomarkers might be involved in airway inflammation and immunity, but the available 
results on the association of some biomarkers with COPD are not consistent. There is a need for 
biological biomarkers for better evaluation of patients with COPD. This study aims to test the 
hypothesis that levels of inflammatory biomarkers are increased in circulation and from 
inflammatory cells in patients with COPD comparing to healthy subjects. Identification of 
plasma, pulmonary, and inflammatory immune cell biomarkers may facilitate improved 
diagnosis and prognosis in COPD.  
 
Chapter 3 
Hypothesis 
In the current study it was proposed that with the progression of pulmonary inflammation, the 
respiratory function will be reduced in COPD patients. Further a number of subjects’ 
demographics features (e.g. age, weight, BMI) could be correlated with pulmonary function data 
of the studied groups. 
Objectives 
1. Studying the baseline demographics, clinical characteristics and lung function tests of the 
study cohort. 
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Chapter 4 
Hypothesis 
It was proposed that with the progression of inflammation the level of systemic and pulmonary 
inflammatory biomarkers will increase too. Such a relationship could be utilized as a disease 
prognostic tool. Based on an analysis of the existing literature a number of potential biomarkers 
was selected for evaluation in the studied groups. 
Objectives 
1. Measure and compare the basal level of selected inflammatory markers in plasma 
samples of the study groups.  
2. Investigate the relationship between plasma level of inflammatory biomarkers and 
pulmonary function parameters in subject with COPD. 
 
Chapter 5 
Hypothesis 
It was proposed that the release of inflammatory biomarkers will increase from stimulated and 
unstimulated PBMCs from COPD patients when compared with PBMCs from healthy subjects. 
This will indicate that immune cell is already activated in COPD patients. Based on an analysis 
of the existing literature a number of inflammatory biomarkers was selected for evaluation in 
PBMCs of the study cohort. Additionally, it was hypothesized that omega-3 PUFAs, EPA and 
DHA could reduce the cytokine responses in PBMCs as these immune cells involved in adaptive 
and innate immunity. 
Objectives 
1. Measure and compare the inflammatory biomarkers basal release from PBMCs in the 
studies groups  
2. Investigation the immunomodulatory effect of omega-3 PUFA on in vitro PBMCs 
inflammatory mediators release in the three studied groups 
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Chapter 6 
Hypothesis 
It was proposed that fatty acids profile in RBCs from subjects with COPD is modified when 
compared to healthy subject; such alteration could be utilized as a disease marker. 
Objectives 
1. Investigating baseline fatty acid profiles of erythrocyte (RBCs) membrane in the study 
cohort and the association with COPD 
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2. Chapter 2 
2.1 Materials and Methods 
2.1.1 Ethical considerations 
The study was approved by the college ethics panel at Salford University. All subjects 
were recruited after informed consent by the Medicines Evaluation Unit (MEU), based at 
University Hospital South Manchester (Wythenshawe). MEU have ethical approval for the 
recruitment of subjects and provision of blood samples for these studies under the terms of the 
approval allows researchers to utilize and store clinical materials at third party (University of 
Salford) laboratories (see appendix A for ethics documents).  
2.1.2 The Characteristics of the Study Population 
2.1.2.1 Patient Population 
 The study population was divided into three groups: (1) Group included 15 patients with 
COPD (COPD). (2) Group included 15 healthy smokers (HS). (3) Group included 12 participants 
who were healthy, nonsmoking volunteers (HNS). Individual involved in collecting study cohort 
demographic features and pulmonary functions are staffs from MEU working in the research 
department. All participants were subjected to the following; through history taking, full clinical 
examination, routine laboratory investigations, body mass index (BMI), pulmonary function 
tests; FEV1, FVC, and FEV1%. The diagnosis of COPD and the assessment of its severity were 
defined and classified according to the criteria reported by GOLD guidelines for COPD 
management with the inclusion and exclusion criteria as stated below (Korani et al., 2016; Meng 
et al., 2016; Queiroz et al., 2016). 
The subjects included in this project were required to meet the following criteria; patients 
with COPD post BD FEV1/FVC ratio <0.70, pack year >10. Smokers with normal lung function, 
pre BD FEV1/FVC ratio >0.70, FEV1 >80% predicted, pack year >10. Healthy never smoked 
subject, pre BD FEV1/FVC ratio >0.70, FEV1 >80% predicted, pack year <1.  
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Exclusion criteria include: 
All healthy subjects with history of a chronic respiratory disorder 
All volunteers with the following;  
History of acute respiratory disease within 6 weeks prior to visit 
History of other non-respiratory inflammatory disease 
Blood safety review: Donated 1 pint (500mls) of blood in the last 16 weeks 
Got a chesty cough, sore throat or active cold sore 
Pregnant or a woman with a baby less than 9 months old 
Taking antibiotics or finished taking them within the last 7 days 
Had hepatitis or jaundice in the last 12 months 
Had acupuncture, ear piercing, and body piercing, tattooing or semi-permanent make-up in the 
last 4 months 
HIV positive or thinks they may be HIV positive 
Ever injected or been injected with drugs including body building drugs 
Been in contact with an infectious disease or been given immunisations in the last 8 weeks 
Any known Haemophilia or a related blood clotting disorder who has received clotting factor 
concentrates or had a history of anaemia 
2.1.3 Collection and Processing of Blood Samples 
Different types of samples can be utilised to identify COPD biomarkers, those samples 
can be obtained either from the lung or from the system. Samples from the lungs could be 
sputum, exhaled breath, BAL fluid and biopsies. However, Sputum requires expertise and time. 
Exhaled breath has poor reproducibility and low protein content. Additionally, BAL fluid and 
biopsies samples techniques are high risk, invasive, and expensive even it provide with more 
data on whole lung sections. Samples obtained from system could be plasma or serum. Although 
systemic samples are easier to obtain, with low risk technique, high reproducibility data, 
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however the blood may have a smaller biomarker signal compared to those obtained directly 
from the lung samples (Bradford et al., 2017). 
Blood have been used as a suitable source of inflammatory cells in many studies 
investigating disease pathogenesis and evaluating the effects of candidate novel therapies. The 
advantage of blood is ease of collection samples, non-invasiveness, high reproducibility, and the 
ability to standardise measurements for most assays (Chen et al., 2016; Bradford et al., 2017). In 
the current study, blood sample was selected for biomarker investigation and also because from 
blood sample other fractions, that are required in the current study, can be recovered includes 
PBMCs and RBCs. Those fractions will be required in the current study for circulating 
biomarkers investigation and fatty acid analysis.  
Patient recruitment and samples collection and started on February 2016 and continued 
until March 2017. Whole blood samples 20 ml were collected into vacutainer tube, containing 
EDTA as an anticoagulant from each patient of the studied groups. Individuals involved in 
sample collect are technicians and staff from MEU working in the research department and with 
experience in research subjects’ recruitment and have knowledge of the study protocol. Blood 
samples were then transported and processed by the academic team at University of Salford. 
Samples were processed and stored according to guidelines at the University of Salford. Samples 
were collected and processed on the same day. However, only few samples were collected on the 
next day. Each sample was provided with patient number, date of collection and study group. 
Assessment of outcome was blinded to exposure status and no patient identifiable data was used 
in the analysis or publication of the results.  
2.1.3.1 Sample Processing 
Each blood sample 20ml was mixed with Roswell Park Memorial Institute 1640 media 
(RPMI 1640) (Bioser, Labtech International Ltd, Sussex, UK) without supplement in a 1:1 ratio 
then diluted blood layered onto Biosera Ficoll lymphocyte separation media (sterile, filter, 
Labtech International Ltd, Sussex, UK) in a ratio 1:1 in a slow stream to maintain the gradient 
and centrifuged (400g, brake setting at 9, accuspin 400centrifuge, Fisher Scientific, 
Leicestershire, UK) for 30 mins in room temperature. The plasma top layer was collect in five 
1ml aliquots and stored at – 80 ͦ C for later analysis. The blood bottom layer (RBCs) was collect 
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in five 0.5ml aliquots and stored at – 80 C for later analysis. Samples were labelled with 3-line 
code using the Brady BMP-21 label printer as follow: 
CPXXXX-YY 
ZZ/ZZ/ZZ 
01 
Abbreviation definition: 
CP=study code (COPD PUFA) 
X=Patient identifier (MEUXXXX)  
Y=sample type (PL=plasma; PB=PBMCs; RB=RBCs) 
Z=date (format 26/03/16, for 26th March 2016) 
01=aliquot number 
 
2.1.3.2 Purification of PBMCs by Ficoll Density Gradient Protocol  
The interface layer of enriched PBMCs was removed carefully using a sterile Pasteur 
pipette to a new tube, washed with RPMI (no supplement) to comprise a 40 ml total volume and 
centrifuged (400g, brake setting at 0, accuspin 400centrifuge, Fisher Scientific, Leicestershire, 
UK), for 10 mins at room temperature. The top layer was aspirated and cell pellet containing 
PBMC was resuspended in RPMI 1640 medium supplemented with 1% (v/v) L-glutamine 
(Lonza, Verviers, Belgium), 10% (v/v)  fetal bovine serum (FBS) (Biosera, Labtech International 
Ltd, Sussex, UK), 1% (v/v) penicillin (100 U/ml), and streptomycin (100 mg/ml) (Biosera 
antibiotic-antimycotic, Labtech International Ltd, Sussex, UK).  
A total cell count was performed using the Marienfeld Neubauer improved 
hemocytometer (Lauda-Königshofen, Germany) and viability was evaluated by the trypan blue 
exclusion method, where a volume of 10 µl of cell suspension was diluted in 10 µl Trypan blue 
solution (0.4%) (Sigma, Ayrshire, UK) in an Eppendorf tube and a viable count was performed 
under light microscopy. Ten microliters of Trypan Blue-cell suspension was applied to 
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the hemocytometer very gently to fill both chambers underneath the coverslip, allowing the cell 
suspension to be drawn out by capillary action. Unstained cells in the four sets of 16 corners 
squares of the hemocytometer were counted using hand tally counter.  The average cell count 
from each of the sets of 16 corner squares was multiplied y by 10,000 (10
4
) and again multiplied 
by 5 to correct for the 1:5 dilution from the Trypan blue addition. The final value is the number 
of viable cells/mL in the original cell suspension 
The cell count was adjusted to a concentration of 1×10
6
 cells/ml and stored in frozen 
media mix, FBS with 10% dimethyl sulfoxide (DMSO) (Fisher Scientific, Leicestershire, UK). 
During cryo-preparation of cells DMSO is act as cryo-protectant for cell membrane during the 
freezing process. Cryovials were placed into a Mr Frosty container (Fisher Scientific, UK), 
which slows the rate of cooling to approximately -1°C per minute. The Mr Frosty container was 
transferred to -80ºC for 24hrs, after which cryovials were then placed in liquid nitrogen storage 
for long term storage (Figure 2.1).  
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Figure ‎2.1: The Ficoll density gradient techniques for separation of PBMCs. Blood is diluted 
with RPMI media (1:1), then layered on Ficoll separation media (1:1) and centrifuged as indicated in the 
text. Top layer plasma were removed and stored, PBMCs are enriched in the interphase between plasma 
and Ficoll layers, whereas red blood cells are pelleted. 
 
2.1.3.3 Recovery of PBMCs 
A cryovial of PBMCs was removed from the liquid nitrogen and thawed with agitation in a 
37°C water bath (Fisher Scientific, Leicestershire, UK) for one minute.  The vial was then wiped 
with 70% ethanol (Fisher Scientific, Leicestershire, UK) before opening it in biological safety 
cabinet (Labgard class II biology safety cabinet, Thermoscientific, UK), and the content of the 
vial was transferred aseptically into a new sterile 50 ml tube containing 10 ml of RPMI 1640 
media without supplement. This was centrifuged at 400g, for 10 mins (plate Eppendorf 
centrifuge 5804/ Heraeus™ Megafuge™ E16 Centrifuge, Fisher Scientific, Loughborough, UK). 
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Cells were re-suspended in 1ml RPMI media with supplement, and then a cell count was 
performed as described earlier (section 2.1.3.2). The cell concentration was adjusted (with RPMI 
media) according to the experiment protocol. 
2.1.3.4 Enzyme-linked Immunosorbant Assays (ELISA) 
Several methodologies have been developed for measuring biomarkers. ELISA is 
currently the most commonly used technique to measure biomarkers due to the high specificity 
and sensitivity. Using the same principle, more rapid, automated method like bead-based 
multiplex immunoassays (MIA) have been developed to detect  multiple cytokines in a single 
sample (Jager et al., 2009).  ELISA is a common laboratory technique which depends on a plate-
based assay designed to measure the concentration of different substances such as proteins, 
antibodies and hormones in a complex biological matrix (e.g. plasma, serum, blood, tissue). In 
the ELISA assay, an antigen must be immobilized to a solid surface usually a polystyrene multi-
well plate and then complexed with an antibody that is linked to an enzyme. Detection is 
achieved by conjugated enzyme activity when incubated with a substrate to produce a 
measureable coloured end product, which reflects the amount of target present in the original 
sample. ELISA assays are rapid and the simple technique permits high throughput of samples. 
2.1.4 ELISA for R&D Systems-based 
2.1.4.1 Reagent Preparation  
ELISA duoset kits (R&D Systems, Oxford, UK) were used to measure the biomarkers 
release in recovered supernatants from PBMC culture and plasma samples. Detail of ELISA 
sensitivity ranges for each biomarker and the required reagents diluent and sample needed for 
each assay is summarised in chapter (4 and 5). Anti-human capture antibody was reconstituted in 
0.5 ml of PBS and further dilution was made in PBS, to the working concentration. Anti-human 
detection antibody was reconstituted in 1.0 ml of reagent diluent 1% BSA in PBS, and further 
dilution was made in reagent diluent to the desire working concentration.  
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2.1.4.2 Standard Preparation 
Each recombinant human standard vial was reconstituted with 0.5 mL of deionized H2O 
or PBS according to manufacture instructions.  After initial reconstitution, 1ml of high standard 
was prepared per plate assayed at the concentration indicated. A seven point standard curve 
using 2-fold serial dilutions in reagent diluent was prepared (Figure 2.2).Working dilutions 
should be prepared on experiment day and used immediately. 
 
 
Figure ‎2.2: The preparation of seven point standard curve using 2-fold serial dilutions in 
reagent diluent (examples; recombinant human IL-6 Standard, rndsystems.com). 
 
2.1.4.3 Sample Preparation and Cell Culture  
The PBMCs were isolated from 20mL of whole blood consisting of anti-coagulant EDTA 
from patients with COPD, healthy smokers and healthy nonsmokers on Ficoll density gradient by 
centrifugation at 400 ×g at the room temperature for 30 minutes as previously mentioned. Before 
performing the experiment, PBMCs from frozen were washed and counted. The total cell count 
was calculated by using trypan blue exclusion method. Cell suspension was diluted 1:1 (v/v) 
with 0.4% trypan blue, and the viable cells were counted and compared with the total amount of 
cells in the suspension and in all of the experiments. The cell suspension was adjusted to 1×10
6
 
cells/ml. 
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2.1.4.4  ELISA Assays Procedures 
The biomarkers measurement was performed on plasma and the supernatant of the 
cultured PBMCs samples. The following procedure is for the R and D System Company. All 
assay steps are summarized in (Figure 2.3). 
Day 1: 
A 96-well plate was coated with 100 μl of the diluted anti-human capture antibody per 
well. The plate was sealed (Greiner Bio-One GmbH, Ltd, Stonehouse, Germany) and incubated 
overnight at room temperature. 
Day 2: 
The 96-well plate was washed twice with wash buffer (0.05% Tween® 20 in PBS, pH 
7.2-7.4) using auto washer equipment (Mikura, West Sussex, UK). After each wash step any 
remaining wash buffer was removed by blotting the plate against clean paper towels. The plate 
was blocked by adding 300μl of reagent diluent, 1% BSA in PBS, pH 7.2-7.4, 0.2 μm filtered, to 
each well, and was incubated at room temperature for a minimum of 1 hour. The wash step was 
repeated and 100μl of sample or standards was added per well as duplicate. The plate was sealed 
with an adhesive strip and incubated 2 hours at room temperature. The wash step was repeated 
and 100μL of the diluted detection antibody was added to each well. The plate was sealed with 
an adhesive strip and incubated 2 hours at room temperature. The wash step was repeated and 
100μl of the working dilution of Streptavidin-HRP (streptavidin conjugated to horseradish-
peroxidase, 1:40) (R&D Systems, Catalog #DY 893975) was added to each well. The plate was 
covered and placed away from direct light for 20 minutes at room temperature. The wash step 
was repeated and 100μl of substrate solution, a mixture of color reagent A (H2O2) and color 
reagent B (Tetramethylbenzidine) (1:1, R&D Systems, Catalog # DY999) was added to each 
well and plate was incubated for 20 minutes at room temperature away from direct light, then 
50μl of stop solution (2 N H2SO4) (R&D Systems, Catalog # DY994) was added to each well.  
The optical density of each well was determined using a microplate reader (Varioskan LUX 
Multimode Microplate Reader, Thermo Fisher Scientific, UK) (see appendix B for software user 
manual guide), set to 450 nm with a wave length correction at 570nm. A standard curve was 
constructed by plotting the mean absorbance for each standard on the y-axis against the 
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concentration on the x-axis and a best fit curve was drawn through the points on the graph. The 
concentration of biomarkers in sample was determined by interpolating the blank control 
subtracted absorbance values against the standard curve. Resulting value was multiplied by the 
appropriate sample dilution factor to obtain the concentration of biomarker in the sample. Three 
experiments were performed and standard error was determined from the standard deviation 
derived from the means of total sample number. 
 
Figure ‎2.3: DouSet ELISA system Assay principles. 1) Analyte- capture antibody is bound to 
polystyrene 96-well microplate. Unbound capture antibody is washed away. Plates are blocked and 
washed.2) Samples or standards are added and any analyte present is bound by the immobilized 
antibody. Unbound materials are washed away. 3) streptavidin-HRP binds to the detection antibody. 
Unbound streptavidin-HRP is washed away. 4) TMB substrate is added to the wells and a blue color 
develops in proportion to the amount of target analyte present in the sample. Color development is 
stopped by stop solution turning the color in the wells to yellow. The absorbance of the color at 450 nm is 
measured (rndsystems.com). 
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3. Chapter 3: Studying the baseline demographics, clinical 
characteristics and lung function tests of the study cohort 
 
 
3.1 Background 
According to GOLD accepted definition COPD is a ‘‘disease state characterised by airflow 
limitation that is not fully reversible’’ (Korani et al., 2016). The diagnosis of COPD is based on 
the presence of respiratory symptoms, and the demonstration of chronic airflow obstruction. The 
main cause of airflow limitation is small airway remodelling and emphysema (Sileikienė et al., 
2017). Many COPD patients are diagnosed on the basis of clinical symptoms and without the 
assessment of airflow limitation with spirometry. Inadequate diagnosis of COPD can lead to 
insufficient treatment, increase health costs and patient’s hospital readmission (Andreeva et al., 
2017). There are several pulmonary function tests that can be used to assess COPD diagnosis, 
including spirometry measurements, gas transfer (diffusing capacity), lung plethysmograph also 
known as total lung capacity (TLC), arterial blood gas analysis, BODE (BMI, airflow 
obstruction, dyspnea and exercise capacity). 
In COPD patients, TLC is increased as a result of the destruction of lung tissue by 
emphysema. This leads to a loss of elastic recoil that allows the lungs volume to increase. 
Another lung function test is diffusing capacity of carbon monoxide (DLCO) which measures the 
ability of the lungs to transfer carbon monoxide (DLCO) from inhaled air to the hemoglobin of 
the red blood cells in pulmonary capillaries. The DLCO decreases with increasing severity of 
COPD because of parenchymal destruction and loss of pulmonary alveoli and capillary bed due 
to emphysema, which lead to decrease surface area available for gas transfer (Bailey 2012; 
Boutou et al., 2013).  
Spirometry measurements of FEV1% and FEV1/FVC reflect disease severity of airflow 
obstruction, and play a fundamental role in classifications of the COPD into different stages 
(FernaÂndez-Villar et al., 2018). Clinical trials in COPD normally include measuring one of the 
main parameters of lung function which is FEV1%. It is importance because it reflects the index 
of airflow obstruction that measures both symptomatic relief and disease progression (Korani et 
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al., 2016). FEV1 is the volume of air that is forcibly exhaled in the first second, whereas forced 
vital capacity (FVC) represents the total volume of air in the lungs can be exhaled after a full 
inspiration. The FEV1 has been used to classify COPD patients to different stages according to 
disease severity and to describe progression of the disease (Cazzola, et al.,  2008).Whereas FVC 
is a parameter for lung restriction, and lung fibrotic diseases (Shibata e al., 2013). GOLD fix cut-
off values of FEV1% <80% with a post-bronchodilator FEV1/FVC ratio <70% were classified as 
having airway limitation with a possibility of COPD. However, there was controversy about the 
fix cutoff value, so the GOLD guidelines and the combined American College of Physicians, 
American College of Chest Physicians, American Thoracic Society (ATS) and the European 
Respiratory Society (ERS) COPD guidelines recommend using the reference cutoff of <0.70, 
regardless of age and gender. Because FEV1/FVC ratio is known to decrease by age, so using 
this cutoff is not perfect as it may lead to an over-diagnosis of COPD in the elderly or an under-
diagnosis in young patients (Bailey 2012). In 2004, the ERS and the ATS recommended the use 
of the lower limit of normal instead of fixed cut-off values.  The lower limit of normal can be 
calculated from age corrected and defined by the lower fifth percentile of the reference 
population (Andreeva et al., 2017). 
Most longitudinal studies of COPD do not have post-bronchodilator lung function 
available. A Previous study analysed data from the Lung Health Study (randomized multicenter 
clinical trial) to determine whether pre- or post-bronchodilator lung function predicts mortality. 
Survival analysis and logistic regression predicting death and controlling for age, sex, smoking 
status, and measures of lung function were conducted. The study found that both pre- and post-
bronchodilator lung function predicted mortality with a similar degree of accuracy (Mannino et 
al. 2011). However a study finds that post-bronchodilator spirometry may be a more accurate 
measure of COPD and should be used for COPD diagnosis and classification (Fortis et al., 
2017). Reversibility of airway obstruction is commonly used in clinical and research studies that 
reflect the COPD patients respond to bronchodilators. The values of FEV1and FVC before and 
after the bronchodilator administration are compared, and the change is calculated. Significant 
reversibility is identified by the ATS as an absolute changes of >12% and > 200 mL in the 
baseline FEV1 and/or FVC, while the ERS recommends a change of >9% of the FEV1 (Richter 
et al., 2008; Tan et al., 2012; Müller et al., 2016). 
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In 2011, ERS published a report in order to establish clear diagnostic criteria and 
standardised methods to examine COPD. Their report strongly recommended measuring many 
different parameters of COPD patients include; spirometry measurements, respiratory symptoms, 
exacerbation frequency, comorbidity assessment, BMI, biological biomarkers, and chest 
radiography, to provide a better understanding of the disease. There are several problems 
regarding the diagnosis of COPD include different COPD definitions, a gap between the 
epidemiological and the clinical studies definition of COPD, and two proposed FEV1/FVC cut-
off values for defining COPD. Further epidemiological and clinical studies are needed to 
improve the diagnosis of COPD (Andreeva et al., 2017). 
 
3.1.1 Objectives 
 To study the comparison of baseline demographics and clinical characteristics between 
COPD patients, healthy smokers and healthy controls. 
 To investigate the association between demographics and clinical characteristics and lung 
functions Parameters in COPD patients 
 
3.2 Method 
The study was conceived and forms an ongoing collaboration with the Medicines 
Evaluation Unit (MEU) and North West Lung Centre (NWLC) at University Hospital South 
Manchester (UHSM), part of Manchester University Foundation Trust. As such they are subject 
to NHS local research ethics committee approval (NREC), in this case South Manchester Ethics 
Committee. These studies are encompassed within an existing NREC approval for the use of 
human lung surgical resections for research into mechanisms of inflammatory lung diseases (ref: 
03/SM/396). A cohort of 42 subjects enrolled in this study; 15 patients with COPD, 15 healthy 
smoking controls and 12 healthy nonsmoking controls was evaluated. All patients met the GOLD 
recommended spirometry criteria included pre-bronchodilator FEV1% (pre FEV1%) of less than 
80% of the reference value with a pre-bronchodilator FEV1 to FVC ratio (pre FEV1/FVC ratio) 
of less than or equal to 70%. Details of the study cohort inclusion and exclusion criteria’s was 
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mentioned earlier (Chapter 2). All patients underwent spirometry to diagnose airflow limitation 
including; the pre- and post-FEV1, FEV1% and FVC, as well as the FEV1/FVC ratio. Smoking 
data was collected by lab technicians from MEU. A form on smoking status was used to record 
the number of cigarettes smoked per day and the years since starting smoking. Then the number 
of pack year history (PYH) was determined as the average number of cigarettes smoked per day 
multiplied by the years since starting smoking. All subjects gave written informed consent and 
the study was approved by the research ethics committee at Salford University (see appendix A). 
 
3.3 Statistical Analysis  
The data were expressed and graphed as mean (standard deviation; SD). The D’Agostino–
Pearson omnibus normality test was performed to test normality of the data distribution. For data 
normally distributed, paired t-tests or one-way ANOVA analysis of variance followed by Tukeys 
multiple comparison post-test was performed to determine whether the differences between the 
groups were statistically significant. Otherwise, if data are nonparametric comparisons were 
made using Kruskal–Wallis analysis followed by Dunn’s multiple comparison tests. Differences 
were considered significant if the probability (P) value was <0.05, highly significant if P value 
was <0.01 and P value <0.001, and insignificant if P value was >0.05. Correlation analyses of 
two variables were carried out using Pearson methods, depending on the normality of the data 
distribution. All statistical analyses were performed using graphpad prism and InStat software, 
version 7.04 and 3.10.32 respectively. During the planning of the study, no power analysis was 
performed. However, a post hoc power analysis (Wilcoxon-Mann-Whitney test) justifies the 
sample size. Power and sample size analysis was calculated using G*power software version 3. 
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3.4 Result 
The data were normally distributed and therefore multiple comparisons between groups 
were made using paired t-tests or one-way ANOVA analysis for unpaired data of variance 
followed by Tukeys multiple comparisons post-test to determine whether the differences 
between the groups were statistically significant. The baseline demographic clinical 
characteristics, and pulmonary function test results of all participants at recruitment, are featured 
in Table 3.1 and Figure 3.1.   
3.4.1 Comparison of Baseline Demographics and Clinical Characteristics between Groups 
at Baseline 
On classifying the patients according to severity of the disease, most of the patients in the 
current study were in the moderate category (73.4%) with a few in the mild (20%), and only 
6.6% patients in the severe category of COPD as per the GOLD guidelines. On average, patients 
with COPD were older than the healthy smoking and healthy nonsmoking subjects. There was a 
significant difference in age average between COPD patients and healthy smokers (66.4 vs 56.3, 
P<0.05). Further, extremely significant difference in age average was observed between COPD 
patients and healthy nonsmokers (66.4 vs 50.1, P<0.001). Healthy nonsmoking subjects were 
slightly younger than healthy smoking subjects. There was a significant difference in weight 
between patients and healthy nonsmokers (P=0.0436). Patients were with low weight when 
compared with healthy nonsmoking control. The body mass index (BMI) was calculated as 
weight in Kg dividing by height square (m
2
). At baseline, 53.3% were of normal weight (BMI 
20–25 kg/m2) and 46.6% were overweight (BMI >25 kg/m2). So, none of patients were 
underweight (BMI <20 kg/m
2
). There were no significant differences between the three groups in 
terms of the body mass index (BMI) (P>0.05).   
The smoking status between the smoker groups was significantly different. As expected 
the mean value of smoking exposure or PYH was significantly higher in COPD group when 
compared with healthy smokers. All patients were regularly using inhaled corticosteroids (ICS) 
and long-term bronchodilators medication except one patient. Patients were using short-acting 
bronchodilators (SABA), long-acting bronchodilators (LABA), and long-acting muscarinic 
antagonists (LAMA) therapies. 
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3.4.2 Comparison of Lung Function and Spirometry Measurements between Groups at 
Baseline  
After spirometry testing it was found that patients with COPD had lower FEV1% 
predicted, and greater airflow obstruction as expected, complained of more symptoms. Healthy 
smoking and healthy nonsmoking subjects had normal spirometry. In general, the mean value of 
FEV1, FVC, FEV1%, and FEV1/FVC ratio were significantly lower in COPD group when 
compared with healthy smoking and healthy nonsmoking groups (p < 0.05). The mean value of 
FEV1% was statistically significantly different between COPD (52%) and healthy smoking 
(99.5%, P < 0.001), as well as healthy nonsmoking groups (99.6%, P < 0.001). The mean value 
of FEV1% is positively correlated with the disease stage. This means that patient respiratory 
functions are decreasing with the increasing of disease severity. The difference in the mean 
FEV1% measured between healthy smoking and healthy nonsmoking was statistically non-
significant (P>0.05). All patients had an FEV1/FVC ratio ≤ 70% of the predicted value and pre 
FEV1% <80%.  
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Table ‎3.1: Demographic, Clinical data and results of the pulmonary function test of study 
subjects. 
Characteristic COPD HS HNS 
Number 15 15 12 
Age, yrs 66.4(7.1) 56.3(6) 50.1(7.3) 
Height 1.67 1.68 1.74 
Weight, Kg 71.94 (12.3) 78.6 (10.8) 85.26 (10.7) 
BMI, Kg/m
2
 25.42 (3.15) 27.83 (4.13) 28.1 (3) 
Pre FEV1, L 1.39 (0.57) 2.92 (0.63) 3.34(0.41) 
Pre FEV1% 52.10 (22) 99.55 (10.2) 99.6(13) 
Pre ratio FEV1/FVC 41.5 (11.9) 74.4 (4.26) 75.6 (5.38) 
Post FEV1, L 1.52 (0.55) 2.95 (0.62) 3.44 (0.37) 
Post FEV1 % 56.88 (0.18) 103.5 (20.81) 103.00 (0.13) 
Post ratio FEV1/FVC 42.9 (11.6) 72.16 (20.57) 78.41 (5.26) 
Reversibility, mls 136 (131.7) 32.33 (43.70) 92.50 (73.50) 
Reversibility % 12.39 % 1.11% 3.22% 
PYH 47 (17.2) 26 (9) 0.19 (0.66) 
 
The data are expressed in term of mean (standard deviation) or as percentage unless otherwise stated. P 
value < 0.05 as determined by one-way ANOVA analysis of variance followed by Tukeys multiple 
comparison post-test indicate a significant difference between the groups. These analyses were performed 
using Graph Pad prism and Instat Software. Definition of abbreviations: COPD, chronic obstructive 
pulmonary disease; HS, healthy smokers; HNS, healthy nonsmokers; FEV1, Forced Expiratory Volume in 
1 second; FVC, forced vital capacity; BMI, Body Mass Index; BD: bronchodilator; PYH, pack year 
history. 
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Figure ‎3.1: Comparison of respiratory function and parameters between the studies 
groups. The mean values of weight in Kg (A), BMI Kg/m2(B), age in years (C), PYH (D), preFEV1% (E), 
and pre FEV1/FVC ratio (F), between the three studied groups. P value < 0.05 as determined by one-way 
ANOVA analysis of variance followed by Tukeys multiple comparison post-test indicate a significant 
difference between the groups. These analyses were performed using Graph Pad prism and Instat 
Software. Definition of abbreviations: COPD, chronic obstructive pulmonary disease; HS, healthy 
smokers; HNS, healthy nonsmokers; FEV1, Forced Expiratory Volume in 1 second; FVC, forced vital 
capacity; BMI, Body Mass Index; BD: bronchodilator; PYH, pack year history 
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Linear regression analysis using Pearson methods, showed a significant correlation between 
FEV1% and age (P=0.0009) as well as BMI (P=0.024) but not with weight of the entire study 
subjects (P>0.05). Linear regression analysis also showed a significant correlation between 
FEV1/FVC ratio and age (P<0.0001), BMI (P=0.0009) as well as weight of entire study subjects 
(P=0.022) (Figure 3.2). However, no significant correlation was observed between FEV1% and 
FEV1/FVC ratio with age or BMI as well as weight of COPD patients (P>0.05). 
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Figure ‎3.2: The correlation between lung severity and subject parameters. Pre FEV1% vs age 
(A), FEV1/FVC vs age (B), pre FEV1% vs weight (C), FEV1/FVC vs weight (D), pre FEV1% vs BMI (E), 
FEV1/FVC vs BMI (F). Significance was tested using a linear regression analysis (spearman method). 
Dotted lines indicate the 95 % confidence intervals. These analyses were performed using Graph Pad 
Software. Definition of abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, Forced 
Expiratory Volume in 1 second; FVC, forced vital capacity.  
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The differences between pre- and post-bronchodilator FEV1% increase in the COPD 
group. The mean values for pre- and post- FEV1% were 52.10% (range, 24.68%- 97.28%) and 
56.88% (range, 37.00%- 96.89%), respectively, in COPD group, compared with 99.55% (range, 
84.77%- 118.23%%) and 103.5% (range, 77.61%- 170.38%), respectively, in healthy smoking 
group, whereas they were 100% (range, 80.47-121.03%) and 103% (range, 81.39-124.72%), 
respectively, in the healthy nonsmoking group. The difference between the mean of pre- FEV1% 
and post- FEV1% was significant difference in the three groups; (COPD, P=0.002; HS, P=0.008; 
HNS, P=0.00009). There was a significant difference in pre- and post-FEV1 when compared the 
COPD patient with healthy smokers and nonsmokers (P<0.0001) (Figure 3.3). 
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Figure ‎3.3: Comparison between pre FEV1% and post FEV1% in the three studied 
groups; COPD = 15 (A), HS =15 (B), and HNS =12 (C). P value < 0.05 as determined by paired t-tests 
indicate a significant difference between the pre- and postFEV1, and one-way ANOVA analysis of 
variance followed by Tukeys multiple comparison post-test indicate a significant difference between the 
three groups. These analyses were performed using Graph Pad prism and Instat Software. Definition of 
abbreviations: COPD, chronic obstructive pulmonary disease; HS, healthy smokers; HNS, healthy 
nonsmokers; FEV1, Forced Expiratory Volume in 1 second. 
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In the current study, the bronchodilator reversibility of the study cohort was also 
evaluated. At baseline, 60% of patients with COPD met ATS/ERS reversibility criteria. The 
reversibility of patients with COPD, healthy smokers and nonsmokers were 12.39 %, 1.11% and 
3.22% respectively (Figure 3.4). There was a significant difference in reversibility when 
compared the COPD patient with healthy smokers (P<0.0001) and nonsmokers groups 
(P<0.002). Interestingly, there was a negative correlations between patients’ reversibility and 
BMI (p=0.0087), as well as weight (p=0.0143), but not with age (p=0.15) (Figure 3.5).  
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Figure ‎3.4: Comparison of the mean values of reversibility between the three studied 
groups. Definition of abbreviations: COPD, chronic obstructive pulmonary disease; HS, healthy 
smokers; HNS, healthy nonsmokers. P value < 0.05 as determined by one-way ANOVA analysis of 
variance followed by Tukeys multiple comparison post-test indicate a significant difference between the 
groups. These analyses were performed using Graph Pad prism and Instat Software. Definition of 
abbreviations: COPD, chronic obstructive pulmonary disease; HS, healthy smokers; HNS, healthy 
nonsmokers. 
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Figure ‎3.5: The correlation between patient’s characteristic and reversibility percentage. 
Reversibility% vs (A) age, (B) weight, and (C) BMI. Significance was tested using a linear regression 
analysis (Pearson method). These analyses were performed using Graph Pad Instat Software. Definition 
of abbreviations: BMI, body mass index. 
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3.4.3 The Influence of Smoking Status on Lung Function Parameters 
Statistically there was a significant negative correlation between smoking status and reversibility 
of COPD patients (p=0.0369), while no association was observed between smoking status and 
reversibility in healthy smokers or healthy nonsmokers groups (P>0.05) (Figure 3.6). The study 
cohort was split into four subgroups according to smoking status category. The total number of 
smoking subject is 30; COPD patient current smokers = 9, COPD patient ex-smokers =6, healthy 
current smokers = 11, and healthy ex-smokers =4.The mean (SD) of PYH were 38.6 (18.5) and 
52.3 (14.7) for former and current smokers with COPD and 26.5 (8.24) and 26 (9.5) for former 
and current smokers with no COPD. There was a statically significant difference of PYH 
between current smokers with COPD and those with no COPD (one-way ANOVA analysis of 
variance followed by Tukeys multiple comparison post-test, P<0.01). The low sample size in 
healthy ex-smoker subgroup did not provide enough data for a statistical comparison with the 
COPD current smokers, as only four subjects were healthy ex-smokers There was no statically 
significant difference of PYH between the other subgroups (P>0.05) (Figure 3.7).  
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Figure ‎3.6: Reversibility in relation to smoking habits in the studied groups; COPD 15 (A), 
HS =15 (B), and HNS =12 (C). Significance was tested using a linear regression analysis (Pearson 
method).These analyses were performed using Graph Pad Software. Abbreviations: COPD, chronic 
obstructive pulmonary disease; HS, healthy smokers; HNS, healthy nonsmokers; FEV1, Forced 
Expiratory Volume in 1 second; PYH, pack year history. 
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Figure ‎3.7: Comparison of PYH between the subgroup of the study cohort. Total=30; ex-
smokers COPD (n=6), current smoker COPD (n=9), ex-smoker HS (n=4) current smoker HS (n=11). 
Unpaired one-way ANOVA analysis of variance followed by Tukeys multiple comparison post-test 
indicate a significant difference between the groups. Test indicates a significant difference between the 
groups. These analyses were performed using Graph Pad and Instat Software. Definition of 
abbreviations: COPD, chronic obstructive pulmonary disease; HS, healthy smokers; PYH, pack year 
history. 
 
Additionally, linear regression analysis showed no relation between smoking and FEV1% in 
smoker’s sub-groups (P>0.05) (Figure 3.8, A-D). However, significant relation was observed 
between smoking and FEV1% when analysing the whole smoking group (P<0.05) (Figure 3.8-
E).  
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Figure ‎3.8: The correlation between pre FEV1% and smoking (PYH) in smokers’ 
subgroups; (A) COPD current smokers, (B) COPD ex-smoker (C) healthy current smokers, (D) healthy 
ex-smokers, and (E) all smoking subjects. Significance was tested using a linear regression analysis 
(Pearson method).These analyses were performed using Graph Pad Software. These analyses were 
performed using Graph Pad Software. Definition of abbreviations: COPD, chronic obstructive pulmonary 
disease; HS, healthy smokers; FEV1, Forced Expiratory Volume in 1 second; PYH, pack year history. 
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3.4.4 Influence of ICS on COPD Severity and Smoking 
The impact of ICS therapy on COPD severity, as well as smoking exposure was also 
investigated. There was significant positive correlation between ICS and PYH (r
2
 =0.3, P = 
0.032). No correlation was found between the ICS and lung function parameters; pre FEV1 (r
2
 
=0.022, P = 0.59), as well as pre FEV1/FVC ratio (r
2
 =0.006, P = 0.78) (Figure 3.9). 
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Figure ‎3.9: Linear regression analysis of the correlation between ICS vs disease severity 
and PYH. ICS vs FEV1 %predicted (A), FEV1/FVC ratio (B) and PYH(C). Significance was tested 
using a linear regression analysis (Pearson method).These analyses were performed using Graph Pad 
Instat Software. Abbreviations: PYH, pack year history; FEV1%, percent predicted forced expiratory 
volume in the first second, FVC, forced vital capacity; ICS, inhaled corticosteroid. 
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3.5 Discussion 
COPD is a multicomponent disease characterised by several pathological changes, which 
include mucus hypersecretion, airway obstruction and loss of alveoli and a systemic 
comorbidities (Cazzola, et al., 2008). Airflow limitation is the main characteristic of patients 
with COPD. It caused by small airway remodelling and emphysema which results from the 
destruction of the parenchyma induced by a chronic inflammatory response after the exposure to 
different toxins like cigarette smoke and environmental irritants. Subsequently resistance to 
airflows is increasing with goblet cell metaplasia, mucous hypersecretion and smooth muscle 
hypertrophy (Barnes 2016). In the present study, a significant decrease was found in the 
pulmonary functions of COPD patients when compared to healthy smokers and healthy controls. 
Patients with COPD suffered from airway restriction comparing to healthy smokers and healthy 
nonsmokers.   The mean value of FEV1% and pre FEV1/FVC ratio of the COPD group is 52% 
and 41.5% respectively which agree well with GOLD recommended spirometry criteria. GOLD 
reference cut-off values of FEV1% <80% with a post-bronchodilator FEV1/FVC ratio <70% 
were classified as having airway limitation with a possibility of COPD. Additionally, a 
significant decrease was found in the respiratory functions of severe COPD patients when 
compared with mild and moderate COPD patients. This means that patient respiratory functions 
are decreasing as the stage of COPD increased. The findings of the present work are consistent 
with those of many authors who found that pulmonary function data; pre FEV1% and pre 
FEV1/FVC ratio, were significantly lower in COPD patients when compared with healthy 
nonsmoking controls (El-shimy et al., 2014, Wang et al., 2014).  
COPD is one of the most common chronic diseases that predominantly affect older people. 
Despite the increasing cases of COPD in older people, under-diagnosis and inadequate treatment 
in elderly patients is still a common problem. Older patients with COPD generally have a poor 
health status because they suffer from more chronic comorbidities, a compromised immune 
system, and decrease in pulmonary function. There are few studies that specifically investigate 
the association between COPD and age, while epidemiologic studies have reported that 
FEV1/FVC decreased with age. Ageing involves structural changes and decline in pulmonary 
functions which can cause poor ventilation and can impair the clearance of airway secretions. 
Thus, COPD is more prevalent in very elderly populations (Valente et al., 2010). In patients with 
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COPD, increasing age was found to reduce quadriceps muscle strength. Increasing age was also 
found to be associated with an increased risk for osteoporosis in patients with COPD (Cielen et 
al., 2014) 
The controversies exist regarding the use of a fixed FEV1 /FVC ratio of 0.7 as it may lead 
to over-diagnosis of COPD in the elderly (Bailey 2012). In the present study, a significant 
difference in the age of patients and healthy subjects was observed.  Patients were significantly 
older than those of healthy groups. The current study data is agreed with Hassanein et al., (2016) 
study, where the COPD patient group was older than the healthy control group. It was difficult to 
recruit age-matched older non-smoking healthy subjects without any medical history fulfilling 
the inclusion and exclusion criteria. Additionally, a significant relation between FEV1% or 
FEV1 /FVC ratio and age was observed in the study subjects. This means that respiratory 
functions were decreased with age. Subsequently; the study confirmed that the proportion of 
COPD severity increased with age.  
It known that  COPD mainly is a lung disease but it is associated with other comorbidities 
such as cardiovascular disorders, chronic kidney disease, lung cancer, diabetes mellitus, loss of 
lean body mass, skeletal muscle weakness, and osteoporosis. Lung cancer and CVD are the main 
comorbidities found in COPD patients (Barnes, 2010). These comorbidities result in reduced 
patient health status, increased hospital readmission, and mortality (Decramer et al., 
2012).Weight loss affects 25% to 40% of COPD patients, with 25% of patients with moderate to 
severe disease. Patients with BMI of <20 kg/m
2
 have a higher risk of acute exacerbations than 
those with a BMI of ≥ 20 kg/m2 (Itoh et al., 2013). Low body weight and BMI have been 
identified as a poor prognosis sign in COPD patients. Further, decreased body weight is 
correlated with disease severity, skeletal muscle weakness and mortality in patients with COPD. 
COPD patients with low weight were found to have a high prevalence of osteoporosis (57%) and 
muscle wasting (93%) (Cielen et al., 2014). GOLD, do not provide any specific nutritional 
guidelines for the management of patients with COPD other than to avoid weight loss. On the 
other hand, obesity (BMI > 40) was associated with a significantly increased risk of death in both 
patients with respiratory disease and chronic lower respiratory disease (Hanson et al., 2014).  
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Dietary supplement have shown to improve patient exercise capacity and quality of life but 
did not show any significant improvement in pulmonary function (Raizada et al., 2014). 
Interestingly, in this study there was a significant difference when comparing the mean weight of 
COPD patients with those of healthy nonsmokers. Patients were with low body weight when 
comparing with healthy nonsmokers which agreed with previous studies. However, none of 
patients were underweight in term of BMI <20 kg/m
2
. This may be because patients were 
shorter. Additionally, a significant association was observed between preFEV1% and BMI and 
between preFEV1/FVC ratio and weight as well as BMI when investigating the whole study 
groups. This means that subject weight or BMI may have impact on disease severity.  
Smoking history and exposure, as quantified by PYH was also evaluated as one of COPD 
main risk factor. Statically there was a significant difference in PYH between patients and 
healthy smokers as well as between patients and healthy nonsmokers. This means that smoking 
habit is higher among patients than healthy smokers. A significant correlation was found 
between PYH and FEV1 in smoking subjects. However, smoking history and exposure seemed 
to have no impact on patient disease severity in smokers’ subgroups analysis including patients’ 
ex-smokers, patient current smokers, healthy ex-smokers, and healthy current smokers. As 
expected patients’ current smokers were with the highest PYH rate among the other subgroups. 
This result is consistence with other study group finding which reported that no correlation was 
observed between smoking status and the percentage of predicted FEV1 (Higashimoto et al., 
2009). It should be noted that smokers’ number was low for linear regression analysis when 
dividing the smokers groups into sub-groups. 
Reversibility is an important diagnostic tool when investigating patients with COPD. In the 
current study the mean value of reversibility in the COPD group agreed with current ATS 
guideline cutoffs for defining a significant reversibility. The ATS/ERS guidelines 
recommendation of >12% and >200 ml increase from the baseline pre-bronchodilator 
FEV1and/or FVC in an individual subject to consider significant reversibility  (Albert et al.,  
2012; Tan et al.,  2012; Müller et al.,  2016). Interestingly, finding from the current study 
indicated that smoking status did influence reversibility of COPD subject, but not in healthy 
smokers. In addition to smoking effect, it was demonstrated that both patient weight and BMI 
but not age did influence the response in patients with COPD. Additionally, predictors of 
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reversibility in COPD weight, BMI and smoking status were also related to pre FEV1 and pre 
ratio.  In summary, these data confirmed that smoking exposure, weight, BMI have impact on 
patients’ reversibility. Previous study showed that high doses of ICS may affect the immune 
system and subsequently may associate with disease severity (Zhu et al., 2009). In the present 
study, all COPD patients received ICS except one. It is assumed that the study results were not 
influenced by the dosage of ICS, as no correlations were found between ICS doses and pre FEV1 
or pre FEV1/FVC ratio. Interestingly, we found a significant association between ICS and 
smoking habit.  
The diagnosis of COPD is based mainly on spirometry measurement and other lung 
functions parameters. Spirometry is easy to perform at low cost for the diagnosis and assessment 
of a clinical stage of COPD. However, it cannot offer much information as gas transfer or lung 
plethysmograph. A previous study found that gas transfer was a significant factor for prediction 
of survival, together with age and arterial oxygen. Applying gas transfer measurement in routine 
practice for patients with COPD will provide them with the best prognostic information, and 
future classifications of COPD instead of relying only on the severity of airflow obstruction 
(Boutou et al., 2013). Also spirometry measurements reflect only the general pulmonary 
ventilation function, but cannot assess the pathologic changes and the regional morphologic and 
functional abnormalities. A study by Šileikienė et al (2017) confirms significant correlations 
between quantitative computed tomography (CT) measurements of emphysema and airflow 
obstruction, diffusion capacity, and lung volumes. Therefore, performing CT scan will enable 
clinicians to assess emphysema in patients even those in mild stage of airflow obstruction, which 
could help in prescribing personalised treatment for each patient. A recent study pointed out the 
role of spirometry in diagnosis for patients with acute exacerbation COPD during hospitalisation. 
The study finding confirmed that spirometry after several days of hospital admission due to acute 
exacerbation COPD is valid and reproducible in most patients and can assess in disease diagnosis 
and evaluation (FernaÂndez-Villar et al., 2018). 
COPD are heterogeneous diseases and many studies showed that individual COPD patient 
shows biological variability in their clinical presentation and disease severity and progression 
(Müller et al., 2016).  Therefore, the addition of a panel of markers to lung function parameters 
known to predict mortality in COPD, such as age, FEV1 or hospitalizations because of 
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exacerbations (Cazzola, et al., 2008), gas transfer, lung plethysmograph, BODE and CT 
measurements will improve diagnosis and prediction of mortality risk in patients with COPD. 
 
3.6 Conclusion 
In this chapter it was shown that patients pulmonary functions  data were significantly 
different from those of healthy smokers and nonsmokers. Patients were with old age, low body 
weight, high in smoking habit, with greater air flow limitation than healthy smokers and healthy 
nonsmokers. Age, weight and BMI have an impact on subject respiratioty functions when 
investigatin the whole study indviduals.However these parameters have no impact on patients 
disease severity when invetigating the patinet group only. This may due to low size of patients 
sample. What is new is that patients smoking habit, weight, BMI affected bronchodilator 
reversibility. For better understanding of the COPD variability between patients, different 
parameters should be evaluted during patient diagnosis at routine clinical practices, including 
lung plethysmography, gas transfer, arterial oxygen, and CT, as well as multiple spirometry. This 
will provides with accurate diagnosis and better disease management. 
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4. Chapter 4: Evaluation of systemic blood biomarkers for COPD  
 
4.1 Background 
The search for circulating blood biomarkers has mainly focused on plasma or serum 
proteins which are known to be involved in the systemic inflammatory response to irritant or 
lung injury (Ongay et al., 2016). A biomarker is any molecule or material, which level or activity 
indicates the disease process, pathogenic processes, or pharmacologic responses to a new 
therapy. Currently no specific biomarkers have been identified and accepted for COPD routine 
clinical application. Thus there is a great interest in developing biomarkers which can assist in 
discovery of an effective treatment that improve health outcomes of patients with COPD. 
However, biomarker development is extremely challenging and expensive (Doubková et al., 
2015). Most of the biomarkers candidates that have been investigated still not clinically 
validated. COPD is heterogeneous disease in terms of the progression and response to treatment 
therefore it is unlikely that a single biomarker will be sufficient for COPD diagnosis, prognosis 
or treatment evaluation (Ongay et al, 2016). Several biomarkers including cytokines, 
chemokines, metalloproteases and acute phase reactants are implicated in inflammatory 
responses and are also involved in the regulation and progression of several inflammatory 
diseases like COPD. They are produced by a broad range of cells including monocytes and 
macrophages, T-lymphocytes, B-lymphocytes and mast cells, as well structural cells like 
endothelial cells, fibroblasts and adipocytes. Biomarkers, particularly cytokines, are associated 
with inflammatory diseases, with higher levels of TNF-α, IL-1β, IL-6 and IL-8 being a common 
feature of many inflammatory conditions (Calder 2015). 
Among these biomarkers fibrinogen, an inflammatory biomarker, that has been considered 
as a promising biomarker in COPD. It is an acute phase soluble plasma glycoprotein, synthesized 
mainly in the parenchymal cell of the hepatocyte and in the megakaryocyte in bone marrow, and 
converted by thrombin into fibrin during blood coagulation. The normal fibrinogen levels in 
blood are between 1.5 and 3.5 g/L but can increase threefold during inflammation in response to 
increased IL-6 production (Duvoix, et al., 2013; Fattouh and Alkady, 2014).  Fibrinogen levels ≥ 
350 mg/dL consider COPD patients at an increased risk of exacerbations and mortality. 
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Fibrinogen is elevated in COPD patients, and associated with the FEV1 (Vestbo et al, 2011) and 
disease severity (Agusti et al., 2012). Higashimoto et al., (2009), found that patients with an 
exacerbation frequency of >2.52 exacerbations per year, were more likely to show a faster rise in 
plasma fibrinogen than those with a history of infrequent exacerbations during 2-year follow-up. 
Further, Mannino and colleagues (2015) analysed pooled data of 6376 individuals with COPD 
and found that plasma fibrinogen was associated with severity in moderate and severe disease. 
High fibrinogen levels at baseline were associated with an increased risk of hospitalized COPD 
exacerbations within 12 months. Additionally, high fibrinogen was associated with an increased 
risk of death within 36 months among all participants. Therefore, fibrinogen has been considered 
by the USFDA and COPD Biomarker Qualification Consortium (CBQC) for the stratification of 
subjects at risk for hospitalization and mortality (Duvoix et al., 2012). 
CRP is another acute phase inflammatory protein synthesized mainly by hepatocytes in 
response to tissue damage or inflammation. It contributes to the recruitment of circulating 
leucocytes, the uptake of low density lipoprotein cholesterol by macrophages, and destabilisation 
of vascular wall atheroma (Pinto-Plata et al., 2006). It has the ability to bind the receptors of 
phagocytes which clear up apoptotic and necrotic cells. The function of CRP is regulated through 
IL-6 and IL-1. CRP level changes with alterations of lung function volumes, severity of disease, 
and development of pneumonia (Heidari 2012). It is involved in COPD pathogenesis and 
considered as a predictor of lung function decline and mortality in COPD (Higashimoto et al., 
2009). Elevated CRP level in plasma of patients with COPD was reported particularly during 
acute bacterial and viral exacerbations (Barnes et al., 2014).Two different mechanisms have 
been suggested to explain the association between baseline CRP levels and COPD. The first 
hypothesis is linked to the effect of lung inflammation in COPD patients. It is known that 
prolonged exposure to cigarettes smoke leads to lung injury and inflammation causing systemic 
reaction. Additionally CRP level increase is secondary to other circulatory pro-inflammatory 
cytokines include TNF-α, IL-6, IL-8 or fibrinogen. The parallel activation of systemic 
inflammation maintains and increases the local airway inflammation, leading to COPD 
progression. The second hypothesis suggested that elevated levels of CRP are related to the 
occurrence of CVD rather than mortality from COPD itself. It is well known that the majority of 
patients with COPD died either from CVD or cancer but not from lung disease. Thus CRP could 
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be used as a prognostic marker in COPD, as inflammation itself may lead both to lung damage 
and CVD in these patients (Leuzzi et al., 2017). 
Cytokines are small proteins that are released by cells, especially, but not exclusively, 
those that act within the inflammatory and immune systems. Cytokines act through specific 
receptors to affect the activity of the same releasing or other cells. Cytokines include TNF, 
various ILs, interferons, chemokines, and lymphokines (Calder 2015). Cytokines play key roles 
in many pathophysiological processes in COPD, particularly in the chronic inflammation and 
emphysema (Ji et al., 2017). For example, IL-6 is associated with a large number of pulmonary 
and extra-pulmonary inflammatory manifestations in COPD (El-Shimy et al., 2014; Ji et al., 
2017). IL-6 is a pleiotropic proinflammatory and immunomodulatory cytokine, synthesized by 
the airway epithelium, macrophages and other cells at the site of inflammation in response to 
environmental irritant or stress such as smoking. Serum IL-6 levels were significantly higher in 
individuals with COPD when compared with controls and increase during exacerbations 
(Higashimoto et al., 2009; Ferrari et al., 2010). IL-6 is the main regulator and activator of CRP 
and fibrinogen in the liver, and it is associated with CRP levels in COPD patients. It also 
involved in hematopoiesis, causing thrombocytosis and leukocytosis with its overexpression 
(Ferrari et al., 2010; El-Shimy et al., 2014).  
TNF-α is another proinflammatory cytokine mainly produced by activated macrophages in 
addition to  monocytes, T-cells, B-lymphocytes, fibroblasts, and endothelial cells. It is a potent 
cytokines that play a critical role in the pathogenesis of COPD by regulating the expression and 
the release of various proinflammatory mediators that cause tissue remodeling and damage 
(Mukhopadhyay et al., 2006). The stimulation of TNF-α by Inhaled lipopolysaccharide (LPS) 
induce pulmonary inflammatory responses in healthy subject (Kawayama et al., 2016).  
In COPD, different immune inflammatory cells are implicated in lung inflammation 
including innate immunity; alveolar macrophages, neutrophils, dendritic cells, eosinophils, 
natural killer cells, and adaptive immunity; T- and B-lymphocytes. Alveolar macrophages 
particularly appear to regulate the inflammatory response by secreting various chemokines to 
attract immune cells from circulation to the injury site and to initiate T-cell immune response. 
Chemokines are a group of chemotactic molecules that regulate and direct the movement of 
leukocytes during inflammation. Chemokines are classified into four subfamilies, CXC, CC, C 
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and CX3C, according to the position of the conserved cysteine residues (Odler et al., 2016; 
Muñoz-Esquerre et al., 2017). The CXC chemokine IL-8, also called CXCL8, is a neutrophil and 
T-cells potent chemoattractant and activator, which involved in inflammation-mediated 
neutrophil infiltration and chemotaxis. It is secreted by monocytes, alveolar macrophages, 
eosinophils, pulmonary epithelium, airways smooth muscles cells, fibroblasts and endothelial 
cells. Bacteria and elastase released from neutrophils may also stimulate epithelial cells to 
produce IL-8 (Chung et al., 2001).  It was found in vitro that cigarette smoke and TNF-α can 
stimulate IL-8 production from macrophages (Sarir et al., 2009). IL-8 levels found to be 
increased in BAL and sputum samples of patients with COPD (Di Stefano et al., 2004).  
An example of the CC-chemokine family is the CC-chemokine ligand-18 (CCL18), 
previously named pulmonary and activation-regulated chemokine (PARC), macrophage 
inflammatory protein-4 (MIP-4), is a 7-kD protein regulatory cytokine that is highly expressed in 
dendritic cells, monocytes and M2-macrophages in the lungs in response to pro-inflammatory 
Th2 cells cytokines (Sin et al., 2011; Plönes et al., 2012). CCL18 was shown to be a macrophage 
differentiation factor and has the possibility to induce an M2 macrophage phenotype, and 
collagen production in lung fibroblasts (Dilektasli et al., 2017). CCL18 is involved in chemotaxis 
of naive T-cells, T-regulatory cells, Th2 cells, dendritic cells and B-cells. Because it 
predominantly produced in the lungs, CCL18 has been evaluated in several pulmonary diseases 
including; idiopathic interstitial pneumonias and systemic sclerosis (Prasse et al., 2007), 
community-acquired pneumonia, and lung cancer (Plönes et al., 2012), COPD (Sin et al., 2011; 
Dilektasli et al., 2017), where CCL18 serum levels have been found to be elevated and in some 
disease was associated to mortality (Spoorenberg et al., 2017). Further, few studies suggest that 
CCL18 might consider as serum biomarker of cardiovascular hospitalization or mortality in 
COPD patients (Sin et al., 2011; Kraaijeveld et al., 2007).   
Another member of the CXC chemokine family is the IFN-γ-inducible protein 10 (IP-10), 
also known as CXCL10, secreted by several inflammatory cells including; monocytes, 
lymphocytes, neutrophils, and bronchial epithelial cells in response to inflammation. The activity 
of this chemokine is regulated by IFN-γ and TNF-α, and mediated by binding to CXCR3 
receptor which is expressed by Th1 cells and in many other cell types including macrophage and 
lung epithelial cells (Torvinen et al., 2007; Quint et al., 2010). IP-10 is potent antiviral 
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chemokine that able to recruit and attract activated monocytes, Th1and Th2 lymphocytes and NK 
cells to the sites of infection. Because respiratory viral infections such as influenza virus, 
rhinoviruses, and respiratory syncytial virus are the main pathogens associated with COPD 
exacerbations, so it is suggested that IP-10 may also play a role in the inflammatory process of 
COPD (Wu et al., 2016).  
Several studies continue to investigate novel biomarkers which seem to show promising 
results that might help in the early diagnosis, progression and treatment of COPD. There has 
been increasing interest in using pulmonary biomarkers to understand and monitor the 
inflammation in the respiratory tract of patients with COPD (Doubková et al., 2015). In the 
current study, Clara cell protein (CC16) and receptors for advances glycation end product 
(RAGE) were investigated as promising biomarkers of COPD. CC16 is specific pulmonary 
protein of the secretoglobin family with an anti-inflammatory and detoxification properties, 
which has been suggested to be a useful marker of airway and lung epithelial injury (Pilette et 
al., 2001). CC16 is a small protein with molecular weight of approximately 16KDa (Doubková 
et al., 2016). It is mainly secreted by non-ciliated, non-mucous club cells or Clara cells, which 
are localized in the respiratory bronchioles and by non-ciliated columnar epithelial cells present 
in the large and small airways (Ongay et al., 2016). It can binds to phospholipids and to different 
cell types, inhibiting inflammation, migration and invasion. The low level of CC16 in COPD 
might associate with a defect in anti-inflammatory action and detoxifying effect of CC16 (Pilette 
et al., 2001). 
RAGE is a transmembrane, multi ligand belong to the immunoglobulin superfamily of cell 
surface molecules that is highly expressed in normal human lung. RAGE is involved in the 
glycation of serum lipids and proteins that alter the structure and function of endothelial and 
epithelial cells in COPD airways (Wu et al., 2011; Cheng et al., 2013; Gopal et al., 2014). It is 
distributed and expressed at low levels in human normal tissues and cell types, but it highly 
expressed in the lung tissue particularly in alveolar type-I epithelial cells, bronchial smooth 
muscle cells, vascular endothelial cells, alveolar macrophages and alveolar type-II epithelial cells 
(Sambamurthy et al., 2015). RAGE exists in the body in two main forms, membrane-bound 
RAGE (RAGE) and the circulating soluble form of RAGE (sRAGE). The latter is a product of 
either alternative splicing events or proteolysis of cleavage of RAGE cell surface receptor 
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(Cheng et al., 2013). The circulating sRAGE can acts as a decoy receptor for Advanced 
Glycation End products (AGEs), preventing binding of AGEs to RAGE and prevents signaling at 
the cell surface receptor subsequently inhibit the activation of transcription factor NF-kB and 
inflammatory responses (Yonchuk et al., 2015; Hassanein et al., 2016).  
NF-κB involved in regulating different aspects of innate and adaptive immune functions 
and serves as a pivotal mediator of inflammatory responses (Liu et al 2017). The AGEs/RAGE 
interaction can activate signalling pathways of NF-kB that in turn activate many 
proinflammatory cytokines such as IL-1, IL-6 and TNF-α. Interestingly, cytokines themselves 
can activate NF-kB, that increases RAGE expression and subsequent RAGE-mediated NF-kB 
activation result in a positive auto-regulatory loop (Wu et al., 2011). Activation of RAGE 
signaling pathway is considered a protective mechanism to promote an inflammatory response 
against inhaled irritant or tissue injury. Thus, increased expression of RAGE and its ligands, and 
decreased sRAGE expression in the lungs suggests that RAGE signaling pathway enhances the 
inflammatory response in COPD (Oczypok et al., 2017). Multiple studies have reported that 
circulating sRAGE could be a useful biomarker for COPD specifically to the presence and 
progression of emphysema (Yonchuk et al., 2015). 
Another lung specific biomarker is SP-D, a large hydrophilic glycoprotein with multimeric 
structure, synthesized and secreted mainly by endoplasmic reticulum of alveolar type II 
pneumocytes and the secretory granules of non-ciliated club cells in the bronchioles (Madsen et 
al., 2000; Sin et al., 2008; Lomas et al., 2009). SP-D modulates the pulmonary immune defense; 
decreases the expression of pro-inflammatory cytokines, decreases oxidative stress and increases, 
facilitates the resolution of lung inflammation. It also enhances clearance of a wide variety of 
pathogens and promotes phagocytosis of apoptotic cells (Sims et al., 2008).  Previous studies 
have described associations between SP-D and COPD, in which SP-D levels were found to be 
elevated in COPD patients when compared to healthy smoking controls (Sin et al., 2008; Lomas 
et al., 2009). It is suggested that SP-D levels may be correlated with disease progression in other 
pulmonary diseases, including community-acquired pneumonia and asthma (Liu at al., 2014). 
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Microparticles (MPs) are small membrane vesicles which are released by shedding from 
the cell plasma membrane following tissue injury and cell apoptosis. There are different types of 
MPs that are defined according to specific cell membrane antigens including; Endothelial and 
platelet cell adhesion molecule 1 (CD31), leukocytes (CD11a), granulocytes (CD66b), and 
monocyte/macrophages (CD11b). Cluster of differentiation 31(CD31), also known as platelet 
endothelial cell adhesion molecule (PECAM), is one of the MPs which are likely to be 
implicated in the pathogenesis of COPD (Lacedonia et al. 2016). CD31 is a heavily 
transmembrane glycoprotein member of the immunoglobulin superfamily that is highly 
expressed on endothelial cells and at a lower level on platelets, macrophages, granulocytes, B-
cells, some T-cells subtypes, dendritic cells and NK cells. CD31 lies outside the adherence 
junctions on endothelial cells, and on the surface of platelets, neutrophils, and T cells (Falati et 
al., 2006).   
CD31 is involved in vascular biology, in particular, in the regulation of platelet function, 
angiogenesis, thrombosis, and apoptosis, and endothelial cell permeability, trans-endothelial 
migration of leukocytes. Additionally, CD31 is able to enhance the activation of T- and B-cells, 
inhibit dendritic cell development. It is highly expressed in the vascular system of kidney, lung, 
and trachea while lower expressed in brain, heart, and liver (Falati et al., 2006; Woodfin et al., 
2007). It is significant for the leukocytes transmigration across the endothelium tissue. For 
example, the interaction between two platelet and endothelial cell adhesion molecule CD31 
expressed at the borders of the endothelial cells and on neutrophils is essential (Blidberg et al., 
2013). Oxidative stress induced by H2O2 or cigarette smoke extract stimulate the release of 
different types of MPs from cultured endothelial cells. An in vitro study by Takahashi et al. 
observed that the majority of CD31 are released from pulmonary endothelial cells in response to 
apoptosis when stimulated by either H2O2 or cigarette smoke extract. H2O2-induced endothelial 
injury and activation promote alveolar destruction in COPD lung (Takahashi et al., 2014). H2O2 
can serve as a signaling molecule at low concentrations as well as a damage agent at higher 
concentrations and thus has a complex cellular role. Moreover, hypochlorous acid (HOCl) 
generated in the presence of H2O2 can further lead to formation of more toxic and damaging ROS 
such as hydroxyl radicals (•OH) (Boukhenouna et al., 2018). 
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In COPD, the search for circulating blood biomarkers has mainly focused on plasma or 
serum proteins which are known to be involved in the systemic inflammatory response (Ongay et 
al, 2016). Several plasma biomarkers have been measured and found to differentiate COPD 
patients from healthy subjects. In the current study, the basal systemic levels of selected 
biomarkers; CRP, Fibrinogen, CC16, CD31, CCL18, IL-6, IL-8, TNFα, IP10, SP-D and RAGE, 
were measured and investigated for their potential utility as an inflammatory biomarkers in 
COPD patients and compared with their levels in healthy smokers and healthy subjects. This 
could facilitate early diagnosis, monitor disease progression, and evaluate treatment outcome. 
 
4.2 Objectives 
 Investigate the levels of systemic blood biomarkers in plasma samples. Data from COPD 
patients, healthy smokers and healthy controls will be compared. 
 Study the association between the level of systemic blood biomarkers in COPD patients 
and disease severity. 
4.3 Method 
4.3.1 Prioritized COPD Protein Biomarkers  
Numerous observational cohort studies have investigated different inflammatory 
biomarkers candidates that were selected according to their studies proposed criteria to 
investigate the effect of systemic inflammation, and its association with comorbidities in patients 
with COPD. A systematic study of previous literature and clinical studies by Ongay et al. (2016) 
provided a panel of biomarker candidates that have the potential of becoming valid and clinically 
useful COPD biomarkers in the near future.  Based on the Ongay review and previous published 
work (Pinto-Plata et al., 2007; Pinto-Plata et al 2012; Faner et al., 2013) and taking account of 
potential biological mechanisms believed to be relevant in the pathogenesis of COPD, a panel of 
11 biomarkers were selected that previously showed some association with COPD and/or 
showed statistically significant differences between COPD patients and healthy controls. They 
were grouped as highly abundant acute phase reactants creative protein: CRP and Fibrinogen; 
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inflammatory biomarkers: IL-6, and TNF-α; chemoattractant biomarkers: IL-8, CCL18 and IP10; 
and pulmonary regulated protein CC16, SP-D, RAGE and MP-CD31 (Table 4.1). The list of 
potential protein biomarkers was further reduced and refined by selecting only those that show 
activity in the circulation of all the studied groups. This follows the recommendation to 
demonstrate a strong, consistent and independent association between a biomarker and COPD. In 
this way, 5 potential proteins remained for the final biomarker panel; fibrinogen, CRP, CCL18, 
CC16 and CD31. 
Table ‎4.1: Biomarkers investigated as potential COPD biomarkers within the study cohort. 
Biomarker Abbreviation Proposed pathophysiological role 
and mediator effects 
Sources Reference 
Tumor necrosis 
factor  
TNF-α Proinflammatory cytokine  
Activates epithelium, endothelium, 
antigen-presenting-cells 
Activates monocytes/macrophages 
Macrophages 
T-cells  
Airway Epithelial 
cells 
Kawayama et 
al., 2016 
 
Interleukin-8  IL -8 
 
Inflammatory chemokine 
Chemoattractant and activator 
for monocytes/macrophages and 
neutrophils 
Monocytes/ 
macrophages 
Pulmonary 
epithelium 
Airways 
fibroblasts &  
endothelial cells 
Chung et al., 
2001 
 
Interleukin-6  IL -6 
 
 Inflammatory cytokine 
Monocytes/macrophages 
T-cell growth factor 
Hematopoiesis 
Monocytes/ 
macrophages  
Airway 
epithelium 
Ferrari et al., 
2010 
El-Shimy et 
al., 2014 
C-reactive 
protein  
CRP Acute phase reactants  Hepatocytes 
/Liver 
Heidari 2012 
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Fibrinogen  NA 
 
Blood coagulation factor  
 
Hepatocyte/Liver 
Megakaryocyte/ 
bone marrow 
Duvoix et al., 
2013  
Fattouh 
&Alkady, 
2014 
Soluble 
receptor for 
advanced 
glycation 
endproducts  
sRAGE Pro-inflammatory pattern 
recognition receptor of cell surface 
Glycation of serum lipids and 
proteins of endothelial and epithelial 
cells 
Alveolar type-I-II 
epithelial 
cells/Bronchial 
smooth muscle 
cells 
Vascular 
endothelial 
cells/Alveolar 
macrophages 
 
 
Wu et al., 
2011 
Cheng et al., 
2013 
Gopal et al., 
2014 
Sambamurthy 
et al., 2015 
 
Surfactant 
protein D  
SP-D Pulmonary protein involved in innate 
immunity  
Decreases the expression of pro-
inflammatory cytokines 
Increases the resolution of lung 
inflammation 
Promotes phagocytosis of apoptotic 
cells 
 
Alveolar type II 
Pneumocytes  
Non-ciliated club 
cells/bronchioles 
Madsen et al., 
2000 
Sin et al., 
2008 
Lomas et al., 
2009 
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Club cell 
protein 16  
CC16 Lung inflammatory protein  
anti-inflammatory and detoxification 
properties 
Inhibit cells inflammation, migration 
and invasion 
Clara cells/ 
bronchioles 
Epithelial 
cell/small 
airways  
Pilette et al., 
2001 
Ongay et al., 
2016 
 
C-C motif 
chemokine 18 
 
CCL18/ PARC Lung-predominant inflammatory 
protein. 
Pulmonary and activation-regulated 
chemokine for naive T-cells, T-
Regulatory cells, Th2 cells, dendritic 
cells and B-cells. 
Dendritic cells 
Monocytes/ 
macrophage 
(M2)/lung 
Sin et al., 
2011 
Plönes et al., 
2012 
 Dilektasli et 
al., 2017 
Interferon 
gamma-induced 
protein 10/ 
C-X-C motif 
chemokine 10  
IP10/CXCL-10 Inflammatory chemokine 
Chemoattractant for monocytes, Th1, 
Th2 lymphocytes and NK cells 
Monocytes 
Lymphocytes 
Neutrophils 
Bronchial 
epithelial 
cells/lung 
Torvinen et 
al., 2007 
Quint et al., 
2010 
Cluster of 
differentiation 
31/ 
Platelet 
endothelial cell 
adhesion 
molecule  
CD31/PECAM  Small membrane vesicles 
/Immunoglobulin 
Trans-endothelial migration of 
leukocytes 
Endothelial cell permeability 
Angiogenesis/Thrombosis 
Endothelial 
cells/lung 
Platelets/ B-cells 
Macrophages 
T-cells /NK cells.  
Falati et al., 
2006  
Woodfin et 
al., 2007 
 
  
95 
 
4.3.2 ELISA for R&D Systems-based assays 
4.3.2.1 Reagent and Standards Preparation  
All ELISA kits were purchased from R&D Systems, except a fibrinogen kit was bought from 
Abcam. Details of the commercial kits composition; standard, capture, detection antibodies stock 
and working solution concentration, standard sensitive range, enzyme substrate reagents dilution 
are summarised in table 4.2 and 4.3. Anti-human capture antibody was reconstituted in 0.5 ml of 
Dulbecco's Phosphate Buffered Saline, (PBS), (sterile, filtered, w/o Calcium w/o Magnesium, 
Biosera, Labtech International Ltd, Sussex, UK and further dilution was made in PBS, to the 
working concentration. Anti-human detection antibody was reconstituted in 1.0 ml of reagent 
diluent 1% BSA, sterile, filtered in PBS, and further dilution was made in reagent diluent to the 
desire working concentration. For standard preparation; each standard vial was reconstituted with 
0.5 mL of deionized or PBS according to manufacture instructions (R&D Systems).  After initial 
reconstitution 1ml of high standard was prepared per plate assayed at the concentration indicated. 
A seven point standard curve using 2-fold serial dilutions in reagent diluent was prepared. 
Working dilutions should be prepared on experiment day and used immediately. 
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Table ‎4.2: Summary of ELISA assay stock and working solution concentration of capture 
and detection antibodies for individual biomarker. 
 
Biomarker Capture 
Antibody 
Detection 
Antibody 
Capture Antibody 
concentration 
Detection Antibody 
concentration 
Stock  Working 
solution  
Stock  Working 
solution  
Human IL-6 
 
DY206 
Mouse Anti-
Human IL-6 
Antibody 
Biotinylated 
Goat Anti-
Human IL-6 
Antibody 
240µg/ml 
 
 
2µg/ml 3µg/ml 50ng/ml 
Human IL-8/ 
CXCL8 
 
DY208 
Mouse Anti-
Human IL-8 
Capture 
Antibody 
Biotinylated 
Goat Anti-
Human IL-8 
Detection 
Antibody 
240µg 
 
4µg/ml 1.2µg/ml 20ng/ml 
CRP 
 
DY1707 
 
 
Mouse Anti-
Human CRP 
Capture 
Antibody 
 
 
Biotinylated 
Mouse Anti-
Human CRP 
Detection 
Antibody 
360µg 2µg/ml 16.2µg/ml 90ng/ml 
Human 
TNF-α 
DY210 
Mouse Anti-
Human TNF-α 
Antibody 
 
Biotinylated 
Goat Anti-
Human TNF-α  
Antibody 
480 µg/ml 
 
4µg/ml 24µg/ml 
 
400ng/ml 
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Human 
CC16/Uterogl
obin 
 
DY4218 
 
Rat Anti-
Human 
Uteroglobin 
Capture 
Antibody 
Biotinylated 
Rat Anti-
Human 
Uteroglobin 
Detection  
Antibody 
360µg/ml 2µg/ml 360µg/ml 500ng/ml 
Human CD31/ 
PECAM-1 
 
DY8064-05 
 
Mouse Anti-
Human CD31 
Capture 
Antibody 
Biotinylated 
Sheep Anti-
Human CD31 
Detection 
Antibody 
480µg/ml 4µg/ml 12µg/ml 200ng/ml 
Human 
CCL18/PARC 
 
DY394-05 
 
Mouse Anti-
Human PARC 
Capture 
Antibody 
Biotinylated 
Goat Anti-
Human PARC 
Detection 
Antibody 
360µg 
 
2µg/ml 18µg/ml 100ng/ml 
Human 
CXCL10/ 
IP-10 
 
DY266-05 
 
 
 
Mouse Anti-
Human IP-10 
Capture  
Antibody 
Biotinylated 
Goat Anti-
Human IP-10 
Detection 
Antibody 
240µg/ml 
 
 
2µg/ml 0.750 
µg/ml 
12.5 
ng/ml 
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Human  SP-D 
 
DY1920 
Mouse Anti-
Human SP-D 
Capture  
Antibody 
 
Biotinylated 
Mouse Anti-
Human SP-D 
Detection 
Antibody 
360µg 2µg/ml 90µg/ml 500ng/ml 
Human RAGE 
 
DY1145 
Mouse Anti-
Human RAGE 
Capture 
Antibody 
Biotinylated 
Goat Anti-
Human RAGE 
Detection 
Antibody 
180µg 
 
1µg/ml 36µg/ml 100ng/ml 
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Table ‎4.3: Summary of ELISA assay standard stock concentration, sensitivity, and enzyme 
substrate dilution for each biomarker. 
Biomarker Standard 
Stock 
concentration 
High 
standard 
limit 
Lower 
standard limit 
Streptavidin-HRP 
Dilution 
 
Human IL-6 
 
90 ng 
 
600 pg/mL 
 
9.38pg/mL 
 
1:40 
 
Human IL8/ 
CXCL8 
 
40 ng 
 
2000pg/mL 
 
31.3pg/mL 
 
1:40 
 
CRP 
 
50 ng 
 
1000 pg/mL 
 
15.6 pg/mL 
 
1:200 
Human 
TNF-α 
 
 
67.5 ng 
 
1000 pg/mL 
 
15.6 pg/mL 
 
1:40 
 
Human CC16 
 
75 ng 
 
2000pg/mL 
 
31.3pg/mL 
 
 
1:200 
Human CD31/ 
PECAM-1 
 
 
190 ng 
 
10,000 
pg/mL 
 
156 pg/mL 
 
 
1:40 
  
100 
 
Human 
CCL18/PARC 
  
 
65 ng 
 
500 pg/mL 
 
 
7.81 pg/mL 
 
 
1:200 
Human 
CXCL10/ 
IP-10 
 
55 ng 
 
2000 pg/mL 
 
31.3pg/mL 
 
1:40 
 
Human  SP-D 
 
75 ng 
 
10,000 
pg/mL 
 
156 pg/mL 
 
 
1:200 
 
 
Human RAGE 
 
25 ng 
 
4000 pg/mL 
 
62.5 pg/mL 
 
1:200 
 
Fibrinogen 
 
 
200ng/ml 
100 
ng/mL 
1.56 
ng/mL 
 
NA 
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4.3.2.2 Assays procedures 
The procedure for ELISA R&D Systems-based assays was previously mentioned in 
details (see section 2.1.4.4). 
4.3.2.3 Plasma Dilution selection  
Measuring biomarkers in plasma is a very useful parameter that gives an indication of 
specific diseases progression or diagnosis. However human plasma is a complex matrix contain 
heterophilic antibodies and may require a dilution in an appropriate buffer to overcome matrix 
effects, and to prevent heterophilic antibodies from binding to the capture and detection 
antibodies used in capture ELISA, causing false positive results. Plasma sample diluent utilised 
as a buffer matrix for diluting out plasma samples in antigen-capture ELISA formats, and for 
diluting standards in ELISA standard curve preparation. Once samples are diluted, the dilution 
factor should be included when calculating results. Dilution of the sample before performing the 
actual experiment is significant parameter for determining the sensitivity of ELISA in human 
samples. It assess in deciding the amount of actual concentration required from the sample to 
obtain a result within the range of reference standard protein. Without dilution, it is difficult to 
achieve highly sensitive results of protein concentration. Therefore, optimum dilution for the 
sample of target protein is a vital parameter for obtaining better results (Thakur et al., 2015). 
In the current study the plasma sample diluent was a buffered BSA protein base which 
provides an assay environment that minimizes nonspecific binding while maintaining proper 
ionic strength and pH for efficient antibody-antigen interaction. The optimization of plasma 
samples dilution was carried out for each biomarker by using PBS supplemented with 1% BSA, 
to dilute plasma samples. Two plasma samples were selected from each of three studied groups; 
COPD, healthy smoker and healthy nonsmoker groups, to be 10-fold diluted, 1:10, 1:100, 
1:1000, and 1:10000, and then assayed in 96-well plate alongside undiluted samples. ELISA 
assay was carried out to detect selected biomarker level in diluted and undiluted plasma samples. 
A 96-well plate was coated with 100 μl of the diluted anti-human capture antibody per well. The 
plate was sealed (Greiner Bio-One GmbH, Ltd, Stonehouse, Germany) and incubated overnight 
at room temperature. After the incubation, the 96-well plate was washed twice with wash buffer 
(0.05% Tween®20 in PBS, pH 7.2-7.4) using auto washer equipment (Mikura, West Sussex, 
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UK). After each wash step any remaining wash buffer was removed by blotting the plate against 
clean paper towels. The plate was blocked by adding 300μl of reagent diluent, 1% BSA in PBS, 
pH 7.2-7.4, 0.2 μm filtered, to each well, and was incubated at room temperature for a minimum 
of 1 hour. The wash step was repeated and 100μl of sample or standards was added per well as 
duplicate. The plate was sealed with an adhesive strip and incubated 2 hours at room 
temperature. The wash step was repeated and 100μL of the diluted detection antibody was added 
to each well. The plate was sealed with an adhesive strip and incubated 2 hours at room 
temperature. The wash step was repeated and 100μl of the working dilution of Streptavidin-HRP 
(streptavidin conjugated to horseradish-peroxidase, 1:40) (R&D Systems, Catalog #DY 893975) 
was added to each well. The plate was covered and placed away from direct light for 20 minutes 
at room temperature. The wash step was repeated and 100μl of substrate solution, a mixture of 
color reagent A (H2O2) and color reagent B (Tetramethylbenzidine) (1:1, R&D Systems, Catalog 
# DY999) was added to each well and plate was incubated for 20 minutes at room temperature 
away from direct light, then 50μl of stop solution (2N H2SO4) (R&D Systems, Catalog # DY994) 
was added to each well.  The optical density of each well was determined using a microplate 
reader (Varioskan LUX Multimode Microplate Reader, Thermo Fisher Scientific, UK) (see 
appendix B for software user manual guide), set to 450 nm with a wave length correction at 
570nm. A standard curve was constructed by plotting the mean absorbance for each standard on 
the y-axis against the concentration on the x-axis and a best fit curve was drawn through the 
points on the graph. The concentration of biomarkers in sample was determined by interpolating 
the blank control subtracted absorbance values against the standard curve. Resulting value was 
multiplied by the appropriate sample dilution factor to obtain the concentration of biomarker in 
the sample. Three experiments were performed and standard error was determined from the 
standard deviation derived from the means of total sample number. Then the appropriate dilution 
factor of each biomarker was used to dilute the plasma sample when assay the entire study 
subject. Based on obtained values undiluted concentration of plasma samples were used when 
dilution not required. 
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4.3.3 Human Fibrinogen ELISA Assay  
The human fibrinogen kit assay (ab208036, Abcam, Cambridge, UK) is based on 
applying an affinity tag labeled capture antibody and a reporter conjugated detection antibody 
which immuno-capture the sample target protein in solution. This entire complex of (capture 
antibody- target protein-detection antibody) is in turn immobilized via immuno-affinity of an 
anti-tag antibody coating the well (Figure 4.1). 
 
 
Figure ‎4.1: Summary of human fibrinogen simple step ELISA assay (Abcam, Cambridge, 
UK). 
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4.3.3.1 Reagent and Standard Preparation 
1× Wash Buffer PT (ab206977), Proclin, was prepared by diluting 10× wash buffer PT 
with deionized water. Antibody mixture was prepared by diluting the capture and detector 
antibodies in antibody diluent CPI, (ab193969), (EDTA disodium salt, Proclin, Alizarin Red S). 
A total of 6 ml of the Antibody mixture was prepared by mixing 600μl 10× capture Antibody 
and 600μL 10× detector. A stock standard solution of 200ng/mL was prepared by reconstitute 
Fibrinogen human protein standard in 250μl water. The solution was mixed thoroughly and 
gently, and then was hold at room temperature for 10 minutes. This is the 200 ng/ml stock 
standard solution. A serial dilution was prepared by adding 150μl sample diluent NS, (ab193972, 
EDTA disodium salt and Proclin), into 8 tubes. A 150μl from the Stock Standard Solution of 200 
ng/ml, (ab208036-CP164706), was added to tube number one to get100 ng/ml and the following 
dilution series was prepared 50, 25, 12.5, 6.25, 3.13, 1.56 ng/ml. Standard number 8 contained 
no protein and is considered as a Blank control. Plasma samples were diluted (1:100,000) in 1× 
wash buffer. 
4.3.3.2 Assay Procedure 
All reagents, working standards, and samples were prepared at room temperature prior to 
use. Fifty microliters of samples or standards was added to appropriate wells. Fifty microliters of 
the Antibody Cocktail was added to each well. Then the plate was sealed and incubated for 1 
hour at room temperature on a plate shaker set to 400 rpm. After the incubation period each well 
with was washed three time with 350 μl 1× Wash Buffer PT to remove unbound material. 
Removal of liquid at each step is essential for good performance. After the last wash the plate 
was inverted and blotted against clean paper towels to remove excess liquid. Hundred microliters 
of TMB substrate, Hydrogen peroxide and TMB, was added to each well and the plate was 
incubated for 10 minutes in the dark on a plate shaker set to 400 rpm. TMB substrate was 
catalyzed by HRP, generating blue coloration. Then the reaction was stopped by addition of 100 
μl of Stop Solution (ab208036-CP164601), phosphoric acid, to each well and was shaken on a 
plate shaker for 1 minute to mix, completing any color change from blue to yellow.  Signal was 
generated proportionally to the amount of bound Fibrinogen and the optical density was 
measured at 450 nm was record by microplate reader. The average absorbance value for the 
blank control standard absorbance was calculated and subtracted from all other absorbance 
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values. A standard curve was created by plotting the average blank control subtracted absorbance 
value for each standard concentration (y-axis) against the target protein concentration (x-axis) of 
the standard. A four parameter curve fit (4PL) was used to plot these values and fit a curve to the 
data. The concentration of the fibrinogen in the plasma sample was determined by interpolating 
the blank control subtracted absorbance values against the standard curve. Resulting value was 
multiplied by the appropriate sample dilution factor to obtain the concentration of fibrinogen in 
the sample. 
4.3.4 Statistical Analysis  
The data were expressed and graphed as mean (standard deviation; SD). The D’Agostino–
Pearson omnibus normality test was performed to test normality of the data distribution. For data 
normally distributed one-way ANOVA analysis of variance followed by Tukeys multiple 
comparison post-test was performed to determine whether the differences between the groups 
were statistically significant. Differences were considered significant if the probability (P) value 
was <0.05, highly significant if P value was <0.01 and P value <0.001, and insignificant if P 
value was >0.05. Correlation analyses of two variables were carried out using Pearson methods, 
depending on the normality of the data distribution. All statistical analyses were performed using 
graphpad prism and InStat software, version 7.04 and 3.10.32 respectively. 
 
4.4 Results 
4.4.1 Plasma Dilution selection  
The assay was carried out to estimate the proper dilution factor for plasma sample before 
measuring our biomarker candidates, IL-6, IL-8, TNF-α, IP-10, fibrinogen, CRP, CC-16, CD31, 
RAGE and CCL18, in the study cohort. Results indicated that undiluted plasma was the best 
option for the following biomarkers; IL-6, IL-8, TNF-α, IP-10, SP-D and RAGE. A dilution of 
1:10 was suitable for CC16 and CD31, whilst 1:100 was the optimum for CCL18. A higher 
dilution was required for CRP of 1:10,000. For Fibrinogen the optimum dilution factor was 
established as 1:100,000 following supplier’s recommendations. All these results are 
summarized in Figure 4.2. 
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Figure ‎4.2: Selection of dilution factor for biomarkers in plasma samples. The figure shows 
the optimum dilution factor using 10-fold dilution of plasma for each biomarker; CRP (A), CC16 (B), 
CD31 (C), and CCL18 (D), in COPD patients, healthy smokers and healthy controls (n=6). These 
analyses were performed using Graph Pad Instat Software. Definition of abbreviations: COPD, chronic 
obstructive pulmonary disease; HS, healthy smokers; HNS, healthy nonsmokers; CRP, creative reactive 
protein; CC16, clara cells 16; CCL18, Chemokine (C-C motif) ligand 18; CD31, cluster of differentiation 
31. 
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4.4.2 Prioritized COPD Protein Biomarkers  
Only five biomarkers from the study candidates list showed activity in the circulation of 
the entire study cohort including; fibrinogen, CRP, CCL18, CC16 and CD31. In contrast, other 
biomarkers; IL6, IL8, TNFα, IP10, SP-D and RAGE, showed no activity in circulation of most 
subjects of the study groups. For example; RAGE was detectable in 26% of the entire subjects of 
the study group, and mostly were healthy nonsmokers. IP10 was detectable in 16% of the studied 
subjects whereas IL-6, TNFα, and SP-D showed activity in circulation of only 10% from the 
total studied subjects. However IL-8 showed no activity at all in three studied groups. There was 
no relation between patients’ disease stage/FEV1 and the undetectable level of biomarkers. 
Summary of the results can be seen in Figure 4.3 
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Figure ‎4.3: Number of subjects with detectable biomarkers compared to the entire cohort. 
These analyses were performed using Graph Pad Instat Software. Definition of abbreviations: IL6; 
Interleukin-6, IL8; Interleukin-8, TNFα; Tumor necrosis factor, IP-10; Interferon gamma-induced protein 
10, SP-D; Surfactant protein D, and RAGE; Soluble receptor for advanced glycation end products. 
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4.4.3 Measuring the level of inflammatory biomarkers in plasma samples 
The plasma level of the biomarker candidates; fibrinogen, CRP, CC16, CCL18 and 
CD31, was measured in patients with COPD, healthy smoker and healthy nonsmokers. The mean 
value and SD of plasma level of CRP was significantly higher in patients with COPD (4.48±28 
mg/l) when compared to those of healthy nonsmoking individuals (2.27±2 mg/l) (p =0.007). 
Similarly, the mean value and SD of CRP in COPD patient was higher than those in healthy 
smokers (p =0.027). Mean value and SD of total circulating fibrinogen was significantly higher 
in COPD patients (409±181mg/dl) when comparing with healthy smokers (136±66 mg/dl) (p 
<0.0001) and healthy nonsmoking controls (137±49 mg/dl) (p<0.0001). In contrast, the mean 
value and SD of CC16 was significantly lower in plasma of COPD group (2.75±1.19 ng/ml) 
compared to healthy nonsmoking group (5.77±2.66 ng/ml) (p =0.014). The mean value and SD of 
CC16 in COPD patient was also lower than those in healthy smokers but differences did not 
reach statistical significance (p >0.05). However, no significant differences correlations among 
COPD patients, healthy smokers and healthy nonsmokers groups were observed in plasma level 
of CD31 (8.7, 7.4, and 7.6 ng/ml respectively) (p > 0.05) and CCL18 (33, 29, and 27 ng/mL 
respectively) (p > 0.05). All these results are summarized in Table 4.4 and Figures 4.4 
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Table ‎4.4: Mean value and significance of CRP, Fibrinogen, CC16, CCL18 and CD31 in the 
plasma of the study cohort 
Biomarkers 
 
COPD HS HNS P value 
COPD vs 
HS 
P value 
COPD vs 
HNS 
P value 
HS vs HNS 
CRP 
mg/L 
4.5 (2.8) 2.4 (1.7) 1.8 (1.5) 0.027 0.007 >0.05 
Fibrinogen 
mg/dL 
409 (181) 136 (66) 137 (49) <0.0001 <0.0001 >0.05 
CC16  
ng/ml 
2.75 (1.2) 
 
4.36 (3.5) 5.77 (2.7) >0.05 0.014 >0.05 
CCL18  
ng/ml 
33 (10) 29 (9.5) 27 (8.2) >0.05 >0.05 >0.05 
CD31  
ng/ml 
8.7 (6) 7.4 (3) 7.6 (6.2) >0.05 >0.05 >0.05 
Data expressed as mean (standard deviation) unless otherwise stated. The data represents the mean ± SD 
from three experiments. P value < 0.05 as determined by one-way ANOVA analysis of variance followed 
by Tukeys multiple comparison post-test indicate a significant difference between the groups. These 
analyses were performed using Graph Pad Instat Software. Definition of abbreviations: COPD, chronic 
obstructive pulmonary disease; HS, healthy smokers; HNS, healthy nonsmokers; CRP, creative reactive 
protein; CC16, clara cells 16; CCL18, Chemokine (C-C motif) ligand 18; CD31, cluster of differentiation 
31.  
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Figure ‎4.4: The plasma level of biomarker candidates in the studied groups. (A) CRP (mg/l), 
(B) Fibrinogen (mg/dl), (C) CC16 (ng/ml), (D) CCL18 (ng/ml), and (E) CD31 (ng/ml), in plasma of 
COPD patients, HS and HNS. Cytokines were measured by ELISA assay (see section 2.1.4.4). P value < 
0.05 as determined by one-way ANOVA analysis of variance followed by Tukeys multiple comparison 
post-test indicate a significant difference between the groups. These analyses were performed using 
Graph Pad Instat Software. Definition of abbreviations: COPD, chronic obstructive pulmonary disease; 
HS, healthy smokers; HNS, healthy nonsmokers; CRP, creative reactive protein; CC16, clara cells 16; 
CCL18, Chemokine (C-C motif) ligand 18; CD31, cluster of differentiation 31.  
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4.4.4 The Correlation between Inflammatory Biomarkers and Disease Severity 
In the current study it was shown that increased plasma level of fibrinogen, CRP, CC16, 
CCL18 and CD31 was positively correlate with worsen disease stage. COPD Patients in mild 
stage have shown lower level of circulating biomarkers that those in moderate or severe stages. 
A possible correlation between biomarkers plasma levels and clinical lung function data (FEV1 
%predicted, preFEV1/FVC ratio) was investigated. There was a statistically significant negative 
correlation between the levels of CRP and the preFEV1/FVC ratio (r
2
 =0.287, P = 0.039), but a 
non-significant correlation between the levels of CRP and the % predicted FEV1 (r
2
 = 0.179, P 
=0.11). A moderate negative association was found between the levels of CC16 and the % 
predicted FEV1 (r
2
 = 0.255, P =0.054). However, no association was observed between the 
levels of CC16 and the pre FEV1/FVC ratio (r
2
 = 0.173, P =0.122). Similarly, plasma 
Fibrinogen, CCL18 and CD31 levels did not show correlation with the FEV1 %predicted and pre 
FEV1/FVC (p>0.05). So, CRP was the only inflammatory biomarker tested associated with 
disease severity and can be used as a predictor of lung function decline. Linear regression 
analysis of the relationship between inflammatory markers and COPD severity at baseline are 
summarised in Table 4.5 and Figure 4.5. 
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Table ‎4.5: Correlation between Plasma Biomarkers and Pulmonary Functions in COPD 
Cohort 
Biomarkers 
 
preFEV1 % preFEV1/FVC ratio 
r
2
 p r
2
 p 
CRP mg/L 0.179 0.115 0.287 0.039 
Fibrinogen mg/dl 0.017 0.635 0.034 0.500 
CC16 ng/ml 0.255 0.054 0.173 0.122 
CCL18  ng/ml 0.060 0.377 0.092 0.272 
CD31 ng/ml 0.009 0.913 0.005 0.934 
Significance was tested using a linear regression analysis (spearman method). These analyses were 
performed using Graph Pad Instat Software. Definition of abbreviations: CRP, creative reactive protein; 
CC16, clara cells 16; CCL18, Chemokine (C-C motif) ligand 18; CD31, cluster of differentiation 31. 
FEV1%, percent predicted forced expiratory volume in the first second, FVC, forced vital capacity.  
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Figure ‎4.5: Linear regression analysis of the correlation between lung severity and plasma 
biomarker levels. FEV1 % and FEV1/FVC ratio vs basal plasma level of (A1-2) CRP (mg/L), (B1-2) 
Fibrinogen (mg/dl), (C1-2), CC-16 (ng/ml), (D1-2) CCL-18 (ng/ml), (E1-2) CD31 (ng/ml). Significance 
was tested using a linear regression analysis (spearman method). Dotted lines indicate the 95 % 
confidence intervals. These analyses were performed using Graph Pad Instat Software. Definition of 
abbreviations: COPD, chronic obstructive pulmonary disease; HS, healthy smokers; HNS, healthy 
nonsmokers; CRP, creative reactive protein; CC16, clara cells 16; CCL18, Chemokine (C-C motif) 
ligand 18; CD31, cluster of differentiation 31; FEV1%, percent predicted forced expiratory volume in the 
first second, FVC, forced vital capacity. 
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4.4.5 Influence of Smoking Status on Inflammatory Biomarkers  
The smoking impact, quantified as PYH on biomarkers plasma levels was investigated. 
There was a significant negative correlation between the plasma CRP level and PYH (r
2
 =0.283, 
P = 0.041). No correlation was found between the Plasma Fibrinogen and PYH (r
2
 =0.063, P = 
0.36). Similarly, plasma CC16, CCL18 and CD31 levels did not show correlation with PYH 
(p>0.05). In subgroup analysis of patients with COPD, no differences in biomarkers level were 
found between smokers and ex-smokers except with CRP. The plasma level of CRP was found 
to be significantly higher in COPD former smokers as compared to current smokers (6.3 vs 3.2 
mg/L, p= 0.049). In summary, smoking affects the plasma level of CRP of COPD patients. 
Linear regression analysis of the relationship between smoking impact and inflammatory 
markers at baseline of COPD patients are summarised in Table 4.6 and Figure 4.6. 
 
Table ‎4.6: The impact of smoking on plasma biomarkers; CRP, fibrinogen, CC16, CCL18, 
and CD31 in COPD cohort. 
 
Biomarkers 
 
PYH 
r
2
 p 
CRP 
mg/L 
 
0.283 
 
0.041 
Fibrinogen 
mg/dl 
 
0.063 
 
 
0.360 
CC16 
ng/ml 
 
0.005 
 
0.790 
CCL18 
ng/ml 
 
0.066 
 
0.350 
CD31 
ng/ml 
 
0.177 
 
0.118 
Significance was tested using a linear regression analysis (spearman method) using Graph Pad Instat 
Software. Definition of abbreviations: CRP, creative reactive protein; CC16, clara cells 16; CCL-18, 
Chemokine (C-C motif) ligand 18; CD31, cluster of differentiation 31; PYH, pack year history.  
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Figure ‎4.6: Linear regression analysis of the correlation between smoking and plasma level 
of biomarkers. (A) CRP (mg/L), (B) Fibrinogen (mg/dl), (C) CC-16 (ng/ml), (D) CCL-18 (ng/ml), and 
(E) CD31(ng/ml). Significance was tested using a linear regression analysis (spearman method). Dotted 
lines indicate the 95 % confidence intervals. These analyses were performed using Graph Pad Instat 
Software. Definition of abbreviations: COPD, chronic obstructive pulmonary disease; HS, healthy 
smokers; HNS, healthy nonsmokers; CRP, creative reactive protein; CC16, clara cells 16; CCL18, 
Chemokine (C-C motif) ligand 18; CD31, cluster of differentiation 31; pack year history. FEV1%, 
percent predicted forced expiratory volume in the first second, FVC, forced vital capacity. 
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4.4.6 Relationship between Plasma Inflammatory Biomarkers Levels 
Plasma levels of CRP and fibrinogen were determined as a measure of systemic 
inflammation. In order to explore the relationship between systemic biomarkers and 
inflammation, correlations were performed between these inflammatory biomarkers. No 
correlation was found between plasma levels CRP and Fibrinogen (r
2
 = 0.181, p=0.63) (Figure 
4.7). 
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Figure ‎4.7: Linear regression analysis of the Correlation between CRP (mg/L) and 
Fibrinogen (mg/dl). Significance was tested using a linear regression analysis (spearman method). 
Dotted lines indicate the 95 % confidence intervals. These analyses were performed using Graph Pad 
Instat Software. Abbreviation: CRP, creative reactive protein. 
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4.5 Discussion 
COPD is a chronic inflammatory disease that affects primarily lung and airway with 
systemic manifestations and exhibits significant heterogeneity. The mechanism of heterogeneity 
in COPD is complex, as several studies observed variations among COPD individual parameters 
including the clinical manifestations, frequency of acute exacerbation, disease progression and 
response to treatment (Sin et al., 2009). Studies have been focused on COPD relevant 
biomarkers as these may associate with the different inflammatory phenotypes of the disease and 
may help to evaluate the individualized management of patients with COPD. Biomarkers can 
assess in evaluation of biological processes and disease pathology, the prediction of progression 
or response to treatment. However many published studies have produced also controversial 
results (Liu et al., 2014). 
The inflammation in COPD patients appeared to extend beyond the lungs causing systemic 
inflammation and COPD associated comorbidities. The biomarkers that were chosen to be 
investigated in the current study have previously been associated with either local or systemic 
inflammation of COPD. Several studies and research were focusing to determine their value as 
candidate COPD biomarkers. In this chapter, comparisons are reported for plasma inflammatory 
biomarker measurements between patients with COPD, healthy smokers and healthy nonsmoker 
groups using ELISA assay. ELISA is very sensitive assay which could detect the amount of 
protein levels in different biological tissues; plasma, serum, and cell culture recovered 
supernatant. Standardization of sample processing and storage, diluent type and dilution is 
necessary to ensure consistent results in ELISA assay. Most common processing technique 
involved separating plasma from the whole blood then storing plasma sample at -80 ͦ C. In the 
current study plasma samples were stored at -80 ͦ C until assayed. It was reported that storage and 
processing of samples have minor effects on plasma biomarker level measured by ELISA. There 
were no significant differences between measurement of plasma processed immediately or after 
storage at 4 ͦ C, -20 ͦ C, or -80 ͦ C (Bratcher and Gaggar 2014). In the current study 1% bovin 
serum albumin (BSA, sterile, filtered, Thermo Fisher Scientific, UK) in Dulbecco's phosphate 
buffered saline (PBS, sterile, filtered, w/o Calcium w/o Magnesium, Biosera, Labtech 
International Ltd, Sussex, UK) was used as a diluent to generate the serial dilutions of 
recombinant human standard according to manufacturer’s recommendation. This diluent was 
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also suggested by Bratcher and Gaggar (2014). Another important factor that may affect ELISA 
measurement is whether the sample should be assayed neat or the diluted. Optimization of 
dilution of samples is highly recommended before starting the entire ELISA experiments for 
better and consistent measurements. 
Dilution of the study plasma samples was vital before performing ELISA experiment to 
reduce the unspecific binding and to obtain better results. It assesses in estimation the values of 
detection range for antibody and target protein concentrations, and informs the amount of actual 
concentration required from plasma sample to start the assay (Thakur et al., 2015). High BSA 
diluent was used to dilute plasma samples and the optimum dilution of each biomarker was used 
to conduct the ELISA experiment for the entire study population. To clarify further, if OD 
against X dilution of sample corresponds to a value fallen within the range of the standard curve, 
so X dilution could be an actual choice of dilution to conduct the experiment. Performing the 
assay with undiluted plasma sample may result in values lies beyond the standard curve range 
applying less or more than the optimum dilution will lead to inconclusive results.  
4.5.1 Acute Phase Proteins  
The main findings of the current study are that plasma CRP and fibrinogen were 
significantly associated with the presence of COPD. Patients with COPD were shown to have 
increased levels of circulating Fibrinogen and CRP when compared with healthy nonsmokers. 
Further, plasma fibrinogen level was also increased in COPD group when comparing to healthy 
smoker group. 
Acute phase proteins like fibrinogen and CRP have been reported to be implicated in 
COPD pathogenesis. These findings are consistent with previous studies that reported elevated 
levels of CRP, and fibrinogen in COPD patients when comparing to healthy controls 
(Higashimoto et al., 2009; Celli et al., 2012; Agarwal et al.., 2013; El-Shimy et al., 2014; 
Truedsson et al., 2016; Korani et al., 2016; Kleniewska et al., 2016). CRP was the first 
biomarker to be investigated in COPD. Most studies have shown that CRP levels are frequently 
elevated in COPD and associated with disease severity, decline in lung function and FEV1, 
quality of life, exercise capacity and response to treatment (De Torres et al., 2006; Tanni et al., 
2010; Fattouh and Alkady, 2014; Paone et al., 2016). A systematic review and meta-analysis was 
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performed to assess the effect of CRP level in COPD patients, found that elevated baseline CRP 
levels were significantly associated with higher mortality (Leuzzi et al., 2017). 
Several studies have shown that the plasma level of fibrinogen is increase in patient with 
COPD, with decline of FEV1 (Comes et al., 2016).  Elevated fibrinogen level in COPD also 
correlated with poor prognosis, an increased risk for exacerbations, hospitalization and death 
(Mannino et al., 2015). In the ECLIPSE biomarker cohort fibrinogen was the most stable 
biomarker for more than 3 months (Dickens et al., 2011). So fibrinogen was the only 
inflammatory biomarker tested associated with disease severity and can be used as a predictor of 
lung function decline. An increased plasma Fibrinogen and CRP level in patients with COPD 
may suggest a systemic inflammatory effect in these patients. But what needs to be clarified is 
whether systemic inflammation is a primary or secondary related to pulmonary inflammation. 
The plasma levels of systemic inflammatory biomarkers of fibrinogen and CRP (Higashimoto et 
al., 2009) are   good candidates as to predict rapid decline of FEV1 in COPD patients. However, 
little information is available on how these inflammatory biomarkers are related to lung function 
decline in COPD. The systemic level of CRP and fibrinogen may reflect the degree of severity of 
airway inflammation but they are not lung specific molecules (Akiki et al., 2016). 
4.5.2 Lung Specific Protein 
The proteins CC16, SP-D, RAGE also were investigated in the current study. These are 
promising COPD biomarkers, because they are highly lung specific.  
4.5.2.1 CC16 
Low plasma CC16 was significantly associated with the presence of COPD, as the 
plasma level of CC16 in the COPD group was the lowest between the three groups. This result is 
in agreement with the studies which previously revealed that serum CC16 levels were decreased 
in patients with COPD when compared to healthy nonsmoking controls (Lomas et al., 2008; 
Agusti et al., 2012), and there was a positive correlation with disease severity and FEV1 decline 
over time (Vestbo et al., 2011), but not with mortality (Celli et al., 2012). Low expression of 
CC16 was reported in healthy smokers and COPD patients’ airway (Laucho-Contreras et al., 
2015).  
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4.5.2.2 SP-D 
In the current study lung specific protein SP-D, showed no activity in circulation of most 
of the study cohort. This result is inconsistent with the previous studies data who found that SP-
D levels were elevated in COPD patients when compared to healthy smoking controls (Lomas et 
al., 2009; Dickens et al., 2011). In large of ECLIPSE study of 1,843 patients, the level of SP-D 
was also higher in COPD group than in the control group (Celli et al., 2012). Moreover, a study 
by Akiki and collaborators found that SP-D is a more specific biomarker than CRP or fibrinogen 
to differentiate patients with COPD from healthy subjects. In their research the elevation of SP-D 
was associated with emphysema and exacerbations risk but not with COPD severity (Akiki et al., 
2016). SP-D plays an important role in pathogenesis of the some lung disorders. The high plasma 
level of lung specific protein may due to increased secretion or leakage of these proteins across 
the alveolar-capillary membrane into the circulation which occurs in many respiratory disorders 
(Madsen et al., 2000, Greene et al., 2002). 
There are several factors influencing the measurement of SP-D by ELISA that may 
explain the variations of serum or plasma SP-D levels reported here and in the published 
literature. These factors include; processing and storage of sample, dilution factor, diluent or 
matrix type and anticoagulant type. Bratcher and Gaggar investigated the effect of these factors, 
and found that sample processing and storage as well as diluent used for the standard and sample 
dilution have little effects on the level of SP-D result by ELISA. However they suggested 
avoiding the use of EDTA as anticoagulant when assaying for SP-D by ELISA, as it gave the 
most inconsistent results, and values that were significantly lower than serum values. This might 
be a reason why SP-D could not be detected in most of the cohort samples as blood samples were 
collected and transported in EDTA vacutainers. Another problem affecting SP-D measurements 
by ELISA, is the multimeric structure of SP-D and posttranslational modifications. The degree of 
SP-D multimerisation has been shown to vary in the lungs during different disease. Further, 
posttranslational modifications of SP-D in human serum or plasma may alter or hide the epitope 
recognised by an ELISA kit antibody, whilst the same antibody could identify unmodified 
epitope of the ELISA kit standard SP-D (Kotecha et al., 2013; Bratcher and Gaggar 2014). 
Additionally, inhaled systemic corticosteroids in conjunction with long-acting b2-adrenergic 
agonist therapy significantly lower serum SP-D levels in plasma of patients with COPD (Sin et 
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al., 2008). However, SP-D levels showed stability and good reproducibility over a period of 3-6 
months such characteristics may validate the utility of this protein as COPD biomarker (Lomas et 
al., 2008; Lomas et al., 2009; Dickens et al., 2011; Paone et al., 2016). 
4.5.2.3 sRAGE  
Previous studies have found that RAGE and sRAGE are involved in COPD pathogenesis. 
However sRAGE was not detected in plasma in most of the current study cohort samples. In fact 
sRAGE was detectable in only 26% of the study cohort, mostly were healthy nonsmoking 
controls. Because of low subject number with detectable sRAGE, it was not possible to 
investigate the relationship between sRAGE and COPD, but could confirm that healthy 
nonsmoking control have shown numerically high level of sRAGE. Many researchers 
demonstrated that sRAGE levels in serum or plasma of COPD patients is lower compared to 
control subjects and is associated with GOLD stage and emphysema (Yonchuk et al., 2015). 
Also a study that investigates plasma sRAGE in 88 patients with COPD and in 55 healthy 
controls, found that sRAGE levels were reduced in patients with COPD compared to healthy ex-
smoking and nonsmoking controls, and its low level was positively associated with preFEV1 and 
preFEV1/FVC (Gopal et al., 2014). Likewise, Hoonhorst and colleagues showed that plasma, 
sRAGE levels were significantly lower in COPD patients compared to young and old healthy 
controls and their value associated with decreased lung function and disease severity (Hoonhorst 
et al., 2016). In contrast to those previous results no statistical significant difference was found 
among all groups regarding sRAGE level in plasma. Furthermore, no significant correlation was 
found between plasma sRAGE level and predicted FEV1% (Hassanein et al., 2016). It can be 
inferred that the lower level of sRAGE, which acts as a decoy receptor to prevent inflammation 
may result in greater RAGE driven inflammation in COPD (Miller et al., 2016).  
4.5.3 Cytokines and Chemokines 
The cytokines group that included TNF-α, IL-6, and chemokine; IL-8, IP10, showed no 
activity in circulation of most of the study cohort including patients with COPD. There was no 
relation between patient disease severity and the undetectable level of cytokines. As a result of 
that it was not possible to evaluate the association between these markers and COPD despite an 
association being described previously. Many authors found that the serum level of IL-6, IL-8 
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and TNF-α were significantly higher in COPD patients when compared with healthy nonsmokers 
(Heidari 2012; El-Shimy et al., 2014; El Gammal et al., 2015; Queiroz et al., 2016; Korani et al., 
2016).  
4.5.3.1 TNF-α 
In this study, TNF-α was only detectable in approximately 10% of the subjects in the 
studied groups. The inability to detect particularly circulating TNF-α in many subjects in the 
current study is similar to that reported in a study by Rennard et al. where circulating TNF-α was 
detectable in approximately half of the subjects in the ECLIPSE biomarker cohort (Rennard et 
al., 2007). In line with these results, TNF-α also was unmeasurable in most patients of ECLIPSE 
study (1,843 patients) had undetectable low levels of TNF-α (Celli et al., 2012). Possible 
explanation for undetectable of TNF-α in plasma is its local and short term effects, its 
degradation and its short half-life, as well as its binding to receptors and renal clearance (Korani 
et al., 2016) 
4.5.3.2 IL-6  
IL-6 was only detectable in 10% of the subjects in the studied groups. Like fibrinogen 
and CRP, IL-6 also belongs to the systemic inflammatory component of COPD, and is increased 
in COPD patients. However, the biological variability of fibrinogen was lower than for IL-6 or 
CRP in stable COPD subjects (Dickens et al., 2011). In large of ECLIPSE study of 1,843 
patients, the level of IL-6 was raised in COPD group than in the control group (Celli et al., 
2012). Also, Serum IL-6 was raised in patients COPD when compared to healthy nonsmokers, 
and there was a significant negative relationship between serum levels of IL-6 and FEV 1 and 
FEV1/FVC (Ardestani and Zaerin 2015). COPD patients also showed increase levels of IL-6 and 
IL-8 in induced sputum (Eickmeier et al., 2010) and elevated levels of IL-6, IL-8, and TNF-α in 
serum (Tanni et al., 2010; Selvarajah et al., 2016) when compared to healthy controls. In 
contrary to the previous results, there was no significant difference between the serums levels of 
IL-6 and TNF-α of COPD patients and healthy subjects (Kleniewska et al., 2016). Another study 
of two large COPD cohorts of 2123 and 1117 subjects observed that IL-6 was associated with 
progressive airflow limitation over 5 years and with emphysema progression over 5 years 
(Bradford et al., 2017).  
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4.5.3.3 IL-8  
Increased IL-8 secretion contributes to the development of COPD, and elevated IL-8 was 
found to be correlated with neutrophils numbers. IL-8 can chemo-attract  and activate neutrophils 
to the site of injury, and then neutrophils can release IL-8 causing further accumulation of 
neutrophils in lung tissue of COPD patient. In this study, IL-8 was also one of the undetectable 
biomarkers in studied groups. The findings presented here are in contrary with literatures 
showing that IL-8 levels are elevated in COPD. The level of IL-8 was higher in COPD patients 
when compared with healthy controls (Zhang et al., 2011). Similarly, IL-8 has been reported to 
be elevated in COPD patients in small study with less than 100 subjects (de-Torres et al., 2013). 
A study by Liu et al. (2014), demonstrated that IL-8 concentrations were increased in serum 
from patients with exacerbated COPD, when compared with patients with asthma attacks. An 
increased serum IL-8 level in COPD patients with exacerbation suggests a systemic 
inflammatory effect in these patients. However, mechanisms that regulated serum IL-8 
expression are not clear (Liu et al., 2014). Another study of two large COPD cohorts of 2123 and 
1117 subjects observed that IL-8 were associated with emphysema progression over 5 years 
(Bradford et al., 2017). In contrast to the previous studies mentioned, Novgorodtseva et al. 
(2013) reported that the level of IL-8 in patients with COPD did not differ from that in the 
control group. The low or undetectable level of IL8 may be explained by the specific functions 
of this cytokine. IL-8 is needed to recruit and activate neutrophils. Most of the previous studies 
that described an association between IL8 level and COPD patient were using sputum, exhaled 
breath condensate and BAL fluid sample rather than plasma. Therefore, IL-8 could be considered 
as a local, rather than systemic, biomarker of inflammation that could be detectable in the 
airways rather than the plasma (Batlle et al., 2012).   
4.5.3.4 IP-10 
Elevated levels of IP-10 have been observed in patients with COPD, and subsequently 
have been reported to be involved in COPD inflammation. However, in the present study no 
detectable basal level of IP-10 was observed in the circulation of most subjects of the study 
cohort. Most of plasma samples were under the limit of detection, and IP10 was only detectable 
in 16% of the whole study population. Torvinen et al. (2007) proved by in vitro study that the 
interactions between lung epithelial cells, lymphocytes and monocytes are needed for basal IP-10 
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secretion. IP-10 was induced when circulating monocytes, T-cells and epithelium are in close co-
culture environment. Furthermore, Eickmeier group could not detect the IP-10 in many of their 
COPD sputum samples and found no significant differences between the COPD patients and 
healthy groups (Eickmeier et al., 2010). The blood levels of IP-10 have not been widely 
investigated in patients with COPD, and most studies investigate their role in combination with 
other diseases where elevated levels of IP-10 were detected (Odler et al., 2016). To give an 
example, patients with COPD have high serum IP-10 levels than controls, and it level increased 
from baseline to exacerbation in patients with rhinovirus induced exacerbations (Quint et al., 
2010). In addition, IP-10 was found significantly elevated in the circulation of systemic lupus 
erythematosus with pulmonary disorders involvement cohort (Odler et al., 2016). 
4.5.3.5 CCL18 
Few studies have investigated CCL18 as a potential biomarker for COPD.  In the current 
study there were no significant differences in plasma level of CCL18 of COPD patients when 
compared to healthy smokers and nonsmokers. This result disagrees with previous studies where 
CLL18 was shown to be elevated in COPD patients when compared to healthy smokers and 
healthy nonsmokers (Dickens et al., 2011). A small study of forty eight patients with COPD has 
observed a significant association between serum levels of CCL18 and FEV1, dyspnea score, 
exercise capacity, exacerbation frequency and mortality (Pinto-Plata et al., 2007). Additionally, 
in two large cohorts, serum CCL18 levels were found to be higher in COPD patients than in 
healthy smokers or healthy nonsmokers. Elevated CCL18 levels were associated with increased 
risk of cardiovascular hospitalization and mortality (Sin et al., 2011).  Another large of ECLIPSE 
study of 1,843 patients, found that the level of CCL18 was raised in COPD group than in the 
control group (Celli et al., 2012).  
Serum CCL18 levels were also found to be elevated in COPD patients when compared to 
the healthy former smokers (Dilektasli et al., 2017). Both CCL18 and SP-D levels were higher in 
patients with more severe pneumonia which may reflect the extent of pulmonary inflammation 
(Spoorenberg et al., 2017). In this study, it was observed that the circulating level of CCL18 was 
numerically higher in the COPD group but as mentioned earlier no statistically significant 
difference was observed in the comparisons between the three studied groups. These findings are 
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consistent with those of Muñoz-Esquerre et al.  (2017), which have shown no significant 
difference in CCL18 level between COPD patients and healthy controls. The relatively small 
cohort size and high biological variability between subjects may have affected the circulation 
value of CCL18 that was found to be associated with mortality in two large cohorts (Sin et al., 
2011). Despite CCL-18 being a predominantly pulmonary marker, it may be secreted by the 
myeloid cells, and different organs such as liver, bone marrow. Hence, measuring CCL-18 
production in BAL fluid might be more revealing. However, a close correlation between CCL-18 
concentration in circulation and BAL was reported by Prasse et al (2007), suggesting that CCL-
18 production within the lungs was reflected by the CCL-18 levels in systemic level of smokers 
(Dilektasli et al., 2017). CCL18 levels showed poor repeatability over time both in COPD 
patients and healthy controls (Dickens et al., 2011). In summary, although there is some 
evidence of association between CCL18 and severity and mortality in COPD, further 
investigation is required to evaluate the utility of CCL18 as COPD biomarker (Pinto-Plata et al., 
2012; Ongay et al., 2016). 
4.5.4 CD31 
Increasing evidence indicated that cardiovascular and not respiratory diseases are the 
main cause of death among individuals with COPD, and that endothelial injury in the pulmonary 
capillary vasculature leads to lung destruction. Because of that endothelial MPs such as CD31 
which is involved in both the pulmonary and systemic vascular biology, are being investigated as 
potential biomarkers for COPD (Takahashi and Kubo, 2014). In this study the presence of CD31 
was detected in plasma samples of all the three groups, and it was found that circulating levels of 
CD31 are higher numerically in COPD subjects compared to healthy smokers and nonsmokers 
groups. However this increase did not reach statistical significance due to the high biological 
variability between subjects and maybe this reflected the limited number of cases available for 
analysis. Most work that investigated the role of MPs CD31 in COPD has been limited to few 
studies. In these studies CD31was identified and determined by flow cytometry in platelet-free 
plasma or sputum according to the expression of membrane specific antigens. Thomashow and 
coworkers (2013) were the first to confirm that endothelial MPs including CD31 are increased in 
in COPD compared with control subjects and this elevation was negatively correlated FEV1 and 
emphysema severity. 
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High plasma and sputum levels of CD31 of COPD patients negatively correlated with the 
severity of disease. The high levels of circulating and local CD31 could reflect a damage in small 
airway, while the presence of CD31 in sputum could indicate lung epithelium and vascular 
endothelium damage in COPD patients (Takahashi et al., 2012). Further, Lacedonia et al. (2016) 
demonstrated that the level of CD31 was raised in the sputum of COPD patients, and was 
negatively correlated with the severity of disease. In agreement with previous studies, a recent 
work found that COPD patients showed significantly elevated levels of total circulating CD31 
compared with healthy smokers and healthy nonsmokers (Garcia-Lucio et al., 2018).  In 
summary, the elevated levels of CD31 could be indicator of endothelial inflammation which is 
closely connected to the pathophysiology of COPD. Thus, CD31 could be a good candidate for 
the study of pulmonary endothelial damage, COPD progression, and for identifying patients who 
are susceptible to exacerbation (Takahashi and Kubo, 2014; Lacedonia et al., 2016). The 
findings of the previous studies are in contrary to the current study data which suggest that CD31 
are unable to different between patients with COPD and healthy control. There are several 
technical difficulties reported with measuring endothelial MPs. For example, there is no standard 
protocol for isolating and detecting circulating MPs from the plasma. In addition, differences in 
centrifugation protocols influence the number of MPs, and differences in flow cytometers 
influence the sensitivity of endothelial MPs detection (Takahashi and Kubo, 2014). 
Several studies aim to identify the relationships between biomarkers and disease 
progression especially for treatment guiding (Comes et al., 2016). In the present study, it was 
noticed that the increasing plasma level of fibrinogen, CRP, CC16, CCL18 and CD31 was 
correlate with worsen disease stage. This means that COPD Patients in mild stage have shown 
lower level of circulating biomarkers that those in moderate or severe stages. These data are in 
line with previous studies data (Akiki et al., 2016; Doubková et al., 2016; Lacedonia et al., 
2016). Unfortunately, some of widely studied biomarkers showed poor repeatability and were 
unstable when measured at a three month interval which may restrict their utility as markers of 
disease progression or measures of the effects of drug intervention. While some other biomarkers 
should have a prognostic role in COPD. It is known that COPD is an inflammatory disease and 
CRP, fibrinogen are components of systemic inflammation, are elevated in COPD subjects 
compared to healthy subjects in this and in other studies (Dickens et al., 2011). CRP is one of the 
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most widely studied biomarkers and may correlates with COPD. However, as CRP is not a 
pulmonary specific protein, it could be unspecific risk biomarker that reflects systemic 
inflammation rather than local inflammation (Liu et al., 2014). Although CRP and IL-6 are both 
significantly raised in COPD; however their level is variable in COPD subjects over three 
months and may have limited utility as useful biomarkers of COPD (Dickens et al., 2011).  
In theory lung specific biomarkers could potentially be used as ideal biomarkers of 
COPD. Among lung specific proteins, SP-D and CC16 have proven to be more stable over time 
than CCL18 which could make them more useful COPD biomarkers. Additionally, CC16 seems 
to have a prognostic role in COPD patients, and the interesting results obtained here regarding 
CC16 should be the focus of further studies. On different note, MPs such as CD31 are known to 
increase in cardiovascular diseases, including myocardial infarction. Therefore, the role of other 
MPs in the comorbidity and the prognosis of COPD would be a great interest. 
The correlation between inflammatory biomarker levels and clinical outcomes was 
investigated in COPD patients. A statistically negative significant correlation was observed 
between the levels of CRP and the predicted FEV1/FVC ratio. CRP values changed significantly 
with rising disease severity. So if plasma CRP level is correlated with FEV1/FVC then it may act 
as a surrogate marker of disease progression in individuals with COPD. This would assess 
clinicians to predict those who may susceptible to COPD. Other researchers have investigated 
the association between CRP and lung function, and shown that the mean serum CRP level was 
found to be significantly increased in severe cases. For example, De Torres and et al. (2006) 
indicated that when lung function worsens CRP levels increase. Similarly, Agarwal co-workers 
(2013) noticed that CRP level in stable COPD patients was correlated with FEV1. This might 
enable identification of patients at a high risk of disease progression and mortality. However, in 
the current study there was no association between CRP level and FEV1%. This result is 
consistent with a previous study finding which indicated that no association between pulmonary 
function test measurements (FEV1) and increase CRP levels in COPD patients (Pinto-Plata et 
al., 2006). The lack of correlation of other biomarkers candidates (Fibrinogen, CC16, CD31 and 
CCL18) with patients lung function data in this study make it difficult to interpret, but may be 
due to the small patient sample size and that 80% of the patients had mild or moderate 
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obstruction. In consequence, it was not possible to provide clear evidence of an association 
between biomarkers levels rather than CRP and lung function parameters. 
In the COPD group, smoking history and exposure seemed to have an impact on systemic 
level of CRP but not on fibrinogen, CC16, CCL18, and CD31. A significant correlation was 
observed between the levels of CRP and PYH. In subgroup analysis of patients with COPD, no 
differences in biomarkers level were found between smokers and ex-smokers except with CRP. 
The plasma level of CRP was found to be significantly higher in COPD former smokers as 
compared to current smokers. However, previous studies indicates that the increase of CRP 
levels in patients with COPD not related to smoking status (Pinto-Plata, et al., 2006; Tanni et al., 
2010).  Additionally, other researchers have shown that serum level of CRP and fibrinogen were 
not affected by smoking status (Higashimoto et al., 2009). Cigarette smoke may enhance the 
inflammatory process in COPD patients, but it is not the leading cause of increased inflammatory 
biomarkers level (Agarwal et al.., 2013). In summary, it seems that a relation between smoking 
and level of CRP in COPD subjects requires further investigation.  A possible relationship 
between the plasma level of CRP and fibrinogen was also evaluated. Acute phase reactants 
protein, CRP and fibrinogen, considered as a measure of systemic inflammation. Disappointedly, 
no correlation was found between plasma levels CRP and Fibrinogen.  
It is known that the selection of biomarkers is incomplete, but believe this must reflect 
involvement of several pathways including acute phase reactant, inflammation, chemo-attraction, 
and pulmonary regulated proteins. The selection of the markers is based on previous studies that 
included stable and unstable COPD patients and smokers and non-smokers controls. COPD is 
heterogeneous disease and because of that the use of a single biomarker is generally considered 
insufficient. Using a combination of novel biomarkers with pulmonary function tests alongside 
other existing tools can optimise the prognosis, diagnosis, treatment of patients with COPD 
(Ongay et al, 2016). 
There are some confounding factors that can affect the results. Factors include; small 
sample size, lack of reproducibility in an independent cohort, heterogeneity and biological 
variability of the patients with COPD, pathological characteristics, inflammatory profiles (Liu et 
al., 2014; Bradford et al., 2017). The number of patients was not sufficient to reach statistical 
significance in associations between inflammatory biomarkers and the presence of COPD. 
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However, the subject number in the present study was similar or larger than the number of 
subjects in some previous studies. For example, the number of the study cohort for Queiroz et al. 
(2016) = 30, El Gammal et al. (2015) = 40, Kawayama et al. ( 2016) = 37, Liu et al. (2014) = 19, 
and Hassanein et al. (2016)= 44.  
Sample size justification is required for all clinical studies (Zheng et al., 2017). Analyzing 
the power of a study depends on the significance level α, the sample size, and the effect size. The 
latter depends on the average difference and the variability of the measurement. It is 
recommended that sample size is estimated for an error (α) of 0.05, statistical power of 0.8 and 
effect size ≥ 0.5. During the planning of the study, no power analysis was performed. However, a 
post hoc power analysis (Wilcoxon-Mann-Whitney test) justifies the sample size. The power 
with the actual sample size for CRP, Fibrinogen and CC16 were 0.91, 1 and 0.98 respectively. It 
is possible that the lack of association between COPD and plasma CCL-18 and CD 31 
concentration in the present study may be a result of inadequate statistical power rather than a 
true lack of association. The post hoc power analysis of CCL-18 and CD 31 data found that 
statistical power was insufficient to detect a significant relationship. Power and sample size 
analysis was calculated using G*power software version 3. 
Thus, further studies with larger sample sizes from multi clinical centres and long term 
study may be necessary to confirm the lack of associations between these biomarkers and the 
presence of COPD (Lee et al., 2018). Additionally, the finding of our study could be affected by 
the specific detection limit in the commercially ELISA kits. The very low values of some 
biomarkers in plasma were determined by the commercial ELISA kits, and most of the measured 
values fell below the validated detection limits of the relevant ELISAs. Since small variations in 
optical density can result in large changes in biomarker concentration and it is possible that there 
was some error in the measurement of low biomarker concentrations. 
4.5.4 Conclusion 
Blood biomarkers that are elevated in COPD subjects when compared to healthy 
nonsmoking controls were identified. This study showed that high level of plasma CRP, 
fibrinogen, and low level CC16 were associated with COPD, which suggests that CRP, 
fibrinogen, and CC16 might be a useful biomarker panel related to the presence of COPD. Thus, 
  
131 
 
plasma level of CRP, fibrinogen and CC16 could distinguish COPD patients from healthy 
controls. These results provide evidence that CRP and Fibrinogen might play a more important 
role in airway and systemic inflammation. Increased plasma CRP, fibrinogen can be used as 
biomarkers of the systemic inflammatory response in COPD patients. Several previous studies 
provide support for the view that CRP is a useful biomarker in COPD, particularly in defining 
lung function decline in COPD patients and in acting as a surrogate marker of treatment success. 
A significant negative correlation was detected between CRP plasma level and FEV1/FVC as 
well as PYH, though this study did not find an association between Fibrinogen, CC16, CD31 and 
CCL18 with pre FEV1% or FEV1/FVC, as well as with PYH in COPD patients. There is a need 
for lung-specific biomarkers derived from proteins that are either highly or only expressed in the 
lung tissue. For example, data presented here for CC16, support this as a promising local 
biomarker of an inflammatory process in the airways of COPD patients. However, further studies 
are required to establish the role of these biomarkers in COPD patients. 
Analysis of biomarker profiles is more important that the measurement of single 
biomarker levels to differentiate patients with COPD from healthy subjects, and to determine the 
severity of lung inflammation. Monitoring the inflammatory biomarker activity is important for 
the assessment and management the chronic airway diseases and the decline in lung function in 
COPD (Pinto Plata et al., 2012). Many studies have been published on the association between a 
specific biomarker and COPD disease, with either positive or negative results being reported. 
The disagreement in results can be attributed to different factors, including the heterogeneity of 
COPD phenotypes, low subject number, or the use of different methodologies and assays. Thus 
the use of advanced analytical methods like cytokine arrays, mass spectrometry, or nuclear 
magnetic resonance, should increase the sensitivity of the assays, and may produce important 
new information in the future (Liu et al., 2014). 
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5. Chapter 5: Immunomodulatory effects of omega-3 PUFA on ex-vivo 
PBMCs  
 
 
5.1 Background 
Inflammation of the airways is the main pathological feature in COPD patients. Although 
the pathogenesis of COPD is still unclear, studies have shown that COPD pathogenesis might 
associate with immune system dysregulation. The initial inflammatory response to damage from 
smoking or irritant agents is characterized by increased number of inflammatory cells migrating 
from the circulation to the lung and accumulating in the airways, including neutrophils, 
monocytes and lymphocytes. These cells release various inflammatory mediators including IL-6, 
IL-8, and TNF-α, interact with each other, with structural cells of the airways, the lung 
parenchymal and pulmonary vasculature, result in increased COPD severity and pathogenic 
consequences (Duvoix et al., 2013; Wu et al., 2014; El-Shimy et al., 2014; Quan et al., 2016).  
PBMCs are the immediate inflammatory cells to respond to any pathogen invasion. Many 
of the proinflammatory mediators produced by PBMCs different cell types play important roles 
in immune system monitoring relevant events and response in an inflammatory manner. PBMCs 
comprise the cellular part of the blood organ containing all blood cells with a mononuclear 
morphology. In humans the PBMC population is heterogeneous and consists from several 
different cell types with different functional states. Lymphocytes and monocytes are the main 
constituents of PBMCs and more than two thirds of the lymphocytes represented by T-cells. It 
includes lymphocytes (70–90%); 50–70% T-cells, 5–15% B-cells, 10–20% monocytes, 2–10% 
natural killer cells, dendritic cells (1–2%) and the remainder of platelets. The proportion of these 
populations differs between individuals. (Debey et al., 2004; Haudek-Prinz et al., 2012; 
Končarević et al., 2014).  
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PBMCs are very important immune cells that are involved in a large number of diseases. In 
healthy individuals, PBMCs circulate in a quiescent cell state but are able to respond quickly and 
efficiently in an inflammatory manner toward any potential pathogens invasion or irritants. 
However, strong inflammatory responses occur in these cells when targeting any foreign particle 
and may also cause severe side effects. During inflammatory activation of these cells, key events 
include; leukocyte migration, proliferation of T-cells, NF-κB signaling and regulation of 
apoptosis (Haudek-Prinz et al., 2012).  
Several studies have evidenced that T-cells play main role in initiating and prolonging 
inflammation in human disease, through the production of proinflammatory mediators and via 
cell to cell contact interactions with different cell types through membrane receptors and their 
ligands. Activated T-cells are important regulators and effectors of inflammatory immune 
response towards tissue damage (Monaco et al., 2004).The major subclasses of T-cells express 
either CD4 or CD8 on their surface. Different immunologic stimuli trigger differentiation of 
naive CD4+ T cells via different developmental pathways give arise to different T-cell 
phenotypes such as; Th1 and Th2 cells. Both phenotypes involved in host defence in different 
pathological or disease states. Other subsets including; Th17 cells and regulatory T cells 
(CD4+CD25+ Treg) also associated in host defence and in inflammatory disease (Calder 2015). 
T-cells, especially Treg cells, have been involved in the regulation of immune response and 
maintaining homeostasis. Previous studies showed that compared to healthy controls, the 
expression and the percentage of CD4+ T-cells and CD4+CD25+ Treg was significantly 
decreased. This suggested that the reduction in the population of Treg cells functioning sup-
pressive immunity, which might promote occurrence and development of COPD (Domagala-
Kulawik et al., 2011; Quan et al., 2016). 
Monocyte functions comprise phagocytosis, presentation of antigens and paracrine 
regulation of inflammation. Monocytes act as regulator and activator of T-cell. In turn activated 
T-cells may further activate endothelial cells, fibroblasts, smooth muscle cells and 
monocytes/macrophages to produce inflammatory cytokines, chemokines, tissue factor and 
extracellular matrix-degrading enzymes, to promote inflammation, angiogenesis and tissue 
damage, and hence  maintain an acute or chronic inflammatory state (Monaco et al., 2004). 
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 During pathogen invasion, monocytes are recruited from the circulation to the tissue and 
differentiated in the two phenotypes M1 or M2 macrophages depending on the signals they 
receive from the micro-environment. The M1 macrophages involved in proinflammatory 
pathways and release several proinflammatory cytokines and eliminate microbial infection.  The 
M2 macrophages have poor antigen-presenting capabilities, implicated in tissue remodeling and 
progression of fibrosis, and are considered to be wound-healing macrophages. The M2 
macrophages secrete a specific types of chemokines including; IL-10, CCL17, CCL22, IL-1Ra, 
and CCL18 (Plönes et al., 2012; Dilektasli et al., 2017).  
Macrophages are among the most abundant cells in the respiratory tract and can be 
classified as alveolar macrophages (AMs) that line the surface of alveoli and interstitial 
macrophages (IMs) that found in the interstitial space between the alveoli epithelium and blood 
vessels. AMs have been reported to clear inhaled irritants, bacteria, cell debris and apoptotic 
cells, and resolve inflammation following injury and infection. Additionally it regulates 
neutrophil and monocyte recruitment to the lung. Both populations display high phagocytic 
capacity, but AMs are larger in size and more potent phagocytes (Kapellos et al., 2018).  AMs 
constitute over 90% of the pulmonary macrophage population and thought to be originating from 
the bone marrow. In COPD macrophages have an impaired ability to clear bacteria, damaged 
tissue and apoptotic cells, which leads to the colonisation of the lung with pathogenic bacteria. 
This may be due to excessive oxidative stress that affects the phagocytic capacity of 
macrophages (Vlahos and Bozinovski, 2014). Different macrophage subpopulations have been 
identified in airways and lung tissue of COPD patients and controls using flow cytometry. Based 
on size and location, macrophage subsets include; Small interstitial macrophages with more pro-
inflammatory function, small alveolar macrophages that had the greatest phagocytic capacity and 
large alveolar macrophages with low pro-inflammatory and phagocytic ability (Dewhurst et al., 
2017). 
Dietary interventions with omega-3 PUFA have been shown to be beneficial in the 
treatment of inflammatory diseases such as rheumatoid arthritis (Miles and Calder 2012), breast 
cancer (Mansara et al., 2015), and CVD (Calder 2017), the latter is the most important 
comorbidity in COPD. Hence, omega-3 PUFA supplementation might also be beneficial for 
people with COPD. Fatty acids are constituents of phospholipids and phospholipids are 
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components of cell membranes. The phospholipids of immune cells including; lymphocytes, 
monocytes, and neutrophils, isolated from the blood of healthy people consuming typical 
Western diets, have been reported to contain about 10 to 20% of fatty acids as; ARA, with about 
0·5-1% of EPA and 1·5-3% of DHA (Miles and Calder 2012). The fatty acid composition of 
human blood leukocytes can be modified by increased oral intake of marine omega-3 PUFA. 
This results in increased proportions of EPA and DHA in cell membrane of blood monocytes, 
neutrophils and PBMCs (Faber et al., 2011). 
Several studies have previously reported on the ability of omega-3 PUFA (EPA and 
DHA) to decrease pro-inflammatory cytokine production from stimulated PBMC, in different 
chronic diseases including multiple sclerosis (Shinto et al., 2011) and rheumatoid arthritis (Miles 
and Calder 2012) . However, most of the studies investigating the role of omega-3 fatty acids on 
immunomodulation have focused on the effects of orally administered EPA and DHA on 
immune cells reflected by cytokine production of T-cells or monocytes. Unfortunately the 
available measurements and outcome data of these studies are highly inconsistent (Jaudszus et 
al., 2013). Further, the numbers of the studies that investigated the immunomodulation effect of 
omega-3 PUFA on human PBMC without COPD patients’ omega-3 PUFA supplementation are 
limited. 
PBMCs have been considered as marker of several diseases, including rheumatoid 
arthritis, and malignant diseases (Edwards et al., 2007). The features of PBMC were also found 
to be altered in COPD (Aggarwal et al., 2016). In Patients with COPD altered PBMCs may fail 
to react to infection, stimuli or hypoxia (Wu et al., 2014). For example, PBMCs from COPD 
patients fail to induce hypoxia-inducible factor1 and VEGF under hypoxic condition because of 
a reduction in histone deacetylase 7 (To et al., 2012).  
PBMC samples are suitable for analysing immune-mediated or associated diseases and 
evaluating therapy response (Debey et al., 2004). PBMCs can be obtained easily from routinely 
collected blood samples, and widely used in in vitro studies, which is in contrast to airway tissue 
or lavage samples. Different methods are available for both in vitro and ex vivo investigations of 
PBMCs to measure activation of specific cells and production of proinflammatory mediators 
(Končarević et al., 2014). The present study employed PBMC as an experimental model to study 
mitogen-specific responses. Mitogen-induced proliferation and cytokine production is often a 
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preferable assay to examine any immuno-toxic therapy, because it reflects the status of immune 
cells. The functions of immune cell are mediated by several cytokines that are stimulated by 
different factors including: bacterial or viral infections, drugs and/or environmental irritants. 
Thus, it is necessary to select a panel of biomarkers that reflects the effects of a given therapy 
(Mandarapu et al., 2014). Data reported in Chapter 4 measured the plasma level of inflammatory 
biomarkers in patients with COPD, and compared these against levels in healthy smokers and 
nonsmoking controls. This chapter will compare release of cellular inflammatory biomarkers 
before and after stimulation of PBMCs recovered from the study groups.  
To induce proliferation PBMCs should be triggered by using several stimulators, 
including different mitogens. The most common used mitogens; Concanavalin A (ConA), LPS 
and Phytohemagglutinin (PHA), are able to stimulate PBMCs (Molaee et al., 2017). LPS which 
is the main structure component of gram-negative bacterial cell wall can stimulate the release of 
IL-8 and IL-6, from human PBMCs, and other pro-inflammatory cytokines towards bacterial 
invasion (Ngkelo et al., 2012). PHA; lectin extracted from red kidney bean (Phaseolus vulgaris), 
is one of the potent mitogens used in cell proliferation experiments in vitro. It binds to cell 
membranes surface receptors and stimulates cell division and metabolic activity (Haudek-Prinz 
et al., 2012).  
Based on the previous findings, it is hypothesized that omega-3 PUFAs may help to reduce 
COPD outcomes induced by cigarette smoke and other irritants. PBMCs samples were chosen 
for the investigation, because they can be easily collected, and are important for the discovery of 
biomarkers for diagnosis and therapeutic management of COPD. The aim of this chapter is to 
investigate the potential effect of the two main omega-3 PUFA; EPA and DHA, on functional 
properties of human PBMC, evaluated through proliferation and cytokine production, in order to 
examine the contribution of these immune cells which are involved in innate and adaptive 
immunity. For this purpose, an ex vivo mitogen-induced PBMC proliferation model was used. 
PHA mitogen was used as a stimulant to induce proliferation in PBMCs which mainly consists 
of a mixture of lymphocytes and monocytes (Haudek-Prinz et al., 2012; Končarević et al., 2014, 
Molaee et al., 2017). PBMCs were treated with different concentration of EPA or DHA, then 
were incubated with PHA for 24hrs (37˚C, 5% CO2 and 95% humidity). 
 
  
137 
 
5.2 Objectives 
 To establish basal release of inflammatory biomarkers from ex-vivo PBMCs  
 To evaluate the effect of different concentrations of EPA and DHA on biomarkers 
secreted from PHA-stimulated and unstimulated ex-vivo PBMCs 
 
5.3 Methods 
5.3.1 Prioritized COPD Biomarkers in PBMCs 
A limited number of studies have investigated PBMCs profile in COPD through 
cytokines production. In the current study a panel of biomarker candidates was selected based on 
a previous study (Kawayama et al., 2016). It is suggested that the production of these biomarker 
from PBMCs may increase during COPD inflammation. These biomarkers include; 
inflammatory biomarkers: IL-6, and TNF-α; chemoattractant biomarkers: IL8, IP10 in addition 
to RAGE and CD31. The list of potential biomarkers was further reduced by selecting only those 
could be measured in PBMCs culture samples of the studied groups. In this way, four potential 
biomarkers remained includes; IL-6, TNF-α, IL-8 and CD31. 
5.3.2 Duoset ELISA Assay  
5.3.2.1 Reagent Preparation  
ELISA duoset kits (R&D Systems, Oxford, UK) were used to measure the biomarkers 
release in recovered supernatants from PBMC culture samples. Detail of ELISA sensitivity 
ranges for each biomarker and the required reagents diluent and sample needed for each assay is 
summarised in Table (5.1, 5.2) Anti-human capture antibody was reconstituted in 0.5 ml of PBS 
and further dilution was made in PBS, to the working concentration. Anti-human detection 
antibody was reconstituted in 1.0 ml of reagent diluent 1% BSA in PBS, and further dilution was 
made in reagent diluent to the desire working concentration.  
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5.3.2.2 Sample and Standards Preparation  
The PBMCs were isolated from 20mL of whole blood consisting of anti-coagulant EDTA 
from patients with COPD, healthy smokers and healthy nonsmokers on Ficoll density gradient by 
centrifugation at 400 ×g at the room temperature for 30 minutes as previously mentioned 
(chapter 2). Before performing the experiment, cryopreserved PBMCs were recovered, washed 
and counted. The total cell count was calculated by using trypan blue exclusion method. Cell 
suspension was diluted 1:1 (v/v) with 0.4% trypan blue, and the viable cells were counted and 
compared with the total amount of cells in the suspension and in all of the experiments. The cell 
suspension was adjusted to 1×10
6
 cells/ml. For standard preparation; each standard vial was 
reconstituted with 0.5 mL of deionized or PBS according to manufacture instructions (R&D 
Systems).  After initial reconstitution 1ml of high standard was prepared per plate assayed at the 
concentration indicated. Seven point standard curves using 2-fold serial dilutions were prepared. 
Working dilutions were prepared on experiment day and used immediately. 
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Table ‎5.1: Summary of stock concertation and sensitivity range of standards used in 
ELISA assay 
Biomarker Standard Stock 
Concentration 
High standard 
limit 
Lower standard 
limit 
 
Human IL-6 
 
90 ng 
 
600 pg/mL 
 
9.38 pg/mL 
 
Human 
IL8/CXCL8 
 
40 ng 
 
2000 pg/mL 
 
31.3 pg/mL 
Human 
TNF-α 
 
67.5 ng 
 
1000 pg/mL 
 
15.6 pg/mL 
Human CD31/ 
PECAM-1 
 
190 ng 
 
10,000 pg/mL 
 
156 pg/mL 
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Table ‎5.2: Summary of dilutions capture and detection antibody for each biomarkers used 
in ELISA assay 
Biomarker Capture 
Antibody 
Detection 
Antibody 
Capture Antibody 
concentration 
Detection Antibody 
concentration 
 
Stock  Working 
solution  
Stock  Working 
solution  
Human IL-6 
DY206 
Mouse Anti-
Human IL-6  
Biotinylated 
Goat Anti-
Human IL-6 
Antibody 
 
240 
µg/ml 
 
 
 
2µg/ml 
 
3µg/ml 
 
50g/ml 
 
Human 
IL8/CXCL8 
DY208 
 
Mouse Anti-
Human IL-8 
Antibody 
 
Biotinylated 
Goat Anti-
Human IL-8 
Antibody 
 
240µg 
 
 
4µg/ml 
 
1.2µg/ml 
 
20ng/ml 
 
Human 
TNF-α 
DY210 
 
Mouse Anti-
Human TNF-α 
Antibody 
 
 
Biotinylated 
Goat Anti-
Human TNF-α  
Antibody 
 
480 µg/ml 
 
4 
µg/ml 
24 
µg/ml 
 
400 
ng/ml 
 
Human CD31/ 
PECAM-1 
DY8064-05 
 
Mouse Anti-
Human CD31 
Antibody 
 
Biotinylated 
Sheep Anti-
Human CD31  
Antibody 
 
480µg/ml 
 
4µg/ml 
 
12µg/ml 
 
200ng/ml 
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5.3.3 ELISA for R&D Systems-based assays procedure 
The procedure for ELISA R&D Systems-based assays was previously mentioned (see 
section 2.1.4.4 ).  
5.3.3.1 Initial Optimizations  
5.3.3.1.1 Supernatant Diluent Selection  
PBMC-recovered supernatants may require a dilution in an appropriate buffer to avoid 
false negative or positive results. In the current study PBS and RPMI media were examined to 
dilute PBMCs-culture supernatant, to determine if PBS or RPMI could provide an assay 
environment that minimizes nonspecific binding, while maintaining proper ionic strength and pH 
for efficient antibody-antigen interaction. PBMCs-culture samples from healthy smokers were 
diluted with PBS or RPMI (1:1, 1:5, and 1:10) and assayed in 96-well plate alongside undiluted 
samples. ELISA assay was carried out as mention in section (2.1.4.4) to detect and compare the 
IL-6 production from PBS- or RPMI-diluted and undiluted samples. The experiments were 
carried out three times. A comparison between the outcomes from using two diluents was made 
and the appropriate diluent was chosen to dilute PBMCs-culture samples for the study 
experiments. 
 
5.3.3.1.2 Supernatant  Dilution Factor Selection 
In the current study two PBMCs culture  samples were selected from each of three 
studied groups; COPD, healthy smoker and healthy nonsmoker groups, to be 10-fold diluted 
(1:10, 1:100, and 1:1000), in RPMI media, and then assayed in 96-well plate alongside undiluted 
samples. ELISA assay was carried out as mention in section (2.1.4.4) to detect selected 
biomarker level in undiluted and diluted samples. Once samples are diluted, the dilution factor 
was included when calculating results. Then the dilution factor was included when assay all 
samples. Otherwise undiluted sample was utilised when dilution not required. Dilution of the 
sample before performing the actual experiment is significant parameter for determining the 
sensitivity of ELISA in human samples. It helps in deciding the amount of actual concentration 
required from the sample to obtain a result within the range of reference standard protein. 
Without dilution, it is difficult to achieve highly sensitive results of protein concentration. 
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Therefore, optimum dilution for the sample of target protein is a vital parameter for obtaining 
better results (Thakur et al., 2015). 
5.3.3.2 Cytotoxicity Assessment 
5.3.3.2.1 Preparation of Fatty Acids  
Omega-3 PUFA; EPA (826mM) and DHA (761mM) (Cambridge Bioscience Ltd, 
Cambridge, UK) stock solutions were aliquoted and stored in ethanol at -20°C. On the 
experiment day stock EPA and DHA solutions were diluted in RPMI media with supplements to 
give a 5mM intermediate stock solution. Then further dilutions were prepared from the 
intermediate stock solution, so that final desired concentrations are achieved in the test wells (10, 
50, 100, and 500 µM). In order to minimize oxidation effects, the fatty acids were freshly 
prepared and were not reused again, see Table 5.3. 
 
Table ‎5.3: The preparation of EPA and DHA final Concentrations 
Final Concentration 1X 
µM 
Volume 5mM 
stock  
µl 
Volume of 
RPMI media 
µl 
10 2.5 997.5 
50 12.5 987.5 
100 25 975 
500 125 875 
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5.3.3.2.2 Assay Procedures 
Preliminary cytotoxicity studies were   performed in order to address the impact of high 
dose EPA and DHA, on PBMC biomarkers release. Five PBMCs samples from five COPD 
patients (10
6
 cells/well, 96-well plate), were incubated without or with 10, 50, 100, and 500μM 
of EPA or DHA for 24hrs in a 5% CO2 humidified atmosphere at 37°C. The PBMCs in RPMI 
medium were considered as a control. Then, culture supernatants from each well were harvested 
(centrifuged at 400g for 10 minutes) and supernatants were collected, and ELISA assay was 
carried out as mentioned in section (2.1.4.4) to detect the impact of high dose of fatty acids on 
the biomarkers production from EPA- or DHA-treated and untreated cells. The experiments were 
carried out three times.  
5.3.3.3 PHA Concentration Selection  
A total amount of 20mg of PHA (Roche Diagnostics GmbH, Mannheim, Germany) was 
reconstituted in sterile double-distilled water, aliquoted into small micro-tubes and stored at -
20°C. On PBMCs activation experiment day 1mg/ml aliquoted of PHA was further diluted with 
RPMI media with supplements to obtain a working solution range of 1-20 µg/ml. To find the 
optimal concentration of PHA mitogen that induce cell proliferation, PBMCs (10
6
 cells/well, 96-
well plate) were stimulated with various concentrations of PHA, including 1, 5, 10, and 20 
µg/ml, and were incubated for 24hrs at 37˚C under 5% CO2 and 95% humidity. The PBMCs in 
RPMI medium were considered as a control for each group. Then, culture supernatants from 
each well were harvested (centrifuged at 400g for 10 minutes) and supernatants were collected. 
ELISA assay was carried out as mention in section (2.1.4.4) to detect IL-6, IL-8, TNF-α, and 
CD31 production from PHA-stimulated and unstimulated cells and the best concentration of 
PHA which induced the highest biomarker production from cells was used to activate PBMCs of 
the actual experiments. The experiments were carried out three times using five PBMCs samples 
from each group; COPD, healthy smokers and nonsmokers groups. 
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5.3.3.4 Biomarkers Detection from Unstimulated PBMC  
Basal release of IL6, IL-8, TNF-α, and CD31 was investigated from unstimulated ex-vivo 
PBMCs from the study groups. PBMCs (10
6
 cells/well, 96-well plate) were incubated for 24hrs 
in a 5% CO2 humidified atmosphere at 37°C.Then, culture supernatants from each well were 
harvested (centrifuged at 400g for 10 minutes) and supernatants were collected. ELISA assay 
was carried out as mentioned in section (2.1.4.4) to detect the IL-6, TNF-α, IL-8, and CD31 
production from unstimulated cells. The experiments were carried out three times using five 
PBMCs samples from each group; COPD, healthy smokers and healthy nonsmokers groups. 
5.3.3.5 Biomarker Detection from Stimulated PBMC 
Production of biomarkers; IL-6, TNF-α, IL-8 and CD31, was evaluated following 
stimulation of PBMCs to mimic an inflammatory in vivo environment. The effects on biomarkers 
can be analysed via direct detection of the relative concentration of biomarkers in the culture 
supernatant following experimental treatment in activated PBMCs (Ai et al., 2013). The 
experiments were carried out three times using five PBMCs samples from five subjects from 
each studied group to assess the cellular cytokine response to an inflammatory stimulus (PHA) in 
the presence or absence of omega-3 PUFA (EPA or DHA). The five selected samples represent 
each group, as much as possible, with the least possible error and without substitution or 
incompleteness. Five random patient samples were selected represent the different disease stage 
and smoking status. Five samples selected from the smokers group represent smokers and ex-
smokers, while five samples selected from the controls group were share a common character. 
This allows obtaining an effect size from each sub-group separately. Therefore, the differences 
between groups become apparent, and it allows obtaining samples from minority or under-
represented populations. PBMCs samples were adjusted to 1×10
6
 cells/ml in RPMI 
supplemented media, and 100 µL of sample was added to each well in a 96-well round bottom 
plates (Sarstedt AG and Co, Numbrecht, Germany). PBMC samples were cultured in either 
RPMI1640 culture media with media supplements with EPA or DHA doses (10, 50, 100, and 
500 µM final concentration) or to RPMI medium alone as a negative control for 1 hour before 
the addition of PHA (5μg/ml) mitogen or medium alone only as a control. The cells were then 
incubated at 37∘C under 5% CO2 and 95% humidity for 24hr. Then, culture supernatants from 
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each well were harvested (centrifuged at 400g for 10 minutes) and supernatants were collected. 
ELISA assay was carried out as mentioned in section (2.1.4.4) to detect the IL-6, TNF-α, IL-8, 
and CD31 production from EPA or DHA treated-PBMCs. 
5.3.4 Statistical Analysis  
Laboratory data were expressed as standard deviation of the mean (SD). Shapiro-Wilk test 
was performed to test normality of the data distribution. All data were expressed and graphed as 
mean ± standard deviation. For data normally distributed, paired t-tests or one-way ANOVA 
analysis of variance followed by Tukeys multiple comparison post-test was performed to 
determine whether the differences between the groups were statistically significant. Differences 
were considered significant if the probability (P) value was <0.05, highly significant if P value 
was <0.01 and P value <0.001, and insignificant if P value was >0.05. Correlation analyses of 
two variables were carried out using Pearson or Spearman methods, depending on the normality 
of the data distribution. All statistical analyses were performed using graphPad Prism and 
graphPad InStat software, version 7.04 and 3.10.32 respectively. 
 
5.4 Results 
5.4.1 Prioritized COPD Biomarkers in PBMCs 
Four candidate biomarkers were detectable in PBMCs culture supernatant samples 
including; IL-6, TNF-α, IL-8 and CD31. In contrast, other biomarkers; IP10 and RAGE were 
undetectable in PBMCs supernatant samples.  
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5.4.2 Initial Optimizations  
5.4.2.1 Supernatant Diluent Selection  
The assay was carried out to address the appropriate diluent  to dilute PBMCs culture 
samples before starting out actual experiments. It was found that there was no difference 
between the IL-6 release from PBMC culture sample diluted with RPMI media or PBS (1:5 and 
1:10, P > 0.05). However, a difference was detected between the IL-6 releases from PBMC 
culture sample diluted with RPMI media or PBS (1:1, P<0.05) (Figure 5.1).  Based on these data, 
all PBMCs culture samples were diluted in RPMI medium in all subsequent experiments. 
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Figure ‎5.1: Dilution medium selection for PBMCs culture samples. ELISA assay bar graph 
comparing IL6 level released from PBMCs when diluting culture samples with PBS or RPMI 1640 
medium. PBMCs separated from whole blood of COPD patients, seeded in a 96-well plate and incubated 
for 24hrs, 5% CO 2 at 37°C. Following the incubation period cell supernatant were recovered and 
assayed as triplicate with dilution (1:1, 1:5, 1:10) with RPMI media or PBS alongside undiluted sample. 
The levels of IL-6 was quantified by ELISA assay (see section 2.1.4.4).Value are expressed as mean (n=3) 
(error bar represent 1 SD). P value < 0.05 as determined by paired t-tests indicates a significant 
difference between the two diluents. These analyses were performed using Graph Pad and Instat 
Software. Abbreviations: IL-6, interleukin-6; PBS, phosphate buffer saline; RPMI, Roswell Park 
Memorial Institute 1640. 
 
  
147 
 
5.4.2.2 Supernatant  Dilution Factor Selection 
The assay was carried out to estimate the proper dilution factor for PBMC cuture samples 
before starting out actual experiments. Undiluted PBMC culture supernatants were the best 
option for TNF-α and CD31, while a dilution of 1:10 was appropriate for IL-6 and IL-8 (Figure 
5.2). 
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Figure ‎5.2: Selection of PBMC culture sample dilution. The figure shows the optimum dilution 
factor using 10-fold dilution of PBMC culture sample for biomarker candidate; IL-6 (A), IL-8 (B), TNF-α 
(C), and CD31 (D). PBMCs separated from whole blood of COPD patients, seeded in a 96-well plate and 
incubated for 24hrs, 5% CO 2 at 37°C. Following the incubation period cell supernatant were recovered 
and assayed as triplicate with dilution (1:10, 1:100, 1:1000) with RPMI media or PBS alongside 
undiluted sample. The level of biomarkers was quantified by ELISA assay (see section 2.1.4.4). Value are 
expressed as mean (n=3, each group).These analyses were performed using Graph Pad and Instat 
Software. Definition of abbreviations: COPD, chronic obstructive pulmonary disease; HS, healthy 
smokers; HNS, healthy nonsmokers; IL-6, interleukin-6; IL-8, interleukin-8; TNF-α, tumor necrotic factor 
alpha; CD31, cluster of differentiation 31. 
  
148 
 
5.4.3 Anti-inflammatory actions of EPA and DHA on cytokine release from PBMCs 
A range of concentrations of EPA or DHA were tested for any cytotoxic impact on ex-
vivo PBMCs from COPD patients over a period of 24 hrs. The range selected encompasses the 
typical concentrations employed in many previous studies. Compared with the control, neither 
EPA nor DHA showed any cytotoxic effect at 100μM (Figure 5.3). The release of IL-6 and TNF-
α from EPA-treated PBMCs was markedly decreased at a concentration of 100μM (p<0.005), 
while release of both cytokines became undetectable level at concentrations of 500μM in PBMCs 
treated with DHA. IL-8 release was markedly decreased at a concentration of 500μM EPA 
(p<0.001), and was undetectable in PBMC treated with 500μM DHA. However, there was no 
difference in CD31 release from PBMC treated with either concentration of EPA or DHA 
(p>0.05). Based on these data, a maximum fatty acid concentration of 500μM was used in all 
subsequent experiments 
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Figure ‎5.3: Biomarkers release from PBMCs culture samples. ELISA assay bar graph showing 
the influence of omega-3 FA; EPA on IL-6 (A), DHA on IL-6 (B), EPA on TNF-α (C), and DHA on TNF-α 
(D), EPA on IL-8 (E), and DHA on IL-8 (F), EPA on CD31 (G), and DHA on CD31 (H), release from 
PBMCs-COPD. Cells were seeded in a 96-well plate and treated with or without increasing 
concentrations of one of the following; DHA and EPA (10, 50, 100, and 500μM) then incubated for 24 
hrs, 5% CO 2 at 37°C. Following the incubation period cell supernatant were recovered and assayed as 
triplicate through ELISA assay to determine the level of biomarkers release (see section 2.1.4.4).Value 
are expressed as mean (n=5) (error bar represent 1 SD). P value < 0.05 as determined by one-way 
ANOVA analysis of variance followed by Tukeys multiple comparison post-test indicate a significant 
difference between different concentrations. Definition of abbreviations: PBMCs, peripheral blood 
mononuclear cells; IL-6, interleukin-6; IL-8, interleukin-8; TNF-α, tumor necrotic factor alpha; CD31, 
cluster of differentiation 31; COPD, chronic obstructive pulmonary disease; EPA, Eicosapentaenoic 
acid; DHA, Docosahexaenoic acid. 
  
151 
 
5.4.4 PHA Optimal Concentration Selection  
Activation of PBMCs can effectively produce a large amount of biomarkers. The study 
aimed to find an optimal concentration of PHA mitogen which can promote a maximum amount 
of biomarker production from human PBMCs. The effect of PHA at different concentrations (1, 
5, 10, and 20µg/ml) on biomarker production was compared to the control, measured after 24hrs 
from PBMCs, as seen in Figure 5.4. The results showed that the maximum production of IL-6 
and TNF-α was obtained by 5µg/ml PHA-stimulated-PBMCs from the COPD group, compared 
to untreated cells (p<0.001). No significant differences were seen in IL-6, TNF-α when 
stimulated with PHA at different concentrations in PBMCs from healthy smokers (p>0.05).  A 
similar trend was seen in IL-8 release from PBMCs of COPD patients. In contrast, there was a 
significant increase in IL-8 release at more than one concentration (1, 5, 10µg/ml) of PHA-
stimulated-PBMCs from healthy smoker controls (p<0.001). Additionally, there was a significant 
increase in IL-8 release in 5 and 10µg/ml PHA-stimulated-PBMCs of healthy nonsmoker 
controls (p<0.001). However, IL-6 and TNF-α were undetectable in PBMCs from healthy 
nonsmokers with PHA at any tested concentration. Surprisingly, there was a tendency in all three 
subject groups for decreased CD31 release with the increasing PHA concentrations particularly 
with 20µg/ml PHA (p<0.001). Based on these data, a 5µg/ml PHA concentration was used for 
PBMCs activation in all subsequent experiments 
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Figure ‎5.4: Biomarkers production from PHA-stimulated PBMCs. ELISA assay bar graph 
showing effect OF PHA on IL-6 (A), TNF-α (B), IL-8 (C), CD31 (D) release of PBMCs from three studied 
groups. Cells were seeded in a 96-well plate, stimulated with or without increasing concentrations of 
PHA (1, 5, 10, and 20µg/ml) and incubated for 24hrs, 5% CO 2 at 37°C. Following the incubation period 
cell supernatant were recovered and assayed as triplicate through ELISA assay to determine the level of 
IL6, IL-8, TNF-α, and CD31  (see section 2.1.4.4).Value are expressed as mean; n=5 in each group, 
(error bar represent 1 SD). P value < 0.05 as determined by one-way ANOVA analysis of variance 
followed by Tukeys multiple comparison post-test indicate a significant difference between the groups. 
Definition of abbreviations: COPD, chronic obstructive pulmonary disease; HS, healthy smokers; HNS, 
healthy nonsmokers; IL-6, interleukin-6; IL-8, interleukin-8; TNF-α, tumor necrotic factor alpha; CD31, 
cluster of differentiation 31; PHA, phytohaemagglutinin. 
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5.4.5 Biomarker release from unstimulated ex-vivo PBMCs 
ELISA assays were performed on PBMCs to monitor secretion of pro-inflammatory 
biomarkers. The basal release of IL-6, IL-8, TNF-α, and CD31 was measured in PBMCs from 
patients with COPD, healthy smokers and healthy nonsmokers. PBMCs obtained from COPD 
patients, released greater amounts of IL-6 (4±0.46 ng/ml), IL-8 (16.3±0.22 ng/ml), and TNF-α 
(219±12 pg/ml), compared to those obtained from healthy nonsmokers (p<0.001). Similarly, the 
mean value and SD of IL-6, IL-8 and TNF-α in COPD patient was higher than those in healthy 
smokers (p <0.05). Similarly, no significant difference was observed in CD31 release in culture 
media from PBMCs of COPD and healthy subjects (p >0.05). In contrast, the mean value and SD 
of CD31 was significantly higher in healthy nonsmoking controls (3.66±0.05 ng/ml) when 
comparing with patients with COPD (2.96±0.11 ng/ml) and healthy smokers (1.82±0.05 ng/ml) 
(p <0.001). All these results are summarized in (Table 5.4) and (Figures 5.5). 
 
Table ‎5.4: The mean value of biomarkers basal release from PBMCs in the studied groups. 
Biomarkers 
 
COPD HS HNS P value 
COPD vs 
HS 
COPD vs 
HNS 
HN vs 
HNS 
IL6 
ng/ml 
4 (0.46) 2.5 (0.14) 0.16 (0.05) <0.05 <0.001 <0.001 
IL8 
ng/ml 
16.3 (0.22) 13.7 (0.3) 6.6 (1.07) <0.05 <0.001 <0.05 
TNFα 
pg/ml 
219 (12) 175 (14.2) 0 <0.01 <0.001 <0.001 
CD31 
(PECAM) 
ng/ml 
2.96 (0.11) 1.82 (0.05) 3.66 (0.05) <0.001 >0.05 <0.001 
 
Data expressed as mean (standard deviation) or as percentage unless otherwise stated. The data 
represents the mean ± SD from 3 experiments. P value < 0.05 as determined by one-way ANOVA analysis 
of variance followed by Tukeys multiple comparison post-test indicate a significant difference between the 
groups. These analyses were performed using Graph Pad Instat Software. Definition of abbreviations: 
COPD, chronic obstructive pulmonary disease; HS, healthy smokers; HNS, healthy nonsmokers; IL-6, 
interleukin-6; IL-8, interleukin-8; TNFα, tumour necrosis factor; CD31, cluster of differentiation 31. 
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Figure ‎5.5: Basal releases of Biomarkers from PBMCs culture samples. ELISA assay bar 
graph showing basal release IL-6 (A), IL-8 (B), TNF-α (C), CD31 (D) from PBMCs in patients with 
COPD, healthy smoker, and healthy nonsmokers. Cells were seeded in a 96-well plate and incubated for 
24hrs, 5% CO 2 at 37°C. Then cell supernatant were recovered and assayed as triplicate through ELISA 
assay to determine the level of IL6, IL-8, TNF-α, and CD31 (see section 2.1.4.4). P value < 0.05 as 
determined by one-way ANOVA analysis of variance followed by Tukeys multiple comparison post-test 
indicate a significant difference between the groups. Value are expressed as mean ± SD; n=5 in each 
group (error bar represent 1 SD). These analyses were performed using Graph Pad Instat Software. 
Definition of abbreviations: COPD, chronic obstructive pulmonary disease; HS, healthy smokers; HNS, 
healthy nonsmokers; IL-6, interleukin-6; IL-8, interleukin-8; TNF-α, tumor necrotic factor alpha; CD31, 
cluster of differentiation 31. 
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5.4.6 Effect of EPA/DHA on Inflammatory Biomarker Production in PBMCs 
Production of candidate biomarkers; IL-6, TNF-α, IL-8 and CD31, from stimulated 
PBMCs was measured to mimic their in vivo natural environment. Possible anti-inflammatory 
properties of EPA and DHA on cellular biomarker release from PHA-stimulated and 
unstimulated human PBMCs were also evaluated.  
 
5.4.6.1 IL-6 
Both EPA and DHA at 100µM reduced IL-6 release in stimulated-PBMCs and 
unstimulated PBMCs of COPD patients and to lesser extent in healthy smokers groups in a dose-
response manner. At the highest dose of EPA and DHA (500µM) IL-6 release in stimulated and 
stimulated PBMCs-COPD was neglible or undetectable. Stimulated PBMCs from COPD patients 
produced significantly higher levels of IL-6 compared to PBMCs from healthy nonsmoker group 
(P <0.001). In COPD patients the production of IL-6 was higher in stimulated PBMCs vs. 
unstimulated cells although significance was not reached (P >0.05). There was no difference in 
IL-6 release in stimulated PBMCs compared to unstimulated cells in healthy smokers group. IL-
6 release was decrease at EPA (100µM), and was undetectable at 500µM in unstimulated cells of 
healthy smokers group. DHA at 500µM and 100µM reduced IL-6 release in unstimulated- and 
stimulated-PBMCs respectively of healthy smokers groups. The release of IL-6 from stimutlated 
and unstimulated EPA/DHA-PBMCs of healthy nonsmokers were udetectable (Figure 5.6). 
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Figure ‎5.6:Histograms represent the Effect of EPA (A-B) or DHA(C-D) on IL-6 release in 
activated PBMCs. Cells from COPD, HS, and HNS groups were stimulated or not with PHA (5µg/ml) 
pretreatment of EPA/DHA (0, 10, 50, 100, and 500μM) for 24hr, 5% CO 2 at 37°C; for each condition IL-
6 release from the cell culture media were assayed as triplicate through ELISA assay (see section 
2.1.4.4). Value are expressed as mean; n=5 in each group. P value < 0.05 as determined by one-way 
ANOVA analysis of variance followed by Tukeys multiple comparison post-test indicate a significant 
difference between concentrations. Definition of abbreviations: COPD, chronic obstructive pulmonary 
disease; HS, healthy smokers; HNS, healthy nonsmokers; IL-6, interleukin-6. 
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5.4.6.2 TNF-α 
Both EPA and DHA at 100µM reduced TNF-α release in stimulated-PBMCs and unstimulated 
PBMCs of COPD patients and to lesser extent in healthy smokers groups in a dose-response 
manner. At the highest dose of EPA and DHA (500µM) TNF-α release in stimulated and 
stimulated PBMCs- COPD was neglible or undetectable. In COPD, the production of TNF-α was 
higher in stimulated PBMCs vs. unstimulated cells although significance was reached with 
≥ 50µM EPA or DHA (P<0.05). The release of TNF-α was decreased at 100µM EPA and 
500µM DHA from stimulated and unstimulated PBMCs of healthy smokers. The release of 
TNF-α from stimutlated and unstimulated EPA/DHA-PBMCs of healthy nonsmokers were 
udetectable (Figure 5.7). 
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Figure ‎5.7: Histograms represent the Effect of EPA (A-B) or DHA (C-D) on TNF-α release 
in activated PBMCs. Cells from COPD, HS, and HNS groups were stimulated in the presence or 
absence of PHA (5µg/ml) plus pretreatment of EPA/DHA (0, 10, 50, 100, and 500μM) for 24hr, 5% CO 2 
at 37°C; for each condition TNF-α  release from the cell culture media were assayed by ELISA(see 
section 2.1.4.4). Value are expressed as mean of three independent experiments; n=5 in each group. P 
value < 0.05 as determined by one-way ANOVA analysis of variance followed by Tukeys multiple 
comparison post-test indicate a significant difference between concentrations. Definition of 
abbreviations: COPD, chronic obstructive pulmonary disease; HS, healthy smokers; HNS, healthy 
nonsmokers; TNF-α, tumor necrotic factor alpha. 
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5.4.6.3 IL8 
EPA at 100µM reduced IL-8 release in unstimulated PBMCs of COPD and healthy 
smokers groups. However, EPA treatment has no imapct on IL-8 release from PHA-stimulated 
PBMCs in the COPD and healthy smokers groups. The release of IL-8 from stimulated and 
unstimulated PBMCs of COPD group remained unaltered with DHA treatment. While DHA 
500µM treatmnet reduced IL-8 release from stimulated and unstimulated PBMCs of healthy 
smokers. Surprisingly,  DHA treatment had no effect on IL-8 production from PBMCs in the 
healthy nonsmokers group. The release of IL-8 from stimutlated and unstimulated PBMCs of 
healthy nonsmokers were changeable in the presence of EPA/DHA different concentrations 
(Figure 5.8).  
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Figure ‎5.8: Histograms represent the Effect of EPA (A-C) or DHA (D-F) on IL-8 release in 
activated PBMCs. IL-8 release were estimated by ELISA (see section 2.1.4.4). Value are expressed as 
mean of three independent experiments; n=5 in each group. P value < 0.05 as determined by one-way 
ANOVA analysis of variance followed by Tukeys multiple comparison post-test indicate a significant 
difference between concentrations. Definition of abbreviations: COPD, chronic obstructive pulmonary 
disease; HS, healthy smokers; HNS, healthy nonsmokers; IL-8, interleukin-8. 
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5.4.6.4 CD31 
It was observed that maximal CD31 release tended to be from stimulated and 
unstimulated PBMCs from the healthy nonsmoking controls, compared with healthy smokers 
(p<0.05). The production of CD31 from PBMCs remained unaffected after treating the cells with 
either EPA or DHA (1, 5, 10, 50, 100, and 500µM) in the three study groups. However, the 
release of CD31 from PBMCs from healthy controls was dose-dependently suppressed by EPA 
although significance was not reached. There were inconsistent findings pre- and post-
stimulation with CD31.  Surprisingly, the production of CD31 from unstimulated-PBMCs was 
higher when comparing to stimulated cells treated with EPA or DHA in all the three groups 
(Figure 5.9). 
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Figure ‎5.9: Histograms represent the Effect of EPA (A-C) or DHA (D-F) on CD31 release 
in activated PBMCs. CD31 release was estimated by ELISA (see section 2.1.4.4). Value are expressed 
as mean from three independent experiments; n=5 in each group. P value < 0.05 as determined by one-
way ANOVA analysis of variance followed by Tukeys multiple comparison post-test indicate a significant 
difference between concentrations. Definition of abbreviations: COPD, chronic obstructive pulmonary 
disease; HS, healthy smokers; HNS, healthy nonsmokers; CD31, cluster of differentiation 31. 
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5.5 Discussion 
Evidence from research work conducted on immune function of COPD patient indicated a 
close correlation between development of COPD and changes in immune function (Quan et al 
2016). The initial inflammatory response to damage from smoking or irritant agent is 
characterized by neutrophils, macrophages, T-lymphocytes infiltration, and increased cytokine 
production such as IL-6, IL-8, and TNF-α (El-Shimy et al., 2014; Korani et al., 2016). Mitogen-
stimulated PBMCs in culture were used as a simple ex vivo natural environment model to reflect 
inflammation in COPD. Experiments were performed with PHA as a mitogenic stimulator, since 
it was previously reported that PHA stimulated human peripheral blood leukocytes. It binds to 
cell membranes surface receptors and stimulates cell division and metabolic activity (Conti et al., 
2001). The selection of PHA concertation range in the current study was based on previous 
studies. Different studies used different PHA concentration which varied from 0.04μg/ml to 
25μg/ml to trigger biomarker production from activated PBMCs (Hou et al., 2010). A previous 
study determined that the best concentration of PHA was 20µg/ml PHA (Conti et al., 2001). 
Moreover, Haller et al (2000) showed that 10µg/ml PHA was essential for the maximal PBMCs 
stimulation. In this study PHA various concentrations (1, 5, 10, and 20 µg/ml) were tested to find 
the optimal concentration of PHA mitogen which can promote a maximum amount of biomarker 
production from human PBMCs. It was observed that the optimum biomarkers release was seen 
in 5μg/ml concentration of PHA. This finding agrees with the previous observation which proved 
that the best concentration of PHA for the maximum production of TNF-α in the PBMCs was 
5μg/ml (Molaee et al., 2017).  Furthermore, in a previous proteome study, PBMCs were 
inflammatory activated with 5μg/ml PHA (Haudek-Prinz et al., 2012). Thus, 5µg/ml 
concentration of PHA was selected, in each case, as the optimal concentration for the human 
PBMCs proliferation and biomarker release.  
Of the note, there were no IL-6 and TNF-α release from the control healthy subjects. This 
may due some cytokines local and short term effects, its degradation and its short half-life, as 
well as its binding to receptors and renal clearance (Korani et al., 2016). Furthermore, PBMCs in 
healthy subject are circulating in a quiescent cell state monitoring potential immune-relevant 
events (Haudek-Prinz et al., 2012). Hence, the production of inflammatory cytokines in PBMCs 
of healthy subject will be undetectable or lower than those in healthy smokers and patients. 
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Candidate biomarkers production was then measured in stimulated PBMCs. The effects on 
biomarkers were analysed via direct detection of the relative concentration of biomarkers in the 
supernatant, mimicking the circulation, following experimental treatment in activated PBMCs 
(Ai et al., 2013). In this study, only four biomarkers from a long candidate list; IL-6, TNF-α, IL-
8 and CD31, were detectable by ELISA assays in PBMCs supernatant samples of the study 
cohort. It was hypothesized that the analysis of these different cytokines and chemokines may 
assist in understanding the inflammatory patterns that underlying the disease. The potential for 
an immunomodulatory effect of the PUFAs EPA and DHA on inflammatory biomarker release 
has therapeutic implications and therefore was also studied using the model.  
Many studies have investigated the role of the immune inflammatory cells in the lungs in 
COPD (Barnes 2016). PBMCs act as a critical component in the immune system to fight 
infection and play an important role in the development of COPD (Wu et al., 2014). It was 
previously reported that circulating T-cells of COPD patients are abnormally activated and 
stimulate pro-inflammatory cytokines production that is involved in COPD pathogenesis. This 
may due to the migration of lymphocytes between inflammatory sites includes lung and systemic 
circulation via lymph nodes. Also peripheral T-cells functions correlate with the severity of 
COPD. Hence, impaired lymphocyte function in peripheral blood of COPD patients may have a 
pathological impact on the lung (Zhu et al., 2009). Inflammation in COPD characterized by 
increased numbers of CD8+ T lymphocytes, neutrophils and macrophages in small and large 
airways and in lung parenchyma and pulmonary vascular system. The increased numbers of T-
cells that present in the alveolar walls are correlated with COPD severity (Paats et al., 2012). 
Alveolar macrophages release of inflammatory cytokines, such as IL-6, that attract neutrophils 
into the airways. IL-6 regulates many pathways that could contribute to its effect on 
inflammatory disease progression. During CD4 T-cell differentiation, IL-6 promotes IL-17 and 
IL-21 production, and suppresses regulatory T-cell function (Ferrari et al., 2013).  
It was important to compare the release of inflammatory mediators from unstimulated 
PBMCs to investigate if PBMCs in COPD show an increased release compared with healthy 
smokers and healthy nonsmokers. Basal levels of TNF-α and IL-6, IL-8, were selected for 
measurement as these cytokines are the most important produced by PBMCs, and are implicated 
in several inflammatory conditions. Results show that there was a significant difference in basal 
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biomarkers release from PBMCs between the COPD and healthy nonsmokers groups. PBMCs 
obtained from COPD patients, released greater amounts of IL-6, TNF-α, and IL-8 compared to 
those obtained from healthy nonsmokers. Together, these observations suggest that PBMC may 
be pre-activated in the circulation in COPD patients, which agrees with findings from several 
previous studies, and supports the notion of systemic inflammation being important in COPD 
(Koethe et al., 2000; Erik-Jan et al., 2006; Kawayama et al., 2016). Pro-inflammatory cytokine 
IL-6 is involve in the homeostasis of immune response, regulate the immune response, and 
prevent inflammatory and autoimmune pathologies (Aldonyte et al., 2003). Furthermore, IL-6 
initiates the acute phase response, while IL-6 trans-signaling controls macrophage recruitment 
during acute inflammation (Ravi et al., 2014). 
TNF-α is a potent inflammatory cytokine that can induce inflammatory effects in COPD 
resulting in the activation of various immune cells, including neutrophils and monocytes (Barnes 
2016). TNF-α is involved in neutrophil chemotaxis and migration by inducing the expression of 
IL-8, which is essential for neutrophil recruitment in COPD. TNF-α is secreted by LPS-
stimulated macrophages, monocytes, fibroblasts, T-cells and endothelial cells. Further, 
overexpression of TNF-α in animal models study induces pathological changes similar to those 
of pulmonary emphysema and fibrosis (Mukhopadhyay, et al., 2006). Elevated level of TNF-α in 
serum and sputum of COPD patients suggest an important role for TNF-α in COPD (Queiroz et 
al., 2016; Korani et al., 2016). However, studies on TNF-α release by PBMCs of COPD patients 
remain limited. The current study finding of increased TNF-α release by PBMCs in COPD 
patients when compared with healthy controls is supported by Paats et al (2012). Likewise, 
Increased TNF-α and IL-8 release from PBMCs of COPD patients has been also reported in 
COPD patients when compared to healthy controls (Lee et al., 2012; Meng et al., 2016).  
These baseline differences in the release of pro-inflammatory biomarkers might be 
important parameters in the chronic inflammatory processes in COPD. Systemic inflammation is 
highly associated with COPD severity. Dysregulation of cytokine production is notable in 
PBMCs from COPD patients. Meng et al. (2016) also demonstrated that normal cells could be 
stimulated to become pro-inflammatory by exposing them to the serum of COPD patients, 
whereas PBMCs from COPD patients were pro-inflammatory and activated even in the absence 
of serum.  
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Cigarette smoking is a major risk factor for COPD and can cause airway inflammation 
characterized by neutrophil, macrophage, and activated T lymphocyte infiltration result in 
increased cytokine concentrations, including TNF-α and IL-8 (Tanni et al., 2010). A previous in 
vitro study reported that cigarette smoke enhanced the production of IL-8 from monocytes in a 
time- and concentration-dependent manner (Sarir et al., 2007). Smoking also associated with 
excessive oxidative stress of lung structural cells, and breakdown of connective tissue leading to 
impaired gas exchange and elastic recoil (Robers et al., 2015). In this study, it was observed that 
the release of inflammatory mediators from PBMCs of healthy smokers was also increased, 
compared with healthy nonsmoker, but this increase was not enough to reach significance. This 
suggests that circulating immune cells like PBMCs may be activated by smoking, with or 
without COPD, and that smoking may directly or indirectly increase systemic inflammation. Our 
results show that inflammation is present in the blood of smokers and patients with COPD 
(Kawayama et al., 2016).  
In contrast, CD31 release was maximal in the healthy nonsmokers rather than in COPD or 
healthy smokers. This glycoprotein membrane is highly expressed on vascular endothelial cells 
and to different degree on monocytes, neutrophils, B lymphocytes, some T lymphocyte subsets 
(Falati et al., 2006). Leukocyte transmigration is a main event during tissue inflammation and is 
a process that is mediated and controlled by different mediators and adhesion pathways. CD31 
mediate leukocyte trans-endothelial migration and inflammation via its ability to inhibit the 
activation of circulating platelets and leukocytes. It regulates migration of leukocytes from the 
vascular lumen into inflammation site which is essential for both innate and adaptive immunity, 
to enable tissue to respond to the inflammatory stimuli. It was reported that the expression of 
CD31 in in vivo animal model studies was found to be reduced on emigrated leukocytes 
(Woodfin 2007). This might explain the reduced release of CD31 in the COPD group as 
increased number of leukocytes including PBMCs migrated from circulation to the lung. 
However, evidence that could confirm this is currently lacking. On the other hand, Higgins et al 
(2008) reported that delayed processing of peripheral blood sample or PBMCs isolation and 
cryopreservation can lead to the detection of higher levels of CD31 expression on naive CD4 T 
cells in both HIV
+
 and HIV
-
 subjects. This could also account for the reported findings.  
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Components of both innate and acquired immunity  are known to be affected by omega-3 
PUFA. EPA and DHA omega-3 PUFA are modulators of lymphocyte functions, and T-cells are 
the main lymphocytes involved in cell-mediated immunity. The serum level and diet content of 
EPA and DHA may affect lymphocyte proliferation, chemotaxis, adhesion molecule expression, 
leucocyte-endothelial adhesive interactions, cytokine production, and other immune cells 
functions (Calder 2012). Also it can affect the ability of inflammatory immune cells to produce 
eicosanoids, such as prostaglandin E2, which are involved in immuno-regulation. Both fatty 
acids are incorporated into the membranes of inflammatory cells from where they may influence 
cell signaling, transcription factor activation, and gene expression (Calder 2015). This study 
investigated the immunomodulatory effect of EPA or DHA on ex-vivo mitogen-stimulated 
PBMCs. Data from the current study show that inflammatory markers production from PBMCs 
is influenced by omega-3 PUFAs. It was found that 100µM EPA and DHA alone, decreased IL-
6, TNF-α, and IL-8 secretion in both unstimulated and activated PBMCs from COPD patients. 
These results echo those reported by Jaudszus et al. (2013). Those authors speculated that 
treating PBMCs with EPA or DHA do not suppress immune cells function but rather promote 
resolution by stimulating the production of pro-resolving cytokines. This was not tested in the 
current study. To test that, anti-inflammatory cytokines such as IL-10 which known to have 
immuno-regulatory and suppressive function on T-cells, could be measured. Further, Jaudszuz et 
al., found both EPA and DHA at 100μM increased anti-inflammatory cytokines IL-10 in 
monocytes without affecting TNF-α and IL-6 production. While EPA and to lesser extent DHA 
reduced TNF-α release in T-cells. In contrast, CD31 production remained unaffected by EPA or 
DHA in the three study groups. However, it was observed that the release of CD31 from healthy 
control PBMC was dose-dependently suppressed by EPA, without reaching significance. Thus, 
both EPA and DHA did show an immunomodulatory activity against activated PBMC, 
suggesting they may have therapeutic value. In the current study, there were no IL-6 and TNF-α 
release from the control healthy subjects. Previous works failed to report strong dose–response 
effects of EPA and/or DHA on the outcomes measured and suggest that healthy subjects are 
relatively insensitive to immunomodulation with omega-3 PUFA. While in patients with 
inflammatory conditions cytokine concentrations or production are influenced by the 
immunomodulatory effects of EPA and/or DHA supplementation. This difference could be due 
to depletion of the buffering capacity present in healthy controls, as a result of a higher turnover 
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rate of immune cells in an inflammatory disease  and of the fatty acids in immune cell 
phospholipids composition for use as substrate for eicosanoid synthesis or as ligands for 
transcription factors (Sijben and Calder 2007). 
Moreover, studies that analysed the effect of EPA and/or DHA on inflammatory cytokines 
in stimulated-PBMCs, in relation to clinical status in COPD patients are extremely rare (Jaudszus 
et al., 2013). Previous studies with PBMC from normal subjects have used oral supplementation 
via fish oil capsules, purified EPA or DHA supplements, fish oil-enriched diets or omega-3 
PUFA enriched foods and generally did not find an effect. Reasons for this are not clear but may 
include: a low omega-3 PUFA therapeutic dose, since actual blood levels were not measured, or 
known before treatment; small sample size; short study duration; and the large variability 
between individual outcomes. The presence of an inflammatory disease like COPD might 
increase the sensitivity to the immunomodulatory effects of EPA and DHA (Sijben and Calder et 
al., 2007; Miles and Calder 2012).  
Only a limited number of previous investigations have specifically examined the 
characteristics and functions of circulating PBMCs among COPD patients, and findings from 
these studies are often inconsistent. This may due to the differences in experimental 
methodologies, small sample size and variability in disease severities (Zhu et al., 2009). The data 
reported here support what in vitro previous studies have shown using human PBMC to assess 
agent-induced changes in endpoints like cells proliferation and cytokine production, which will 
certainly contribute to a better understanding of the effects of omega-3 PUFA on immune cells 
function. Blood is a good source for biomarker discovery; however it is difficult to understand 
the contributions of individual cells in whole blood (Roberts et al., 2015). There was a limitation 
in the current study which worth mentioning. There was a lack of investigating the effect of EPA 
or DHA concertation values lies between 200-400 µM, as the release of some cytokines from 
cells treated with 500 µM EPA/DHA was undetectable. This may due to the effect of high 
concentration on PBMCs viability which was not tested in the current study. 
A more comprehensive study using additional stimuli such as cigarette extract followed by 
novel inflammatory mediators’ investigation in PBMCs sub-population or proteomics analysis 
might provide further understanding of the complex interplay between stimuli and cellular 
response. EPA and DHA gave rise to a variety of monohydroxylated derivatives of highly anti-
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inflammatory and protective properties, such as resolvins and their precursors (Jaudszus et al., 
2013). Recent study by Mochimaru et al. (2018) revealed that 12-OH-17,18-EpETE, an EPA-
derived endogenous metabolite, may overcome limitations of dietary EPA and DHA 
supplementation and provide novel options for the treatment of asthma and airway inflammatory 
diseases. There would be merit in investigating these bioactive lipid metabolites for their anti-
inflammatory effect on PBMCs in COPD. 
 
5.6 Conclusion 
The findings presented here indicate that circulating PBMCs isolated from COPD patients 
show a profile of pro-inflammatory biomarkers distinct from control PBMCs. At the basal level 
PBMCs from patients produce significantly more inflammatory cytokines; IL-6, TNF-α, and IL-
8, when compared to healthy controls. An impact from smoking can be seen in the increased 
release of inflammatory cytokines in PBMCs from healthy smokers when compared with healthy 
controls. The data confirmed that EPA and DHA individually exerted potential 
immunomodulatory effects characterized by significant reductions in PHA-induced cytokines 
release. The results here agreed with those in vivo previous findings and indicated that the EPA 
and DHA affected immune cells. Additionally, these observation may contribute to 
understanding of the regulatory action of EPA and DHA in immune cells and, therefore, to 
increasing knowledge in terms of fatty acid assessment from an immunological point of view. 
The findings suggest pre-activation of circulating inflammatory cells such as PBMC exists in 
patients. COPD is a complex disease that can be influenced by multiple factors such as genetic 
predisposition, cigarette smoking, and bacterial or viral infection (Sandford and Silverman 
2002), and these results support the assumption that COPD is a multicomponent disease which 
involves systemic inflammation (Kawayama et al., 2016). Importantly, the results suggest that 
DHA and EPA omega-3 PUFA may have an immunomodulatory impact on activated immune 
cells during inflammation and that further investigation of these actions in COPD are justified.  
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6. Chapter 6: Investigating baseline fatty acid profiles from erythrocytes 
(RBC) in the study cohort and the association with COPD 
 
 
6.1 Background 
Poly unsaturated fatty acids (PUFA) specifically omega-3 PUFAs, also known as ω-3 fatty 
acids or n-3 fatty acids, are important substrates for energy production and storage, and also 
involved in structural and functional properties of body cells. They are essential components of 
cell membranes and affect biological membrane structure and functions, including membrane 
fluidity, and subsequently organ functions. For example, different immune cells functions, such 
as secretion, chemotaxis, and sensitivity to microorganisms depend on the fluidity of the 
membrane. Fatty acids also mediate cellular metabolism and signalling pathways and contribute 
to the development and maintenance of body tissues (Allaire et al., 2017; Schober et al., 2017; 
(Antus and Kardos, 2015). Alteration in the PUFA composition of the cell membranes may 
affect the activity of membrane-bound enzymes and the expression of receptors, the membrane 
permeability and transport Properties. PUFA are substrates for synthesis of lipid inflammatory 
mediator eicosanoids which are involved in the inflammation progression in pulmonary diseases. 
Eicosanoids like; prostaglandins, leukotrienes, thromboxanes, are also the final products of the 
metabolism of PUFAs (Barnes 2008; Celli et al., 2012; Novgorodtseva et al., 2013). 
Concentrations of all major fatty acids can be measured in the RBC membrane, whole 
blood and plasma. The major PUFA include EPA (20: 5n-3), DHA (22: 6n-3), and ARA (20: 4n-
6). Whereas omega-3 PUFA, DHA, is essential for vision, brain neurons, and cell signaling, EPA 
is involved in vascular blood flow and down-regulates the production of ARA metabolites to 
maintain homeostasis. Several studies suggest that high intake of omega-3  fatty acid to low ratio 
of omega-6 fatty acid is reducing the risk of some of the chronic diseases that are associated with 
inflammation. It is known that diet enriched with omega-3 PUFAs tend to be positively 
associated with a range of health benefits especially for CVD. However, the mechanisms by 
which these PUFAs are involved in delivering health benefits are still unknown (Calder 2008; 
Bell et al., 2011). It is known that western diets contained higher omega-6 ratio than omega-3 
PUFA. However the balance between omega-6 and omega-3 PUFA is important for brain 
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development and function, and in decreasing the risk for chronic diseases. A recommended ratio 
of 1:1 to 2:1 omega-6/omega-3 PUFA should be the target ratio for health benefits (Simopoulos 
2010). 
Omega-3 PUFA, DHA   and    EPA are    known   to be anti-inflammatory mediators that 
are involved in several mechanisms including altering cell membrane phospholipid fatty acid 
composition, and stimulating anti-inflammatory and inhibiting pro-inflammatory transcription 
factors. Further, both have been shown to be effective in improving different inflammatory 
conditions including COPD (Calder et al., 2018). Multiple studies suggesting that using a 
mixture of EPA and DHA in different forms and proportions may associate with a positive 
impact on inflammatory biomarkers. However, the specific effects of EPA and DHA on 
inflammation pathways in COPD is less understood (Allaire et al., 2017).  
An Omega-3 Index is considered as a parameter that reflects the dietary intake of omega-3 
PUFA. It is the measurement of the amount of EPA and DHA present in RBCs membranes and 
is expressed as a percentage to the total fatty acids contents (Harris 2008). A high omega-3 Index 
(8–12%) has been associated with a lower risk of CVD and mortality in epidemiological studies. 
Supplementation with EPA and DHA is recommended by several health agencies including the 
American Heart Association for secondary coronary heart disease prevention or management of 
plasma triglycerides. Long-term supplementation with EPA and DHA would increase omega-3 
Index value. Data from randomized double-blind study shows increase in the omega-3 Index is 
greater with high dose DHA, (10 weeks with 2.7 g/d), supplementation than with high dose EPA 
(Allaire et al., 2017).  Unlike CVD, there is not much evidence in the literatures that analysed the 
effect omega-3 index in COPD patients. To our knowledge there is no estimated omega-3 index 
value for COPD.  
It is well known that weight loss and muscle wasting in patients with COPD affect 
respiratory and muscle function, exercise capacity, and health status. Few studies suggest that 
nutrition supplemented with high doses of PUFAs may improve body composition and exercise 
capacity and reduce inflammatory activity (Sugawara et al., 2010). In an 8-week randomized, 
controlled trial, daily supplementation with EPA, DHA, and ALA in 80 patients with COPD 
significantly improved exercise capacity (Broekhuizen et al., 2005). In another randomized, 
controlled trial, daily supplementation with omega-3 PUFAs with low intensity exercise for 12 
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weeks improve the outcomes of exercise capacity and health quality of life in malnourished 
patients with COPD (Sugawara et al., 2010). Cachexia is a condition frequently present in 
malnourished patients with COPD, heart failure and cancer, can cause weight loss, muscle 
weakness, fatigue, and reduced mobility. In 12-week double-blind, randomized, controlled trial, 
a targeted medical nutrition containing high dose omega-3 fatty acids, vitamin D, and high 
quality protein has positive effects on blood pressure, blood lipids and on exercise-induced 
fatigue and dyspnea. Therefore, such medical nutrition could be clinically beneficial for pre- 
cachectic and cachectic patients with COPD (Calder et al., 2018).  
Research studies are lacking in information about the qualitative and quantitative 
composition of fatty acids of RBCs membranes in COPD patients. In addition, the few available 
studies are significantly differing in their findings, which may be related to the different samples 
and methods applied for fatty acids analysis and variability between patients disease severity 
(Novgorodtseva et al.  2013). There is very limited information on the effect of omega-3 PUFA 
on lung function and inflammation in COPD.  
To begin to address this, the present study compares data from RBC fatty acid analysis 
including the following parameters; ARA/EPA ratio, the percentage of omega-3 PUFA/Total 
PUFA ratio, and Omega-3 Index between the three groups; patients with COPD, healthy smokers 
and healthy nonsmokers. Analysis were conducted to elucidate the potential relationship between 
measurements of RBC fatty acid analysis with chronic inflammation, pulmonary function 
outcomes (preFEV1% and pre FEV1/FVC ratio) and the impact of smoking on blood lipid 
profiles in patients with COPD. 
 
6.2 Objectives 
 To analyse the association between fatty acid profiles in RBC and the risk of COPD. Data 
from the three subject groups will be compared. 
 To identify the association of omega-3 and omega-6 PUFA, with chronic inflammation 
and respiratory function outcomes in patients with COPD 
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6.3 Methods 
6.3.1 Determination of RBC Fatty Acid Profile of Participants 
The most reported biological sample used in analysis of fatty acid composition that 
reflect nutritional status is RBCs. Analysis of erythrocyte fatty acid has been used to measure the 
status of the PUFA, especially EPA and DHA. A previous study showed good correlations, 
between erythrocyte and whole blood in fatty acids concentrations (Bell et al., 2011). Using RBC 
membrane for fatty acids determination is better than plasma, for reflecting long term dietary 
PUFA intake and body status with low individual biological variability. While plasma fatty acids 
analysis is more sensitive to recent food intake (Sun et al., 2007; Harris and Thomas 2010). The 
profile of fatty acids was measured in RBC fractions separated by Ficoll density gradient 
protocol from 42 EDTA-anticoagulated blood samples of the entire study cohort, and was stored 
at -80 ͦ C for analysis (See chapter 2 for details). RBCs aliquots samples contain 0.5ml were sent 
to the nutrition group laboratories at the University of Stirling for fatty acid. 
The lipid extraction of erythrocytes was performed by lab technicians in University of 
Stirling according to Bell et al (2011). It is non-invasive, economical, and accurate assay for of 
PUFA quantification. A single RBCs drop onto Whatman collector cards was air-dried. Then the 
RBCs sample was detached from the collection device using forceps and placed into a screw cap 
vial containing 1ml of a methylating solution (1.25 M-methanol–HCl). The vials were sealed and 
incubated in a hot block at 70 ͦ C for 1h, and then cooled to room temperature. Later, 2ml of 
distilled water and 2ml of saturated HCl solution were added. Fatty acid methylesters (FAME) 
were then extracted by adding 2×2ml of isohexane. FAME were separated and quantified by 
GLC using a 60m × 0·32mm × 0·25mm film thickness capillary column. H2 was used as a 
carrier gas at a flow rate of 4ml/min and the temperature range was from 50 to 150 ͦ C at 40  ͦ
C/min then to 195 ͦ C at 2 ͦ C/min, and finally to 215 ͦ C at 0·5 ͦ C/min. Individual FAME was 
identified by comparison with well-characterised in-house standards as well as commercial 
FAME mixtures. FAME composition was reported as weight percent of total identified FAMEs. 
All samples were analyzed together, and all samples from each subject were analyzed in the 
same batch to minimize analytical variability. The precision of the RBCs fatty acid analysis was 
conducted by measuring triplicate samples over four successive days to provide mean and 
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standard deviation and CV%. The ratio of ARA: EPA as well as the percentage of omega-3 
PUFA/total PUFA, and Omega-3 index has been measured. This assay provides a reliable 
method of PUFA quantification with the percentage of omega-3 PUFA value providing a 
potential blood biomarker for large-scale nutritional trials. 
However, specific and sensitive, less time consuming and cost-effective methods are 
required to measure body fatty acid profiles and to monitor their changes during clinical trials 
supplementation. A new method for fatty acid analysis was developed by Schober et al (2017), 
where they combined chemical ionization and tandem mass spectrometry after gas 
chromatography separation for measurement of fatty acid. This method is highly specific, 
sensitive, and rapid to analysis of fatty acid in biological specimens such as erythrocyte 
membranes. 
6.3.2 Statistical Analysis  
Laboratory data were expressed as standard deviation of the mean (SD). The D’Agostino–
Pearson omnibus normality test was performed to test normality of the data distribution. All data 
were expressed and graphed as mean ± standard deviation. For data normally distributed, one-
way ANOVA analysis of variance followed by Tukeys multiple comparison post-test was 
performed to determine whether the differences between the groups were statistically significant. 
Differences were considered significant if the probability (P) value was <0.05, highly significant 
if P value was <0.01 and P value <0.001, and insignificant if P value was >0.05. Correlation 
analyses of two variables were carried out using Pearson or Spearman methods, depending on 
the normality of the data distribution. All statistical analyses were performed using graphPad 
Prism and graphPad InStat software, version 7.04 and 3.10.32 respectively.  
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6.4 Results 
6.4.1 Comparison of Fatty Acids between the Studied Groups 
RBC membrane PUFA composition was analysed at baseline and values were expressed 
as mean (SD). The data for of ARA: EPA ratio as well as the percentage of omega-3 PUFA/total 
PUFA, and Omega 3 index of the studied groups measured in this study is listed in Table 6.1. 
The mean (SD) value of RBCs membrane levels of omega-3 index were 5.6 (1.7), 5.3(1.4) and 
5.6 (1.3) for COPD, healthy smokers and healthy nonsmokers groups, respectively. The mean 
(SD) value of the percentage of omega-3 PUFA/total PUFA% were 27.2 (5), 25.7 (4) and 27.3 
(3) for COPD, healthy smokers and healthy nonsmokers groups, respectively. The mean (SD) of 
ARA/EPA ratio were; 20 (8.5) for COPD, 20.8 (6.5) for healthy smokers and 20.2 (5.5) for 
healthy nonsmokers groups (Table 6.1). There were no significant differences in fatty acids 
measurements (ARA/EPA, omega-3 PUFA/total PUFA% and Omega 3 index) between the 
COPD group, healthy smokers and healthy nonsmokers groups. Although the percentage of 
omega-3 PUFA/Total PUFA was lower numerically in healthy smokers group compared to 
patients and healthy nonsmokers, it did not reach statistical significance (Figure 6.1).  
 
Table ‎6.1 Comparison of RBC fatty acids composition between the studied groups 
Studied Group COPD HS HNS 
%Omega-3 PUFA/Total 
PUFA 
27.2 (5) 25.7 (4) 27.3 (3) 
ARA/EPA 20 (8.5) 20.8 (6.5) 20.2 (5.5) 
Omega-3 Index 5.6 (1.7) 5.3 (1.4) 5.6 (1.3) 
 
The data expressed in term of mean (standard deviation) unless otherwise stated. These analyses were 
performed using Graph Pad Instat Software. Definition of abbreviations: COPD, chronic obstructive 
pulmonary disease; HS, healthy smokers; HNS, healthy nonsmokers; PUFA; poly unsaturated fatty acids; 
ARA, arachidonic acid; EPA, eicosapentaenoic acid. 
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Figure ‎6.1: Comparison of (A) omega-3 PUFA/total PUFA, (B) ARA: EPA ratio, (C) 
omega-3 index. P value < 0.05 as determined by one-way ANOVA analysis of variance followed by 
Tukeys multiple comparison post-test indicate a significant difference between the groups. These analyses 
were performed using Graph Pad Instat Software. Definition of abbreviations: COPD, chronic 
obstructive pulmonary disease; HS, healthy smokers; HNS, healthy nonsmokers PUFA; poly unsaturated 
fatty acids; ARA, arachidonic acid; EPA, eicosapentaenoic acid. 
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6.4.2 Associations between Membrane Fatty Acids and Smoking in COPD  
The effect of smoking on RBCs fatty acid composition of COPD patients was 
investigated. There was no statistically significant relation between smoking habits and the 
percentage of omega-3 PUFA/total PUFA, using PYH as a marker (r
2
 = 0.06; P = 0.34). 
Likewise, the relationship between smoking and ARA: EPA ratio or and omega-3 index was also 
not statistically significant. The correlation coefficient was r
2
 = 0.16; P = 0.13 and r
2
 = 0.13; P = 
0.17 respectively (Figure 6.2). COPD patients were further split according to smoking status into 
former and current smokers’ sub-groups. However, there was a weak to moderate negative 
correlations between omega-3 index and PYH in current smokers with COPD (r
2
 = 0.36; P = 
0.08) (Figure 6.3). 
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Figure ‎6.2: Smoking impact (PYH) in relation to fatty acid measurement, (A) percentage of omega-
3 PUFA/total PUFA, (B) ARA/EPA ratio, and (C) omega-3 index in patients group. Significance was 
tested using a linear regression analysis (spearman method). These analyses were performed using 
Graph Pad Instat Software. Abbreviations: PUFA; poly unsaturated fatty acids; ARA, arachidonic acid; 
EPA, eicosapentaenoic acid.; PYH, pack year history.  
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Figure ‎6.3: Smoking impact (PYH) in relation to omega-3 index in smoker sub-groups. (A) 
Former smokers with COPD (n=6), (B) current smokers with COPD (n=9). Significance was tested using 
a linear regression analysis (spearman method). These analyses were performed using Graph Pad Instat 
Software. Abbreviations: PYH, pack year history.  
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6.4.3 Associations between RBC Fatty Acids and Pulmonary Function in COPD  
The relationship between fatty acid measurements and patients’ pulmonary function 
outcome were investigated. Linear regression analysis using Pearson method showed no 
significant relationship between FEV1 and the percentage of omega-3 PUFA/total PUFA (r
2
 = 
0.001; P = 0.88), ARA: EPA ratio (r
2
 = 0.006; P = 0.77), as well as Omega 3 index (r
2
 = 0.016; P 
= 0.65). Likewise, the relationship between pre FEV1/FCV ratio and the percentage of omega-3 
PUFA/total PUFA or ARA: EPA ratio, as well as omega-3 index was also not statistically 
significant. The correlation coefficient was r
2
 = 0.006; P = 0.77, r
2
 = 0.018; P = 0.63 and r
2
 = 
0.0005; P = 0.99 respectively (Figure 6.4). Linear regression analysis also showed no significant 
relationship between FEV1 and fatty acid measurements for the entire study cohort. 
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Figure ‎6.4: The correlation between patient’s fatty acid measurement and lung severity; (1) 
pre FEV1% with (A) percentage of omega-3 PUFA/total PUFA, (B) ARA/EPA ratio, (C) omega-3 index, 
(2) pre FEV1/FVC ratio with (D) % of omega-3 PUFA/total PUFA, (E) ARA/EPA ratio (F) omega-3 
index. Significance was tested using a linear regression analysis (spearman method). These analyses 
were performed using Graph Pad Instat Software. Definition of abbreviations: COPD, chronic 
obstructive pulmonary disease; FEV1, Forced Expiratory Volume in 1 second; FVC, forced vital 
capacity, PUFA; poly unsaturated fatty acids; ARA, arachidonic acid; EPA, eicosapentaenoic acid. 
  
187 
 
6.4.4 Associations between Membrane Fatty Acids and Inflammatory biomarkers in 
COPD  
A possible relationship between fatty acid measurements and the plasma level of 
inflammatory biomarkers of patients were investigated.  There was no statically significant 
relationship between plasma CRP level of patients with COPD and RBCs fatty acid 
measurement including; the percentage of omega-3 PUFA/total PUFA (r
2
 = 0.006; P = 0.77), 
ARA: EPA ratio (r
2
 = 0.013; P = 0.68), as well as omega-3 index (r
2
 = 0.002; P = 0.86). 
Likewise, no statically significant relation was found between patients’ plasma fibrinogen level 
and RBCs fatty acid measurements. The correlation coefficient of the percentage of omega-3 
PUFA/total PUFA, ARA: EPA ratio and omega-3 index was r
2
 = 0.03; P = 0.49, r
2
 = 0.012; P = 
0.69 and r
2
 = 0.02; P = 0.58 respectively (Figure 6.5). 
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Figure ‎6.5: The correlation between patients’ fatty acid measurements and inflammation 
biomarkers level. CRP with (A) omega-3 PUFA/total PUFA (B) ARA/EPA ratio (C) omega-3 index, 
Fibrinogen with (D) omega-3 PUFA/total PUFA (E) ARA/EPA ratio (F) omega-3 index. Significance was 
tested using a linear regression analysis (spearman method). These analyses were performed using 
Graph Pad Instat Software. Definition of abbreviations: COPD, chronic obstructive pulmonary disease; 
FEV1, Forced Expiratory Volume in 1 second; FVC, forced vital capacity, : PUFA; poly unsaturated 
fatty acids; ARA, arachidonic acid; EPA, eicosapentaenoic acid; CRP, C-creative protein.  
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6.5 Discussion 
Fatty acids control the structure and function of biological membrane including membrane 
fluidity. Thus modification of the fatty acid composition in the membranes of the RBCs in 
patients with COPD may result in disruption of the cell structure and function and immune 
response (Novgorodtseva et al., 2013). For example, increased omega-6 PUFAs stimulates the 
formation of inflammatory mediators that involve in platelet aggregation, immune system 
functions, and bronchospasm. Early detection of the fatty acid alteration in patients with 
respiratory diseases can prevent the progression of a more severe pulmonary disease 
(Novgorodtseva et al., 2013).  
Erythrocyte membrane content is considered to be the most reliable, biologically relevant 
sample of dietary omega-3PUFAs intake. The ratio between omega3 and omega6 PUFA intakes 
has been studied by using the ratio of ARA to EPA and/or DHA. While Omega-3 Index reflects 
the amount of EPA and DHA present in RBCs membrane (Cai et al., 2017).  In the present work, 
the fatty acid profiles of total lipid in RBCs from the three studied groups were analysed, to 
detect potential fatty acids that could be used as biomarkers test for the diagnosis and 
management of COPD. There are no previous studies examining the use of fatty acid profiles in 
this context for COPD. Unlike this study, previous studies have investigated the effect of omega-
3 PUFA supplementation, either as a fixed-dose therapy or as a dietary supplement, in patients 
with COPD.  
RBC PUFA measurements for the percentage of omega-3 PUFA/total PUFA, ARA: EPA 
and Omega 3 index showed no significant differences between the three studied groups. No 
correlation was observed between fatty acid measurements of erythrocyte membranes and 
patients’ health status, and the study findings prove that the fatty acid composition of the 
erythrocyte membranes in our patients group was unmodified. These results are in agreement 
with a previous study which analysed the fatty acid profiles of RBCs and found contrasting 
results showing modification in fatty acids from patients with different types of lung cancers, 
whereas fatty acid profiles were unmodified in patients with COPD, asthma, and healthy controls 
(De Castro et al., 2014). 
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In contrast to the current study, previous study by Novgorodtseva et al (2013), revealed an 
increase of omega-6 PUFAs/omega-3 PUFAs ratio by 3-fold, and a decreased in EPA value by 
2-fold in COPD patients when compared to the control group. During the current study, similar 
work has been published by Kentson et al. (2018) in which the omega-3 index was significantly 
reduced in COPD subjects compared to controls. In that study it was observed that COPD 
subjects’ food intake was not rich in omega-3 PUFA, less healthy, and that they ate smaller food 
portions than control subjects, which could be the cause of the reduced level of omega-3 PUFAs 
in patients rather than the disease itself. The mean value for the omega-3 Index in the present 
study was 5.6 for the COPD group, which is comparable with the level reported in Kentson’s 
study, where the value was 5.16, and 5.79 for controls. However the omega-3 Index value 
reported in the current study of the controls group was similar to those of patients which may 
suggest the less healthy diet style of both group subjects. Interestingly, in the current study the 
omega-3 Index and the percentage of omega-3 PUFA/Total PUFA was lower numerically in the 
healthy smoker group compared to patients and healthy nonsmokers. However this low level did 
not reach statistical significance and may be due to smoking effect on healthy smokers’ diet style 
and health status. 
Smoking is a major risk factor for COPD especially in developed countries. Smoking can 
activate oxidative stress causing increase in lipid peroxidation of PUFAs. It also may affect the 
synthesis and metabolism of fatty acids result in alteration of omega-3 PUFA levels (Scaglia et 
al., 2016). The literature reports inconsistent findings in relation to the effect of smoking of 
PUFA composition. In this study, the effects of cigarette smoking on RBCs cell membrane fatty 
acid levels of COPD patients were examined. It was found that smoking, as quantified by PYH, 
statistically seemed to have no significant impact on fatty acid composition of COPD subject 
including; the percentage of omega-3 PUFA/total PUFA, ARA/EPA ratio and omega-3 index.  
The current study results are in agreement with Batlle et al. (2012) study who observed no 
effect of smoking status on the levels of PUFA in COPD patients. However, a weak to moderate 
negative correlation between omega-3 index ratio and smoking habits in current smoker with 
COPD was observed. These findings indicate that smoking habit may affect the dietary intake of 
omega-3 PUFA in COPD patients. A similar observation was made by several other research 
groups, for example; Scaglia et al. (2016) reported a lower intake of omega-3 PUFAs by 
  
191 
 
smokers was associated with lower DHA levels. Additionally, a cross-sectional case-controlled 
clinical study revealed a decrease in serum omega-3 PUFAs in smokers, especially with COPD 
compared with nonsmokers (Titz et al., 2016).  
In the present study plasma levels of inflammatory biomarkers (CRP and fibrinogen) were 
found to be significantly higher in the COPD group than in healthy smoking and nonsmoking 
groups. In addition, several epidemiologic studies indicated a relationship between the low ratio 
of EPA and DHA intake and high level of CRP. It has been proposed that omega-3 PUFA can 
modulate the inflammatory process by inhibiting the production of pro-inflammatory factors. 
Therefore, a possible relationship between the plasma level of inflammatory biomarkers and 
RBCs cell membrane PUFA composition was investigated. There was no correlation of PUFA 
with inflammatory biomarkers CRP, as well as fibrinogen, in COPD patients. These findings 
confirmed that PUFA have no effect on systemic inflammation in patient with COPD. The 
present results matched a previous 8-week trial, which found that daily supplementation with 
EPA, DHA, and ALA in 80 patients with COPD did not affect the level of CRP, IL-6, and TNF-
α (Broekhuizen et al., 2005). Likewise, a study by Matsuyama et al (2005) also reported that diet 
enriched with omega-3 PUFA did not change serum levels of IL-8 and TNF-α. However it did 
improve exercise capacity and decrease serum LTB4, sputum LTB4, IL-8, and TNF-α level in 
patients with COPD. Similarly, the plasma level of CRP was unchanged in COPD patients 
supplemented with rosuvastatin, omega-3 fatty acids and lycopene (Williams et al., 2016). In 
contrast, daily supplementation with omega-3 PUFA significantly decreases the serum level of 
CRP, IL-6, IL-8, and TNFα in the low-intensity exercise group (Sugawara et al., 2010). In line 
with the previous study result, Batlle et al. (2012) observed an inverse association between 
omega-3 PUFA intake and several serum pro-inflammatory biomarkers level, including CRP, IL-
6 and TNFα. However the latter study relied on a food frequency questionnaire to assess the 
individual dietary data of PUFA intake. 
Data from this study showed that pulmonary function including preFEV1% and pre 
FEV1/FVC ratio were significantly reduced in COPD patients when compared to healthy 
smoking and nonsmoking groups. A possible protective association between omega-3 PUFA 
measurements and lung function outcomes was therefore investigated. Unfortunately, there was 
no relationship between omega-3 PUFA measurements and lung function outcome in COPD 
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patients. However, the results agree with previous studies which reported that omega-3 PUFA 
intake does not have a major protective effect on lung function or disease symptoms and severity 
(Broekhuizen et al., 2005; McKeever et al., 2008).  
There are several limitations in previous studies worth to be mentioned. First, the most 
important limitation is that most of the studies are cross-sectional observational cohort studies. 
Second, omega-3 PUFA sources are indirectly measured using food frequency questionnaires 
instead of using laboratory method to analyse RBCs membrane fatty acid. Subsequently, this 
may lead to inaccurate omega-3 PUFA consumption estimation. Finally, COPD patients and 
smokers may have changed their lifestyles and dietary habits, reducing fish consumption.  
The current study data gave no indication of the possible involvement of RBCs membrane 
fatty acid composition in the relation with COPD, but the size of the patients sample maybe 
insufficient for that purpose. A limitation of the present study that might have contributed to the 
absence of a significant relationship between PUFA measurements and COPD is insufficient 
statistical power. A post hoc power analysis (Wilcoxon-Mann-Whitney test) could not be 
performed because the means and standard deviation for the variables were unavailable. The 
principal finding of this chapter was that patients PUFA profile was not affected by COPD 
severity. Thus, the relationships between RBCs PUFA and COPD remain controversial in the 
literature.  
 
6.6 Conclusions 
Measurement of PUFAs from RBCs total lipids analysis was considered as a potential 
useful stable metric for COPD severity. Unfortunately, there was no observed alteration in 
PUFAs composition in the patients group. Additionally, there was no correlation between 
patients respiratory function parameters or systemic inflammatory biomarkers and PUFAs 
measurements.  Subsequently our findings indicated that RBC membrane Omega-3 PUFA does 
not seem to have a major protective effect on lung function or disease symptoms. The results 
from this study did not support the findings of a number of reports which have revealed that 
PUFAs composition is modified and omega-3 index is reduced in patients with COPD.  
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Although consistent with findings in a very recent report by Kentson (2018), an omega-3 
index value of 5.6% reported here for COPD patients (and control subjects), is much below the 
suggested 8-12% that has been associated with achieving health benefits for other conditions.  
Interventional studies use supplementation of food enriched with omega-3 PUFA to elicit a 
response. However, there is a failure to evaluate baseline omega-3 and whether supplementation 
causes any change to achieve higher levels of omega-3 and therefore is unsupportive of a direct 
benefit from enhancing omega-3 PUFA. This needs to be addressed in future interventional 
studies. There is no consistent evidence confirming that a diet enriched with omega-3 PUFA 
reduces chronic inflammation. Only limited evidence shows that the use of omega-3 PUFA 
supplementation is improving functional capacity in COPD patients. More evidence and further 
investigation are required to confirm the potential effects of omega-3 PUFA on COPD patient 
health, before routinely incorporating this therapy within COPD treatment and management 
(Atlantis Cochrane, 2016). The relationship between omega-3 PUFAs and inflammation in 
patients with COPD remains unclear. The absence or weakness of a significant relationship may 
be due to the small patients’ number and individual biological variability. Increasing the sample 
size may have assisted in finding a significant relationship between blood levels of omega-3 
PUFA and COPD patients’ health status. Collectively the data show that the severity of COPD 
does not seem to reflect the fatty acid composition of the RBCs membrane, but it is tempting to 
speculate that enhancing levels of omega-3 from around 5% observed in this study population, to 
at least 8% may have a different outcome. Further research is needed to study the formation and 
activity of fatty acid in COPD. 
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7. Chapter 7: General Discussion and Conclusion/ Future works 
 
COPD is a chronic lung disease characterised by persistent airflow limitation. It is 
associated with systemic inflammation, extra-pulmonary manifestations, comorbidities and poor 
outcomes (Barnes 2016). COPD is a major cause of mortality worldwide (Bajpai et al., 2017), 
and by 2030 COPD is expected to become the 3rd leading cause of death worldwide (Vestbo et 
al., 2013). It is a complex disease which is influenced by multiple factors such as genetic factors, 
environmental factors, and genotype–environment interactions (Sandford and Silverman 2002). 
Severity of COPD is positively associated with systemic inflammation. The presence of 
increased level of inflammatory markers in circulation, sputum, and BAL fluid suggests that 
systemic inflammation is one of the potential mechanisms responsible for COPD (Naik et al., 
2014). Inflammatory biomarkers are becoming a useful means of characterizing the extent of 
both airway and systemic inflammation associated with COPD (Barnes 2016). In this regard, 
disease heterogeneity and a lack of disease specific biomarkers are particularly challenging for 
the development of effective therapy for COPD. Current therapies are able to attenuate 
symptoms and prevent exacerbations but they do not prevent the decline in lung function or 
disease progression. Therefore the development of blood biomarkers would enhance the 
understanding of COPD pathophysiology and facilitate patient subdivision (Roberts et al., 2015).  
In the current programme of studies, a significant decrease was found in the pulmonary 
functions of COPD patients when compared with healthy controls. These findings are consistent 
with those of other researchers who have demonstrated that pulmonary function data were 
significantly lower in COPD patients when compared with controls (El-Shimy et al., 2014). Age, 
weight and BMI have an impact on subject respiratioty functions when investigating the whole 
study indviduals. Addionally, pateints  parameters including; weight, BMI as well as smoking 
exposure seemed to have impact on patients’ reversibility, but not on disease severity. This may 
due to low size of patients sample. Furthermore, smoking may impairs the effectiveness of ICS 
therapy in patients with COPD. However no effect of ICS was found on patients’ lung functions. 
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Blood biomarkers may clinically assist in predicting COPD severity (Augusti et al., 2012; 
Vestbo et al., 2014; Faner et al., 2014). For example, fibrinogen and CRP, both biomarkers of 
inflammation were found to be correlated with COPD severity and risk of exacerbations (De-
toress et al., 2006; Higashimoto et al., 2009; Vestbo et al., 2011; Augusti et al., 2012, Celli et 
al., 2012, Duvoix et al., 2013; Fattouh and Alkady, 2014; Manino et al., 2015; Paone et al., 
2016). IL-6 was also associated with FEV 1 and FEV1/FVC (Ardestani and Zaerin 2015). 
Importantly, lung specific proteins such as SP-D and CC16 are also attractive COPD biomarkers. 
SP-D has been associated with COPD (Vestbo et al., 2014, Lomas et al., 2008), and emphysema 
and possibly exacerbation frequency (Lomas et al., 2009; Akiki et al., 2016). CC16 may 
correlate with disease severity and FEV1 decline over time (Lomas et al., 2008; Lomas et al., 
2009; Vestbo et al 2014). Plasma sRAGE is inversely correlated with decreased lung function, 
disease severity and emphysema (Change et al., 2013; Gopal et al., 2014; Hoonhorst et al., 
2016). Serum levels of CCL18 were correlated with FEV1, exercise capacity, exacerbation 
frequency and mortality (Pinto-Plata et al., 2007; Sin et al., 2011; Paone et al., 2016). 
However, most of the available studies are either observational cohort or small-sized 
experimental studies, while large clinical trials that evaluating changes in biomarkers in relation 
to clinical outcome are insufficient. Most of the current biomarker candidates are not lung-
specific but may reflect the systemic aspects of COPD and its associated comorbidities. There is 
a need for lung-specific biomarkers derived from proteins that are either only expressed in the 
lung tissue (CC16, SPD), or highly over-expressed in the lung (RAGE). Due to the complexity 
and heterogeneity of COPD, a panel of biomarkers may be required to address personalized 
treatments of COPD patients, as single biomarker will not be able to identify the different 
characteristic and phenotypes of COPD (Ongay et al., 2016) 
COPD is characterised not only by a local pulmonary inflammation but also by a systemic 
inflammation. In this study (chapter 4), the associations between circulating inflammatory 
markers and COPD were investigated. High plasma levels of CRP and Fibrinogen together with 
a low level of CC16 were observed in COPD patients compared with healthy controls. This is 
consistent with previous data where elevated plasma inflammation-sensitive protein levels, such 
as fibrinogen and CRP were associated with the presence of COPD (Agusti et al., 2012; 
Kleniewska et al., 2016). However, the use of CRP alone as a biomarker for COPD is limited 
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because of its low specificity as any inflammation or infection not related to the lung, can modify 
CRP level (Paone et al., 2016). Additionally, the levels of plasma CRP increased as the severity 
of COPD increased. An increased plasma fibrinogen and CRP level in patients with COPD may 
suggest a systemic inflammatory effect in these patients. Further clarification is required as to 
whether systemic inflammation is a primary or secondary related to pulmonary inflammation.   
Lung specific proteins can be potential biomarkers that can assist in disease prognosis and 
severity, predict outcomes, and treatment (Doubková et al., 2016). Findings in this study, from 
the COPD patient group, indicate the lung-specific protein CC16, could be promising as a local 
biomarker of an inflammatory process in the airways of COPD patients. However, further studies 
are required to establish the role of CC16 in COPD patients. An ideal biomarker must be 
reproducible in stable disease like; SP-D, fibrinogen and CC16, while other biomarkers, 
including CCL18 and CRP, need further evaluation (Paone et al., 2016). Therefore, novel and 
possibly more pulmonary specific biomarkers should be tested, perhaps using combinations of 
(systemic and lung-specific) biomarkers in a ‘mini-panel’. 
There is no specific accepted systemic biomarker for assessing COPD severity and 
evaluating the effectiveness of treatment (El Gammal et al., 2015). This study provides evidence 
that COPD patients have a pro-inflammatory state, with increased circulating levels of 
inflammatory cytokines and acute-phase reactants. However, circulating TNF-α, IL6, IL8, IP10, 
SPD and RAGE were not detected in most subjects of the study cohort despite recognized 
associations with inflammation and COPD. These inconsistencies between studies are often 
found in the literature and efforts to understand why are necessary. Methodological differences 
and the heterogeneity of COPD itself may partly explain this.  
Assessment of blood markers can be useful for diagnosis, prognosis and treatment of COPD 
patients. However, due to inconsistent results of published studies of inflammatory biomarkers 
their evaluation has not been accepted so their routine application requires further studies. The 
first step of treatment for COPD is to suppress the inflammation process and to prevent its 
consequences (Heidari 2012). COPD is associated with systemic inflammation but it remains 
unclear how the systemic inflammation arises. Does it start in parallel to the pulmonary 
inflammation, or it may due to the spillover of pulmonary inflammation? (Agusti et al., 2012).  
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Of note, unstimulated ex-vivo PBMCs in COPD released significantly higher levels of (IL-6, IL-
8 and TNF-α) cytokines compared to healthy nonsmoking controls, suggesting that the PBMCs 
are already activated in the patients’ circulation. Altered peripheral lymphocyte functions in 
COPD patients have previously been reported. Additionally, several immunological functions of 
circulating T-cells are abnormal and correlated with COPD severity and thus further support that 
adaptive immune processes contribute to progression of this disease (Zhu et al., 2009). 
Additionally smoking seemed to have an impact on patients’ systemic level of CRP but not on 
fibrinogen, CC16, CCL18, and CD31. Cigarette smoking, which is a leading risk factor for 
COPD, can also induce systemic inflammation as the cytokines release from PBMCs of healthy 
smoker were higher than those of healthy nonsmoking control. 
One of the aims of this work was to explore the anti-inflammatory properties of EPA and 
DHA omega-3 PUFA. Data (chapter 5) indicates that EPA and DHA individually possess 
potential immunomodulatory effects characterized by significant reductions in PHA-induced IL-
6, IL-8 and TNF-α release from ex-vivo PBMC. Studies are limited regarding the possibility for 
omega-3 PUFAs to be used therapeutically in chronic inflammatory diseases such as COPD. 
Clinical evidence of benefits from omega-3 PUFAs in COPD were reported in observational and 
interventional studies. Observational studies (de Batlle et al., 2012; Novgorodtseva et al, 2013) 
demonstrate that omega-3 PUFA levels are associated with both systemic inflammation and 
clinical COPD outcomes. Moreover, a very recent study has reported an increased ratio of (total) 
omega-6:omega-3 PUFAs in asthma patients (Zhou et al. 2018).  Data from this study, using 
RBC-based measurements, found that levels of the EPA and DHA omega-3 PUFAs were 
generally low across the study population (indicated by an omega-3 index of approximately 5.6% 
- in itself an interesting finding), but were not correlated with patients respiratory function 
parameters or systemic inflammatory biomarkers. In a previous report, Novgorodtseva et al., 
(2013) found a 3-fold increase in the ratio of the omega-6 to omega-3 PUFA (ARA/EPA) in 
COPD patients compared to controls, whereas ARA/EPA from this study was not different 
between groups.  It is difficult to compare the studies directly but notable that the Novgorodtseva 
control group comprised both ex-smokers and non-smokers and the COPD patients were all 
GOLD 1 (mild severity of disease). In this study, controls were separated by smoking status and 
most (73%) COPD patients were GOLD 2 (moderate severity). However, when both control 
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groups (healthy smokers and nonsmokers) were combined to re-evaluate the data the outcome 
remain the same.  
Clinical interventional studies tend to use omega-3 PUFAs in nutrient supplement 
combinations, which makes it difficult to attribute omega-3 PUFAs specific effects. They are 
also delivered at fixed doses, with compliance recorded by questionnaire, so it is unknown as to 
whether a therapeutic dose of the omega-3 PUFA is ever achieved in vivo. Further, the dose 
levels of EPA and DHA which was used in previous studies on ex vivo lymphocyte proliferation 
in healthy subjects varied from 0.1 to 7 g/day EPA+ DHA/day. Significant increased lymphocyte 
proliferation was observed at a dose level of 2.0g EPA+ DHA/day. However, most these studies 
did not include a formal power calculation (Miles and Calder 2012). 
Given the variations observed here between individuals’ omega-3 index values, this may 
help to explain why interventional studies so far are inconclusive. A better approach may be to 
measure RBC omega-3 pre-and post-intervention, in order to ‘personalise’ dosing to achieve 
appropriate in-vivo levels.  However, there are a few clinical trials ongoing for COPD that are 
using purified omega-3 PUFAs alone but those results are yet to be confirmed (Wood 2015).   
More evidence and further investigation are required to confirm the potential effects of omega-3 
PUFA on COPD patient health, before routinely incorporating this therapy within COPD 
treatment and management (Atlantis Cochrane 2016). 
As omega-3 PUFAs are natural products they could easily be incorporated as part of a 
general lifestyle change for the patient and self-monitoring via blood spots is feasible. Studies 
incorporating the above suggestions are needed on a larger scale and for a longer period of time 
to more carefully assess the effectiveness of omega-3 PUFAs for treating COPD. This could be 
in conjunction with biomarkers, antioxidant or other agents (Bajpai et al., 2017). If future studies 
prove that these therapies are effective and safe it might be more useful to introduce these early 
in the course of the disease to prevent disease progression and possibly to reduce comorbidities 
(Barnes 2016).  
 
 
 
  
199 
 
Limitation 
There are some limitations of the present study that deserve to be discussed. First, the 
definition of COPD was based on post FEV1/FVC <0.70 at a single examination. Although this 
is the most widely accepted definition for COPD, it represents a simplified case definition for 
epidemiological purposes and not for clinical diagnosis. Second, this is a clinical-case study 
looking at a population at a given point in time and not a longitudinal study. Therefore it only 
provides the frequency and characteristics of the disease in this population taking place when the 
study was conducted. Third, of the COPD group in this study, all patients used ICS and systemic 
corticosteroids. This could contribute to the underestimation of the difference in biomarkers 
between COPD patients and control subjects. Nevertheless, the effect of ICS on inflammatory 
biomarkers is still controversial.  
Fourth, the biology of the inflammatory response is complex and the current study 
investigates only a limited panel of biomarkers. However, the selected biomarkers were chosen 
correspond to those investigated by the majority of previous studies, and are often and easily 
measured in clinical practice. On the other hand, evaluation of markers of oxidative stress and 
lipid peroxidation; MDA, Hydrogen peroxide and 8-isoprostane, antioxidants; superoxide 
dismutase 3, glutathione peroxidase, catalase, and ceruloplasmin ferroxidase activity (Bajpai et 
al., 2017), antioxidant; total bilirubin and uric acid (Lee et al., 2018), extracellular matrix 
breakdown; MMP-8 and MMP-9 (Duvoix et al., 2012), protease/anti-protease biomarkers, other 
cytokines include; IL-2, IL-4, and IFN-γ, Adiponectine, Apolipoprotein A1 and lipocallin-1and 
are suggested to interpret the results accurately (Agusti et al., 2012; Comes et al., 2016). For 
example, what emerges from literature is that MDA, a lipid peroxidation product, could be used 
as specific biomarkers of oxidative stress in COPD patients. Furthermore, the use of advanced 
analytical methods like cytokine arrays, mass spectrometry, or nuclear magnetic resonance, 
should increase the sensitivity of the assays, and may produce important new information in the 
future (Liu et al., 2014). 
Fifth, this was a single-center study and the number of subjects was not sufficient to be 
equally categorized to COPD four stages; mild, moderate, sever, very sever; and this may have 
hampered efforts to clearly define differences between the groups in some cases. Some 
biomarker data are known to be variable and the PBMCs sample size was sometimes insufficient 
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to overcome this variability. In addition, direct measurement of inflammatory biomarkers in 
peripheral blood is known to be difficult due to their short half-lives, low concentrations, and 
their binding to soluble receptors and the effects of renal clearance (Kawayama et al., 2016). 
Other factors to consider include; lack of reproducibility in an independent cohort, heterogeneity 
and subject biological variability of the patients with COPD, pathological characteristics, the use 
of different methodologies and assays. Therefore, a large-scale and long-term multi-center 
population-based study with sufficient subjects in each GOLD category may be necessary in the 
future to investigate the lack of associations between these biomarkers and the presence of 
COPD (Lee et al., 2018).  
Another limitation was the absence of other important measures of COPD, such as diffusion 
capacity or CT scan. Pervious works (Bailey et al., 2012; Boutou et al., 2013; Šileikienė et al., 
2017), in COPD has highlighted that measures other than pulmonary function are important 
predictors of impaired function and poor outcomes. However, the Lung function remains the 
primary means of diagnosing and classifying COPD at the present time. For better understanding 
of the COPD variability between patients, additional parameters sholud be evaluted during 
patient attendance at routine clinics. The addition of a panel of biomarkers to lung function 
parameters known to predict mortality in COPD (Cazzola, et al., 2008), alongside lung 
plethysmography, gas transfer, arterial oxygen, and CT, as well as multiple spirometry will 
improve diagnosis and prediction of mortality risk in patients with COPD.  
Finally, a limitation of the present study that might have contributed to the absence of a 
significant relationship between variables is the insufficient statistical power. During the 
planning of the study, no power analysis was performed, and a post hoc power analysis 
(Wilcoxon-Mann-Whitney test) justifies the sample size. However for some data sample 
justification could not be performed because the means and standard deviation were unavailable.  
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Future works 
The possibility to continue the current work will be a good opportunity to address some of the 
limitation, and to make the study data more robust. For example, Apply more pulmonary 
function and structural test from each patient during clinic presentation such as; CT scan, gas 
transfer, arterial oxygen, along side spirometry measurments. These tests together could allow 
clinicians for earlier diagnosis of COPD patients, reduce hospital readmission, and could help 
governments to plan their healthcare budgets and financial resources. Unlimited resources 
available will assist to expand the biomarker panel and to add more specific pulmonary markers, 
and to use more advanced detection methods which will improve the sensitivity and validity of 
the measurement of several biomarkers in COPD. For example, flow cytometric assay will help 
to identify various cell types from blood samples of COPD patients, and will allow further 
investigation of cell characteristics, such as cell count, cytokine production and receptor 
expression, and apoptosis for different cell types. Furthermore, the use of advanced analytical 
methods should save time, process more samples, increase the sensitivity of the assays, and may 
produce new information.  
Future investigation should focus on pulmonary marker and other marker related to event and 
comorbidities usually seen in COPD. For examples, markers for oxidative stress, lipid 
peroxidation, CVD, angiogenesis, and tissue damage as well as extracellular matrix-degrading 
enzymes. Apply sample justification analysis prior starting the experiment to estimate the sample 
size required for the study, to detect a significant relationship. Increase the subject number to be 
equally categorized to COPD four stages via collecting samples from multi-centres with long-
term studies. Additionally, investigate the effect of different concertation range of omega-3 
PUFAs on PBMCs biomarker release is worth to be investigated. A concentration range of 100, 
200, 300, 400 µM will be a good point to start from. To date, plasma omega-3 PUFA 
concentrations of participants remained unclear in most the previous studies. It would therefore 
be useful to investigate the potential relationship between plasma omega-3 PUFAs level and 
COPD will be interesting, to elucidate the potential influence factors of omega-3 PUFAs. 
Research into the benefits of omega-3 PUFAs should be continue and include fatty acid blood 
measurements in COPD patients. This will provide physicians information on individual patient 
risk classification and anticipated response to treatment that may be of clinical value. 
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Study Ethical Approval + Sample Collection Plan 
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DS618: Evaluation of polyunsaturated fatty acids (PUFAs) on inflammatory biomarkers in 
whole fresh blood of COPD, HS and HNS subjects. 
 
 Friday PM NJ should email Salford group with possible patients for the following week. 
Up to 2-3 per day maximum. 
DS618 Salford e-mail group to include Jeremy Allen [J.T.Allen@salford.ac.uk]; Lucy Smyth 
[L.Smyth@salford.ac.uk]; Amal Al-Haidose (PG) [A.Al-Haidose@edu.salford.ac.uk] 
 For cancellations or additional bookings through the week, MEU should also e-mail 
Salford Group. 
 If too short notice or unable to collect sample on the specified day, Salford to inform 
MEU ASAP on Academic-MEU@meu.org.uk or 0161 9464065 
 Patients who meet the criteria in Appendix 1 on the day of screen (or historical data 
within 1 year if MEU blood donation visit only) will have 2 additional 10ml EDTA tubes 
taken. 
 MEU to notify Amal of screen failures or non-attendance ASAP (see contact numbers 
below). 
 Blood stored at room temp. in MEU Lab 2 until collection by Salford 
 Salford staff to come to MEU reception and state they are here from Salford Uni to 
collect samples from the academic team. 
 On collection of samples, the ‘Material Transfer Record From’ (appendix 2) must be 
signed by MEU and Salford representative and filed at MEU. 
 Suitable Blood transfer packaging to be supplied by Salford. 
 Blood will be discarded at the end of day if not collected. 
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Inclusion/Exclusion Criteria 
Inclusion: 
1) COPD 
Age 40-80 years 
Post BD FEV1/FVC ratio <0.70  
Pack Years >10 
2) Smokers with normal lung function  
Age 40-80 years 
Pre BD FEV1/FVC ratio >0.70 
FEV1>80% predicted 
Current smoker 
Pack years >10 
3) Never smokers 
Age 40-80 years 
Pre FEV1/FVC >0.70  
FEV1>80% predicted 
Pack years <1 
Exclusion: 
1) All Healthy volunteers:  
History of a chronic respiratory disorder 
2) All volunteers  
History of acute respiratory disease within 6 weeks prior to visit 
History of other non-respiratory inflammatory disease  
  Blood safety at Dr review: 
  Donated 1 pint (500mls) of blood in the last 16 weeks:     
 Got a chesty cough, sore throat or active cold sore:      
  Pregnant or a woman with a baby less than 9 months old:     
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 Taking antibiotics NOW or finished taking them within the last 7 days:   
 Had hepatitis or jaundice in the last 12 months:     
 Had acupuncture, ear piercing, body piercing, tattooing or semi-permanent 
  make-up in the last 4 months:        
 HIV positive or thinks they may be HIV positive:      
  Ever injected or been injected with drugs including body building drugs:   
Been in contact with an infectious disease or been given  
  immunisations in the last 8 weeks:        
Any known Haemophilia or a related blood clotting disorder who has received clotting factor 
concentrates: Had a history of anaemia.  
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Appendix B 
 
Skanlt Software Operating 
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